

University of California, Davis
IACUC Business Administration System

January 07, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M102, M111, M090, M042, A095, M004, M092, A019, M119, M087, A109, M110, A013, M016, M024, M001, M112

Excused:

M093, M114

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the November 12, 2020, meeting minutes as written.

IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16

The IACUC reviewed and approved the December 3, 2020, meeting minutes as written.

IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16

The IACUC reviewed and approved the December 17, 2020, meeting minutes as written.

IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

	Action: Physical breach in isolators housing gnotobiotic mice; required euthanasia
	Action: Genotyping policy not followed. PAM and amendment.
	Action: Neck lesions; amendment forthcoming.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Chem</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Chem, Remains DMR</p>			
2. # [REDACTED]	D	[REDACTED]	12-18-2020
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Still pending BUA</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains DMR</p>			
4. # [REDACTED]	D	[REDACTED]	01-07-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Requested more information for the Rationale for Numbers and Species and more clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	C	[REDACTED]	01-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
6. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA amendment.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
7. # [REDACTED]	D	[REDACTED]	01-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	C	[REDACTED]	01-06-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of and incentive amount and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
10. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending CHEM.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
11. # [REDACTED]	C	[REDACTED]	12-18-2020
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure and administration of drug</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
13. # [REDACTED]	C	[REDACTED]	01-04-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
14. #	C		01-07-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
15. #	B		01-06-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Administrative protocol for ordering animals. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		01-07-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
2. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
3. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI response.			
4. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI's response to chemical safety officers statement regarding VHSS and contacting waste management. Additional discussion during the meeting included: a. Remains in DMR.			
5. #	D		01-07-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of animal numbers. Additional discussion during the meeting included: a. None.			

6. # [REDACTED]	E	[REDACTED]	01-06-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	C Y	[REDACTED]	01-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	C	[REDACTED]	12-17-2020
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	C	[REDACTED]	01-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	01-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on blood collection</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D	[REDACTED]	01-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	D	[REDACTED]	01-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer confirmed no new VHSS was required for this study.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C Y	[REDACTED]	12-17-2020
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding disposition provided by PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D Y	[REDACTED]	12-18-2020
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

15. # [REDACTED]	E	[REDACTED]	12-17-2020
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	D	[REDACTED]	01-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure and animal grouping</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. To DR pending CVS input.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 153 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	E	[REDACTED]											
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI responses. Sent to DR.</p> <table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>18</td> </tr> </tbody> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
2. # [REDACTED]	B	[REDACTED]	01-07-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarification these are fish relocated due to the pandemic, and will receive fish from the holding protocol that are onsite.</p> <table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>18</td> </tr> </tbody> </table>				IACUC Vote		Approval	18						
IACUC Vote													
Approval	18												

<table><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				Withhold Approval	0	Abstain	0	Present	18				
Withhold Approval	0												
Abstain	0												
Present	18												
3. #	D		01-21-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding adverse effects requested.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
4. #	D		01-07-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer confirmed VHSS requirements. Biosafety officer confirmed BUA and staff addition.</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved by vote.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
5. #	D Y		02-04-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Final approval pending BUA amendment. Biosafety officer noted review of BUA is scheduled for January meeting.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	D	[REDACTED]	01-07-2019	01-07-2021	01-07-2022
	D		01-19-2019	01-07-2021	01-19-2022

	D		01-10-2019	01-07-2021	01-10-2022
	D		01-17-2019	01-07-2021	01-17-2022
	D		01-10-2019	01-07-2021	01-10-2022
	C		01-09-2019	01-07-2021	01-09-2022
	D		01-10-2019	01-07-2021	01-10-2022
	C		01-10-2019	01-07-2021	01-10-2022
	C		01-22-2019	01-07-2021	01-22-2022
	C		01-22-2019	01-07-2021	01-22-2022
	C		01-22-2019	01-07-2021	01-22-2022
	D		01-10-2019	01-07-2021	01-10-2022
	C Y		01-10-2019	01-07-2021	01-10-2022
	B		01-18-2019	01-07-2021	01-18-2022
	D		01-23-2020	01-20-2022	04-27-2022
	C		01-21-2020	01-06-2022	01-21-2023
	D Y		01-23-2020	01-20-2022	01-23-2023
	D		01-23-2020	01-20-2022	01-23-2023
	D Y		01-16-2020	01-20-2022	01-16-2023
	C		01-23-2020	01-20-2022	01-23-2023
	D		01-23-2020	01-20-2022	01-23-2023
	C		01-23-2020	01-07-2021	01-23-2022
	C		01-13-2020	01-06-2022	01-13-2023
	D		01-23-2020	01-20-2022	01-23-2023
	D		01-23-2020	01-20-2022	01-23-2023
	D		01-23-2020	01-07-2021	01-23-2022
	D		01-23-2020	01-07-2021	01-12-2022
	C		01-23-2020	01-20-2022	01-23-2023

Discussion: None.

Action Items:	None.
---------------	-------

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	01-07-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
2. # [REDACTED]	D Y	[REDACTED]	01-07-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Original protocol mentioned urine analysis in section 12 however details were not included in section 14a.</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved by vote.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
3. # [REDACTED]	E	[REDACTED]	02-03-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI response to review suggestion regarding preventive measures, and slow progress going forward to preclude a repeat of this incidence in several birds at a time. Sent to DR.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 07-02-2020	[REDACTED]

2. 07-27-2020	
3. 07-29-2020	
4. 08-05-2020	
5. 08-05-2020	
6. 08-05-2020	
7. 08-11-2020	
8. 08-13-2020	
9. 08-19-2020	
10. 09-24-2020	
11. 09-28-2020	
12. 11-04-2020	
13. 11-16-2020	
14. 11-17-2020	
15. 11-18-2020	
16. 11-18-2020	
17. 11-19-2020	
18. 11-19-2020	
19. 11-20-2020	
20. 11-24-2020	
21. 11-25-2020	
22. 11-25-2020	
23. 11-25-2020	
24. 11-30-2020	
25. 12-01-2020	
26. 12-03-2020	
27. 12-10-2020	
28. 12-16-2020	

Discussion:	None.										
Action:	None.										
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>15</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>15</td> </tr> </table>		IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote											
Approval	15										
Withhold Approval	0										
Abstain	0										
Present	15										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 03-12-2020	LAB	
2. 07-14-2020	LAB	
3. 07-20-2020	LAB	
4. 07-20-2020	LAB	
5. 07-20-2020	LAB	
6. 07-22-2020	LAB	
7. 07-24-2020	LAB	
8. 07-27-2020	LAB	
9. 07-28-2020	LAB	
10. 07-28-2020	LAB	

11. 07-30-2020	LAB	
12. 07-30-2020	LAB	
13. 07-30-2020	LAB	
14. 08-03-2020	LAB	
15. 08-03-2020	LAB	
16. 08-05-2020	LAB	
17. 08-10-2020	LAB	
18. 08-10-2020	LAB	
19. 08-10-2020	LAB	
20. 08-11-2020	LAB	
21. 08-20-2020	LAB	
22. 08-26-2020	LAB	
23. 09-16-2020	LAB	
24. 09-17-2020	LAB	
25. 09-23-2020	LAB	
26. 09-24-2020	LAB	
27. 09-25-2020	LAB	
28. 09-29-2020	LAB	
29. 10-13-2020	LAB	
30. 10-23-2020	LAB	
31. 10-30-2020	LAB	
32. 11-05-2020	LAB	
33. 11-10-2020	LAB	
34. 11-13-2020	LAB	
35. 11-13-2020	LAB	
36. 11-16-2020	LAB	
37. 11-18-2020	LAB	
38. 11-18-2020	LAB	
39. 11-18-2020	LAB	
40. 11-20-2020	LAB	
41. 11-25-2020	LAB	
42. 11-25-2020	LAB	
43. 12-01-2020	LAB	
44. 12-02-2020	LAB	
45. 12-02-2020	LAB	
46. 12-07-2020	LAB	
47. 12-24-2020	LAB	
48. 12-28-2020	LAB	
49. 12-31-2020	LAB	
50. 12-22-2020	PAM	

Discussion: None.

Action: None.

IACUC Vote

Approval	14
Withhold Approval	0
Abstain	0
Present	14

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. Facility and lab inspections moving forward under continued pandemic conditions	
Discussion:	Waiver still in effect. Will conduct in person where feasible, otherwise remote. Limit number of people to minimum needed. Ensure current COVID guidelines followed per county and campus.
Action:	Limit number of people to minimum needed. Ensure current COVID guidelines followed per county and campus. Communicate plan and options with each facility manager.
2. Time-mated Breeding Colony Evaluations	
Discussion:	Summary presented by CNPRC veterinarian per USDA exemption requirement.
Action:	None.
3. UC ANR IACUC oversight	
Discussion:	FYI - ANR has requested UCD IACUC to serve as ANR IACUC. Under discussion with VCR. More information
Action:	Obtain more information and suggest alternatives.
4. Transparency Statement draft proposal	
Discussion:	Update website to increase campus and public awareness.
Action:	Include additional statement on IACUC.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

January 21, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M111, M042, A095, M092, A019, M119, M087, A109, M110, A013, M016, M024, M001, M114

Excused:

M102, M090, M004, M093, M112

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
mouse pup
Action: Unidentified mouse pup found in hood.
██████
Action: Discussed PAM and revisions to replacement protocol to correct deficiencies.
██████
Action: Deviation from toe clipping policy; PAM.
██████ & ██████
Action: Discussed PAM and added additional deficiencies recommended by the committee. Hazard deficiency moved to a significant.
██████
Action: Adverse effect from depilatory cream on mice. PI submitting amendment for depilatory cream and side effects.
Sheep Facility incident
Action: Add isolated and not common but potential adverse events in herd protocol.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
Power outage Friday January 15th

Action Items:

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Chem			
2. # [REDACTED]	E	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
3. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA Additional discussion during the meeting included: a. None.			
4. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
5. # [REDACTED]	D	[REDACTED]	01-18-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of possible complications. Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	D	[REDACTED]	01-13-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures, drug table, and adverse effects. Additional discussion during the meeting included: a. None.			
7. # [REDACTED]	D Y	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA amendment.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
8. # [REDACTED]	D	[REDACTED]	01-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	C	[REDACTED]	01-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of statistical justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending CHEM</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
12. # [REDACTED]	C	[REDACTED]	01-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
14. # [REDACTED]	C	[REDACTED]	01-20-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D	[REDACTED]	01-21-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. IACUC staff to confirm with PI all grant sources are included.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
16. #	C		01-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
18. #	D		01-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures and animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D		01-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Typo correction.</p> <p>b. Clarification of numbers justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending MOU with ANR.</p>			
21. #	C		01-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		01-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	B		01-08-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	C	[REDACTED]	01-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Potentially useful references provided.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	D	[REDACTED]	01-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
27. # [REDACTED]	D	[REDACTED]	01-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of order of events and timing of repetition.</p> <p>b. Addition of potential complication.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
2. # [REDACTED]		[REDACTED]	01-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. Pending PI.			
4. # [REDACTED]	D Y	[REDACTED]	01-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed her review and provided an updated VHSS. Additional discussion during the meeting included: a. None.			
5. # [REDACTED]	D Y	[REDACTED]	01-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	D	[REDACTED]	01-20-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
7. # [REDACTED]	D	[REDACTED]	01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. # [REDACTED]	D	[REDACTED]	01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
9. # [REDACTED]	D	[REDACTED]	01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. VHSS added to protocol Additional discussion during the meeting included: a. None.			
10. # [REDACTED]	E	[REDACTED]	01-20-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
11. # [REDACTED]	E	[REDACTED]	01-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on procedure and potential adverse effects Additional discussion during the meeting included:			

	a. None.		
12. #			01-20-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on terminology</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	D		01-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding negative outcomes and fur growth.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D		01-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	C		01-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of sampling time points.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	C		01-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of dose and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
18. #	C		01-20-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	E		01-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		01-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
21. #	D		01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
22. #	C		01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
23. #	D		01-08-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
24. #	D		01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
25. #	E		01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
26. #	D		01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
27. #	D Y		01-12-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
28. #	D Y		01-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Suggested veterinary referral.			
Additional discussion during the meeting included:			
a. None.			
29. #	D		01-21-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
30. # [REDACTED]	E	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer			
31. # [REDACTED]	E	[REDACTED]	01-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 152 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	01-21-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Addition of water testing parameter.b. Addition of antifungal. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. Discussed water quality testing parameters and CVS recommendations. <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
2. # [REDACTED]	E	[REDACTED]	01-21-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0		
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												

	Present	18											
3. #	D		01-21-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
4. #	D		01-29-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Done. Additional discussion during the meeting included: a. Pending PI. Voted to send to DR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
5. #	E		01-21-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Need updated EPA justification for endpoint													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	1	Present	18
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	1												
Present	18												
6. #	D		02-04-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification requested on several procedures. PI has not completed required training and OHSS. Chemical safety review in progress. Additional discussion during the meeting included: a. Tabled.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												

7. # [REDACTED]	D	[REDACTED]	02-18-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested on several procedures. PI has not completed required training and OHSS. Chemical safety review in progress.</p> <p>Additional discussion during the meeting included:</p> <p>a. Tabled.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
8. # [REDACTED]	D Y	[REDACTED]	01-26-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Committee agreed PI needs to include a literature search due to potential adverse effects and change category to D.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
9. # [REDACTED]	D Y	[REDACTED]	01-22-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Vendor correction.</p> <p>b. Recommend including LRD rate range.</p> <p>c. Anesthetic clarification and recommendation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
10. # [REDACTED]	C	[REDACTED]	01-21-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of rodent survival surgery policy.</p> <p>b. Clarification of non-usp designation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												

11. # [REDACTED]	C Y [REDACTED]	01-21-2021
------------------	----------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		01-31-2019	01-21-2021	01-31-2022
	D		01-24-2019	01-21-2021	01-24-2022
	D		01-24-2019	01-21-2021	01-24-2022
	D		01-30-2019	01-21-2021	01-30-2022
	D		01-24-2019	01-21-2021	01-24-2022
	D		01-31-2019	01-21-2021	01-31-2022
	D Y		01-16-2019	01-21-2021	01-16-2022
	C		02-05-2019	01-21-2021	02-05-2022
	C		01-30-2019	01-21-2021	01-30-2022
	C		02-04-2019	01-21-2021	02-04-2022
	D		02-05-2019	01-21-2021	02-05-2022
	C Y		01-25-2019	01-21-2021	01-25-2022
	C		01-24-2019	01-21-2021	01-24-2022
	D		02-05-2019	01-21-2021	02-05-2022
	D Y		01-25-2019	01-21-2021	01-25-2022
	D		02-04-2019	01-21-2021	02-04-2022
	C		02-05-2019	01-21-2021	02-05-2022

	C		02-04-2019	01-21-2021	02-04-2022
	D		01-24-2019	01-21-2021	01-24-2022
	C		01-24-2019	01-21-2021	01-24-2022
	C		02-01-2019	01-21-2021	02-01-2022
	C		02-05-2019	01-21-2021	02-05-2022
	C		01-28-2020	01-20-2022	01-28-2023
	D Y		01-23-2020	01-20-2022	01-23-2023
	C		02-06-2020	02-03-2022	02-06-2023
	C		02-06-2020	02-03-2022	02-06-2023
	D		02-05-2020	02-03-2022	02-05-2023
	C		02-06-2020	01-21-2021	02-06-2022
	D		02-06-2020	02-03-2022	02-06-2023
	D		02-06-2020	02-03-2022	02-06-2023
	D		01-24-2020	01-20-2022	01-24-2023
	C Y		02-06-2020	02-03-2022	02-06-2023
	C Y		01-27-2020	01-20-2022	01-27-2023
	D		02-06-2020	02-03-2022	02-06-2023
	C		02-06-2020	02-03-2022	02-06-2023
	D Y		02-06-2020	02-03-2022	02-06-2023
	C		02-04-2020	01-20-2022	02-04-2023
	C		02-06-2020	02-03-2022	02-06-2023
	C		02-06-2020	02-03-2022	02-06-2023
	C		02-04-2020	01-20-2022	02-04-2023
	D		02-06-2020	02-03-2022	02-06-2023
	D Y		02-06-2020	02-03-2022	02-06-2023
	D		02-06-2020	02-03-2022	02-06-2023
	D		02-06-2020	02-03-2022	02-06-2023

	D		02-06-2020	02-03-2022	02-06-2023
--	---	--	------------	------------	------------

Discussion:	<p>Permit information on protocol is expired. PI provided updated information.</p> <p>-SOP for husbandry care had been inadvertently left off during the original review. PI provided SOP.</p> <p>and At least one staff member is showing as having an expired occupational health process. They are all on the last step; appointment.</p>										
Action Items:	<p>-Committee approved updating the permit information.</p> <p>-Committee approved attaching the SOP to the protocol</p> <p>and -The committee approved the annual renewals with those statuses pending.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>16</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	01-21-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chem safety review and VHSS. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	1	Present	18
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	1												
Present	18												
2. # [REDACTED]	C Y	[REDACTED]	01-21-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
3. # [REDACTED]	D	[REDACTED]	01-21-2021										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. 2nd reviewer approved verbally.

IACUC Vote

Approval	16
Withhold Approval	0
Abstain	1
Present	17

4. #	D Y	01-21-2021
------	-----	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Chem safety review and VHSS.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	17
Withhold Approval	0
Abstain	1
Present	18

5. #		01-21-2021
------	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	18
Withhold Approval	0
Abstain	0
Present	18

6. #	D	01-21-2021
------	---	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	18
Withhold Approval	0
Abstain	0
Present	18

7. #	D Y	01-21-2021
------	-----	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote


<table><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>18</td></tr></table>				Approval	17	Withhold Approval	0	Abstain	1	Present	18		
Approval	17												
Withhold Approval	0												
Abstain	1												
Present	18												
8. #		D Y	01-21-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	1	Present	18
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	1												
Present	18												
9. #		D Y	01-21-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	1	Present	18
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	1												
Present	18												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
Discussion:	None.
Action:	None.

There are no Animal Housing Facility Inspections for this agenda.

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 01-13-2021	LAB	
2. 01-13-2021	LAB	
3. 01-19-2021	LAB	
4. 01-19-2021	LAB	
Discussion: None.		
Action: None.		
<div><div>IACUC Vote</div><div>Approval 18</div><div>Withhold Approval 0</div></div>		

Abstain	0
Present	18

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. Completion of AALAS Library Courses.	
Discussion:	5 members have not completed all assigned classes to date. 2 members reported they were having IT issues.
Action:	IACUC staff to send out an additional reminder email to the 5 members who still have courses to complete.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

February 04, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M111, A095, M092, A019, M119, M087, A109, M110, M093, A013, M024, M001, M114

Excused:

M102, M090, M042, M004, M016, M112

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the January 21, 2021, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

II. Protocols Tabled From Previous Meetings:

1. # [REDACTED]	Category: D										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI clarified potential adverse effects and local anesthesia for genotyping. Additional discussion during the meeting included: a. Approved by committee vote.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>15</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>		IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote											
Approval	15										
Withhold Approval	0										
Abstain	0										
Present	15										
2. # [REDACTED]	Category: D										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI clarified potential adverse effects and local anesthesia for genotyping. The protocol is still pending final chemical safety review. Additional discussion during the meeting included: a. Voted to send to DMR.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0				
IACUC Vote											
Approval	0										
Withhold Approval	0										

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA. Biosafety officer stated the BUA will be reviewed at the 2/22/21 meeting.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
6. # [REDACTED]	D	[REDACTED]	01-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. clarification of statistical justification</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	02-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures and postop care</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D	[REDACTED]	02-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of endpoints.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	C	[REDACTED]	02-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	01-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Protocol updated to include all funding sources.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D Y	[REDACTED]	02-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Biosafety officer confirmed the BUA had been approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

12. # [REDACTED]	D	[REDACTED]	01-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of drugs.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures, drugs, adverse effects, and personnel.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer's verbiage recommendation.</p>			
14. # [REDACTED]	B	[REDACTED]	01-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending MOU.</p>			
16. # [REDACTED]	D	[REDACTED]	01-29-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of source of animals and locations.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	02-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	02-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D Y	[REDACTED]	01-26-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI provided clarification regarding final disposition of any animals that sero-convert.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending verbiage recommendation of reviewer.</p>			
21. #	D Y		01-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify source.</p> <p>b. LRS rate range recommended for increased flexibility.</p> <p>c. Clarify the use of xylazine vs dexmedetomidine; suggest including dexmedetomidine as alternative option to xylazine. (DR)</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of objectives and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
23. #	B		02-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	C		02-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	C		01-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	B Y		02-04-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
28. #	D		01-26-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
29. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending clarification on animal numbers and potential adverse effects. Additional discussion during the meeting included: a. Remains in DMR.			
30. #	D		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding procedure details. Additional discussion during the meeting included: a. Remains in DMR.			
31. #	C Y		02-04-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
32. #	C		02-04-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
33. #	D		02-04-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification provided regarding animals numbers, anesthesia details, monitoring and potential adverse effects. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	C		02-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			

Additional discussion during the meeting included: a. None.			
2. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
3. #	D Y		02-01-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
4. #	D		02-01-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
5. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
6. #	D		02-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
7. #	D Y		02-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. #	D		02-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on justification Additional discussion during the meeting included: a. None.			
9. #	D Y		01-25-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
10. #	D Y		02-02-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on adverse effect</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D Y		01-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	D Y		01-25-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D Y		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D Y		01-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D	nograft	01-25-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D Y		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	D Y		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D		02-04-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		01-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	C		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D Y		02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D Y		01-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	D		02-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	D Y		02-04-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
29. #	C		01-29-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
30. #	D		01-29-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on procedure Additional discussion during the meeting included: a. None.			
31. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response to CHEM Additional discussion during the meeting included: a. None.			
32. #	E		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
33. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending BIO			
34. #	D Y		02-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
35. #	E		02-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
36. #	D		02-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer confirmed no new VHSS was required.			

Additional discussion during the meeting included:
a. None.

VIII. Administrative and Veterinary Verification Amendments:

Total of 73 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	02-18-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI Response, voted for DR</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
2. # [REDACTED]	D Y	[REDACTED]	02-17-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Wording clarification.</p> <p>b. Additional search strategy recommended.</p> <p>c. VHSS required for Anakinra and Celestone; attached per Chemical Safety Officer.</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved for DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
3. # [REDACTED]	D	[REDACTED]	02-04-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested regarding MTD studies. Pending final review by the chemical safety officer.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to designated review.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												

4. #	D		02-04-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of LPS reference. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>16</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	16	Withhold Approval	0	Abstain	1	Present	17
IACUC Vote													
Approval	16												
Withhold Approval	0												
Abstain	1												
Present	17												
5. #	D		02-04-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. VHSS updated as well as BUA staff roster. Additional discussion during the meeting included: a. Approved by committee vote.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
6. #	D		02-16-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI's OHSS. Reviewers request clarification on procedures. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
7. #	B Y		02-04-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>16</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>16</td></tr></table>				IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote													
Approval	16												
Withhold Approval	0												
Abstain	0												
Present	16												
8. #	E		02-04-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. request DMR so PI can add more about monitoring.													

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	17

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		02-11-2019	02-04-2021	02-11-2022
	D		02-07-2019	02-04-2021	02-07-2022
	D		02-07-2019	02-04-2021	02-07-2022
	C		02-13-2019	02-04-2021	02-13-2022
	D Y		02-07-2019	02-04-2021	02-07-2022
	C		02-07-2019	02-04-2021	02-07-2022
	C		02-07-2019	02-04-2021	02-07-2022
	D		02-07-2019	02-04-2021	02-07-2022
	D		02-11-2019	02-04-2021	02-11-2022
	C		02-11-2019	02-04-2021	02-11-2022
	C		02-06-2019	02-04-2021	02-06-2022
	C		02-06-2019	02-04-2021	02-06-2022
	D Y		02-14-2019	02-04-2021	02-14-2022
	D Y		02-07-2019	02-04-2021	02-07-2022
	B Y		02-11-2019	02-04-2021	02-11-2022
	C		02-19-2019	02-04-2021	02-19-2022
	D		02-20-2020	02-17-2022	02-20-2023
	E		02-12-2020	02-04-2021	02-12-2022
	C		02-13-2020	02-03-2022	02-13-2023
	C		02-11-2020	02-03-2022	02-11-2023

	E		02-11-2020	02-04-2021	02-11-2022
	C		02-12-2020	02-03-2022	02-12-2023
	C		02-12-2020	02-03-2022	02-12-2023
	D Y		02-13-2020	02-03-2022	02-13-2023
	D Y		02-20-2020	02-17-2022	02-20-2023
	C		02-13-2020	02-03-2022	02-13-2023
	E Y		02-20-2020	02-17-2022	02-20-2023
	C		02-20-2020	02-04-2021	02-20-2022
	D Y		02-07-2020	02-03-2022	02-07-2023
	D		02-12-2020	02-03-2022	02-12-2023
	D		02-18-2020	02-03-2022	02-18-2023
	C		02-18-2020	02-03-2022	02-18-2023
	C		02-18-2020	02-03-2022	02-18-2023
	D		02-11-2020	02-03-2022	02-11-2023
	C		02-19-2020	02-17-2022	02-19-2023
	C		02-20-2020	02-17-2022	02-20-2023
	C		02-19-2020	02-17-2022	02-19-2023
	C Y		02-20-2020	02-17-2022	02-20-2023

Discussion:	<p>PI listed in section 11.</p> <p>& -permit listed on protocol has expired. PI's provided updated permit information.</p> <p>-Review of physical methods of euthanasia and 2020 AVMA Guidelines. PI provided updated wording for justification for RCC method.</p> <p>and</p> <p>One or more persons is in process of completing their OHSS renewal. They are pending the final step of completing an in person appointment.</p>
Action Items:	<p>working on MOU.</p> <p>& -Committee approved updating the protocols with the permit information.</p> <p>-PI provided an update to justification for physical method. Committee approved adding the wording to the protocol.</p> <p>and</p> <p>Committee approved annual renewals.</p>

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D	[REDACTED]	02-04-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure justification</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>16</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>1</td> </tr> <tr> <td>Present</td> <td>17</td> </tr> </table>				IACUC Vote		Approval	16	Withhold Approval	0	Abstain	1	Present	17
IACUC Vote													
Approval	16												
Withhold Approval	0												
Abstain	1												
Present	17												
2. # [REDACTED]	E	[REDACTED]	02-04-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>16</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>1</td> </tr> <tr> <td>Present</td> <td>17</td> </tr> </table>				IACUC Vote		Approval	16	Withhold Approval	0	Abstain	1	Present	17
IACUC Vote													
Approval	16												
Withhold Approval	0												
Abstain	1												
Present	17												
3. # [REDACTED]	D	[REDACTED]	02-04-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed proposed plan to ameliorate adverse effect.</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved by committee vote.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>17</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>17</td> </tr> </table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
4. # [REDACTED]	D Y	[REDACTED]	02-04-2021										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>16</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	16	Withhold Approval	0	Abstain	1	Present	17
IACUC Vote													
Approval	16												
Withhold Approval	0												
Abstain	1												
Present	17												
5. #	C		02-04-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed stage of development and whether an amendment was required. Committee agreed the PI had provided justification to ensure animals are immediately deemed unconscious and would not experience pain or distress. Additional discussion during the meeting included: a. Approved by committee vote.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
6. #	D Y		02-04-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>16</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	16	Withhold Approval	0	Abstain	1	Present	17
IACUC Vote													
Approval	16												
Withhold Approval	0												
Abstain	1												
Present	17												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 01-19-2021	
2. 01-21-2021	
3. 01-26-2021	

Discussion:	None.
Action:	None.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	LAB	
	PAM	
	PAM	
	PAM	
	PAM	

Discussion:	14. After the last IACUC meeting and discussion, the PAM was resented to the PI to update her protocol grants. 16. The PAM was updated after the last meeting to include additional deficiencies and request for PI to hire a well trained lab manager.										
Action:	14. PI updated new protocol to include all granting sources. 16. PI has agreed to supervisor staff during procedures until a lab manager has been hired.										
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. 4th qrtr fluid report	
Discussion:	One husbandry staff fluid error previously reported; no animal welfare concerns.
Action:	.
2. VMTH Equine anesthesia SOP	
Discussion:	Only minor typos and grammatical changes were suggested.
Action:	Approved by committee vote.
3. Wild geese	
Discussion:	None.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

February 18, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M111, M090, M042, A095, M004, M092, A019, M119, M087, A109, M110, M120, M093, A013, M024, M001, M114

Excused:

M102, M016, M112

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
CARU fire
Action: Under investigation. Storage area only, no animal housing.
■ ■
Action: Amendment submitted will be reviewed at the next meeting.
■ ■
Action: Miscommunication regarding housing return and monitoring. No animal welfare issues; noted as PAM.
■ ■
Action: Discrepancy in genotyping dates and procedures.
Holding protocol - ■ ■
Action: Animals ordered via special order were not entered into the ATS as an import request. AV working with vendor to clarify health status before putting animals in the general population.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Chem</p>			
2. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
3. # [REDACTED]	D	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on terminology</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
5. # [REDACTED]	C	[REDACTED]	02-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	C	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

8. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending MOU</p>			
9. # [REDACTED]	C	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of study design, procedures, and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final review by chemical safety.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
11. # [REDACTED]	D Y	[REDACTED]	02-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Typos corrected for clarification.</p> <p>b. Additional search strategy suggested for PI's consideration.</p> <p>c. New VHSS sheets uploaded from Chem Safety.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C	[REDACTED]	02-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. Pending PI.			
15. # [REDACTED]	D	[REDACTED]	02-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of MTD study details and animal numbers justification provided by PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	02-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on timepoints</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	C	[REDACTED]	02-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding potential adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	02-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided numbers justification and demographics of study animals.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	D	[REDACTED]	02-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Final review completed by the biosafety office and VHSS' updated based on biosafety review.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	C	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. Pending Review of responses			
23. # [REDACTED]	E	[REDACTED]	02-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of anesthesia and analgesia. b. clarification of post procedure monitoring. c. Clarification of timeline. d. Clarification of when CVS will be contacted. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
24. # [REDACTED]	C Y	[REDACTED]	02-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
25. # [REDACTED]	C	[REDACTED]	02-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
26. # [REDACTED]	C Y	[REDACTED]	02-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
27. # [REDACTED]	C	[REDACTED]	02-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. PI confirmed campus breeding SOP would be followed. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI. 			
2. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending reviewer. 			

3. # [REDACTED]	C	[REDACTED]	02-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
5. # [REDACTED]	D	[REDACTED]	02-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D	[REDACTED]	02-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	E	[REDACTED]	02-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	C	[REDACTED]	02-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Discussed the intent of the amendment and the original objective of the protocol.</p>			
9. # [REDACTED]	D Y	[REDACTED]	02-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	02-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D Y	[REDACTED]	02-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

12. # [REDACTED]	C	[REDACTED]	02-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C Y	[REDACTED]	02-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Anesthetic choice and procedure clarifications.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	B	[REDACTED]	02-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D Y	[REDACTED]	02-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	02-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	02-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending verification of Lab SOP</p>			
19. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending verification of Lab SOP</p>			
20. # [REDACTED]	C	[REDACTED]	02-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on contaminated bedding disposal.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

21. # [REDACTED]	D Y	[REDACTED]	02-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
22. # [REDACTED]	C	[REDACTED]	02-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
23. # [REDACTED]	E	[REDACTED]	02-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
24. # [REDACTED]	D Y	[REDACTED]	02-10-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of adverse effects. Additional discussion during the meeting included: a. None.			
25. # [REDACTED]	D	[REDACTED]	02-08-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 174 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	E	[REDACTED]	02-22-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Pending final edit by PI

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	21

2. #	D Y	04-14-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Voted for DR, responses need to be reviewed, and new questions have arisen												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	21											
3. #	D Y	02-18-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Expand literature date range. b. Reword for clarity. c. Edited to reflects standard text and SOPs. Additional discussion during the meeting included: a. None.												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	21											
Withhold Approval	0											
Abstain	0											
Present	21											
4. #	D	02-18-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification provided regarding humane endpoints and weight loss and chemical safety provided updated VHSS. Additional discussion during the meeting included: a. Voted to approve.												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>			IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	20											
Withhold Approval	0											
Abstain	0											
Present	20											
5. #	D Y	03-30-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Voted for DR, responses need to be reviewed, and new questions have arisen												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	21											
6. #	D Y	02-18-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarify study groups.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

7. # [REDACTED] B Y [REDACTED] 02-22-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Pending PI response

Additional discussion during the meeting included:

- a. Assigned to DMR

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

8. # [REDACTED] D Y [REDACTED] 02-18-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

9. # [REDACTED] C Y [REDACTED] 02-18-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

10. # [REDACTED] D Y [REDACTED] 02-24-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Ongoing discussion between veterinarians regarding appropriate anesthetic plan

Additional discussion during the meeting included:

- a. Assigned to DMR

IACUC Vote	
Approval	0

<table><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				Withhold Approval	0	Abstain	0	Present	21				
Withhold Approval	0												
Abstain	0												
Present	21												
11. #	D Y		02-24-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. Ongoing discussion between veterinarians regarding appropriate anesthetic plan													
Additional discussion during the meeting included:													
a. Assigned to DMR													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		02-21-2019	02-18-2021	02-21-2022
	C		02-19-2019	02-18-2021	02-19-2022
	D Y		02-21-2019	02-18-2021	02-21-2022
	D		03-01-2019	02-18-2021	03-01-2022
	C		02-21-2019	02-18-2021	02-21-2022
	D Y		02-21-2019	02-18-2021	02-21-2022
	D		02-21-2019	02-18-2021	02-21-2022
			02-28-2019	02-18-2021	02-28-2022
	D Y		02-22-2019	02-18-2021	02-22-2022
	D		02-21-2019	02-18-2021	02-21-2022
	C		02-21-2019	02-18-2021	02-21-2022
	C		02-20-2019	02-18-2021	02-20-2022
	D		02-21-2019	02-18-2021	02-21-2022
	C Y		02-21-2019	02-18-2021	02-21-2022
	D Y		02-21-2019	02-18-2021	02-21-2022
			02-20-2020	02-17-2022	02-20-2023

	D		02-25-2020	02-17-2022	02-25-2023
	C		02-04-2020	02-18-2021	02-04-2022
	C Y		02-05-2020	02-17-2022	02-05-2023
	D		02-25-2020	02-17-2022	02-25-2023
	C		02-28-2020	02-17-2022	02-28-2023
	C		03-05-2020	03-03-2022	03-05-2023
	D Y		03-04-2020	02-17-2022	03-04-2023
	D		03-04-2020	02-17-2022	03-04-2023
	C		03-05-2020	03-03-2022	03-05-2023
	D Y		03-04-2020	02-17-2022	03-04-2023
	D Y		02-21-2020	02-17-2022	02-21-2023
	C		03-03-2020	02-17-2022	03-03-2023
	D		03-05-2020	03-17-2022	03-05-2023
	C		03-05-2020	03-17-2022	03-05-2023
	C Y		02-28-2020	02-18-2021	02-28-2022
	D		03-02-2020	02-17-2022	03-02-2023
	D		03-05-2020	03-03-2022	03-05-2023
	C		02-24-2020	02-17-2022	02-24-2023
	D		03-05-2020	02-18-2021	03-05-2022
	C		03-04-2020	02-17-2022	03-04-2023
	D		03-05-2020	03-03-2022	03-05-2023
	C		03-05-2020	03-03-2022	03-05-2023
	C		03-04-2020	02-17-2022	03-04-2023
	C		03-04-2020	02-17-2022	03-04-2023
	C		03-05-2020	03-03-2022	03-05-2023

Discussion: [REDACTED] and
 [REDACTED]: At least one staff member is in the process of renewing their
 occupational health status. All are in the last step either requiring an

██████████ and ██████████-permits on protocols are expired. ██████████ is not active and permit will be obtained prior to starting studies again. ██████████ permit is pending CDFW.

██████████ and ██████████-Annual renewals approved.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

Discussion: 2. PI maintained area approved for hand washing with QA testing verification. Re-testing was not performed on cage that failed QA testing.

Action: 2. PI acknowledges and will follow plan to implement QA testing in advance to ensure re-testing occurs prior to animals being housed on campus.

IACUC Vote

Approval	20
Withhold Approval	0
Abstain	0
Present	20

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 11-10-2020	LAB	
2. 01-20-2021	LAB	
3. 11-27-2019	PAM	
4. 06-30-2020	PAM	
5. 07-07-2020	PAM	
6. 10-15-2020	PAM	
7. 10-23-2020	PAM	
8. 11-10-2020	PAM	
9. 12-01-2020	PAM	
10. 12-01-2020	PAM	
11. 12-02-2020	PAM	
12. 12-23-2020	PAM	
13. 12-27-2020	PAM	
14. 01-15-2021	PAM	
15. 01-28-2021	PAM	
16. 02-05-2021	PAM	
17. 02-10-2021	PAM	

Discussion: None.

Action: Approved.

IACUC Vote

Approval	20
Withhold Approval	0
Abstain	0
Present	20

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic
1) Policy Subcommittee re-instatement- call for volunteers
Discussion: Role of subcommittee, anticipated meeting frequency, and current members. Request for additional volunteers.
Action: Volunteers asked to contact IACUC Chair or Director. If no volunteers, subcommittee appointments will be made by IACUC Chair per policy.
2) Ag Animal: Analgesia and Anesthesia subcommittee

Discussion:	Role of subcommittee, anticipated meeting frequency, and current members. Request for additional volunteers.
Action:	Volunteers asked to contact IACUC Chair or Director. If no volunteers, subcommittee appointments will be made by IACUC Chair per policy.
3) [REDACTED]	47 mice to holding protocol
Discussion:	None.
Action:	None.
4) FYI - USDA incentive program ending	
Discussion:	FYI.
Action:	None.
5) FYI - OHSS: COVID vaccination and TB testing delay	
Discussion:	FYI. 4 week delay recommended. May delay completion of TB testing in timely manner for individuals receiving COVID-19 vaccination if there is overlap. Recognize individuals receiving vaccine may not always have ability to plan ahead or around this depending on short notice of vaccine distribution and availability.
Action:	Approved.
6) New IACUC member introduction.	
Discussion:	Attendance of first required meeting.
Action:	In training with IACUC staff.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

March 04, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M222, M102, M111, M090, A095, M004, M092, A019, M119, M087, A109, M110, M120, M093, A013, M016, M024, M001, M112, M114

Excused:

M042

Guests:

M116, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the January 7, 2021, meeting minutes as written.

IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16

The IACUC reviewed and approved the February 4, 2021, meeting minutes as written.

IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16

The IACUC reviewed and approved the February 18, 2021, meeting minutes as written.

IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

	Action: PI submitted an amendment to change behavioral testing time point. Reviewed under FC amendments along with PAM.
	SAEN "news release" and USDA complaint
	Action: FYI only, "news release" not factual and non event. Old USDA complaint; previously addressed.
	Action: PI submitted an amendment to clarify incident. Approved procedure followed with euthanasia.
Expired	
	Action: ATS issue, not procedural issue.
	CARU break-in
	Action: FYI; under police investigation.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. #	E		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. #	D Y		02-23-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA approved by biosafety.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	E		02-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

5. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's response to clarify procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
6. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	02-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed their review and provided VHSS for section 19.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D	[REDACTED]	02-24-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of numbers and drugs.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	B Y	[REDACTED]	02-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	C	[REDACTED]	03-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of drug dose.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of standard-of-care and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
13. # [REDACTED]	C	[REDACTED]	03-04-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of abbreviations and stem cell dose.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
15. #	D		03-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of blood collection.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
17. #	C		03-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	D		03-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on husbandry care</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of post-sedation monitoring and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
20. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of numbers justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		03-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. None.			
22. #	D Y		02-24-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on procedure, anesthesia and blood collection Additional discussion during the meeting included: a. None.			
23. #	C Y		03-03-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on husbandry care Additional discussion during the meeting included: a. None.			
24. #	C		02-25-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
25. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures in pre and post-weaned mice. Additional discussion during the meeting included: a. Pending PI.			
2. #	C Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Disposition. Additional discussion during the meeting included: a. Reviewer requested additional time to review disposition.			
3. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI response.			

4. # [REDACTED]	C	[REDACTED]	03-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
5. # [REDACTED]	D Y	[REDACTED]	02-25-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	D Y	[REDACTED]	02-26-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
7. # [REDACTED]	D	[REDACTED]	03-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. # [REDACTED]	D	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
9. # [REDACTED]	E	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
10. # [REDACTED]	C	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
11. # [REDACTED]	D	[REDACTED]	03-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
12. # [REDACTED]	C Y	[REDACTED]	03-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

13. # [REDACTED]	C	[REDACTED]	03-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of caging process.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	C	[REDACTED]	03-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI.</p>			
16. # [REDACTED]	D	[REDACTED]	03-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	03-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	03-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]		[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
20. # [REDACTED]	C	[REDACTED]	03-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on husbandry care.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]		[REDACTED]	02-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
22. #	D		03-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided about change in dose applying to all animals in highest dose group. No other changes requested and no new adverse effects are anticipated.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #			03-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	E		03-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding padding under equipment.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	D		02-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed their review and provided a new VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D Y		03-04-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
31. #	C		03-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 146 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	03-08-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Clarify duration between lens replacement.b. Clarify exclusion criteria. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. Approved for designated review. <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	23												
2. # [REDACTED]	C Y	[REDACTED]	03-04-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. Final OHSS clearance step delay approved through Employee Health. <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	1	Present	23
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	1												
Present	23												
3. # [REDACTED]	D Y	[REDACTED]	03-04-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. None. <p>Additional discussion during the meeting included:</p>													

a. None.

IACUC Vote	
Approval	23
Withhold Approval	0
Abstain	0
Present	23

4. #

D

03-04-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification on procedure and adverse effects

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	24
Withhold Approval	0
Abstain	0
Present	24

5. #

D

03-04-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	24
Withhold Approval	0
Abstain	0
Present	24

6. #

D Y

03-04-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	23
Withhold Approval	0
Abstain	0
Present	23

7. #

D Y

03-04-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. All question addressed during the pre-review process.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	24
Withhold Approval	0

	Abstain	0
	Present	24

8. # [REDACTED]	C	[REDACTED]	03-04-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification on literature search and disposition

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	24
Withhold Approval	0
Abstain	0
Present	24

9. # [REDACTED]	D	[REDACTED]	03-17-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification on injections

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	24

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	C	[REDACTED]	03-06-2019	03-04-2021	03-06-2022
[REDACTED]	D Y	[REDACTED]	03-12-2019	03-04-2021	03-12-2022
[REDACTED]	D	[REDACTED]	03-06-2019	03-04-2021	03-06-2022
[REDACTED]	D Y	[REDACTED]	03-07-2019	03-04-2021	03-07-2022
[REDACTED]	D	[REDACTED]	03-12-2019	03-04-2021	03-12-2022
[REDACTED]	E	[REDACTED]	03-07-2019	03-04-2021	03-07-2022
[REDACTED]	C Y	[REDACTED]	03-07-2019	03-04-2021	03-07-2022
[REDACTED]	C	[REDACTED]	03-07-2019	03-04-2021	03-07-2022
[REDACTED]	C	[REDACTED]	03-18-2019	03-04-2021	03-18-2022
[REDACTED]	C	[REDACTED]	03-19-2019	03-04-2021	03-19-2022
[REDACTED]	D Y	[REDACTED]	03-09-2020	03-03-2022	03-09-2023

	B		03-13-2020	03-03-2022	03-13-2023
	D		03-19-2020	03-17-2022	03-19-2023
	C		03-19-2020	03-17-2022	03-19-2023
	D		03-19-2020	03-17-2022	03-19-2023
	D		03-10-2020	03-03-2022	03-10-2023
	D Y		03-19-2020	03-17-2022	03-19-2023
	D		03-06-2020	03-03-2022	03-06-2023
	D Y		03-19-2020	03-17-2022	03-19-2023
	C		03-19-2020	03-17-2022	03-19-2023
	D		03-19-2020	03-17-2022	03-19-2023
	D Y		03-19-2020	03-17-2022	03-19-2023
	D		03-19-2020	03-17-2022	03-19-2023
	D		03-19-2020	03-17-2022	03-19-2023
	D Y		03-19-2020	03-17-2022	03-19-2023
	C		03-19-2020	03-17-2022	03-19-2023
	D		03-18-2020	03-03-2022	03-18-2023

Discussion: [REDACTED] Permit information on protocol is expired. PI provided updated permit information.

[REDACTED] -Permit information on protocol is expired. PI reports no work is being done and permit will be acquired prior to work starting again.

[REDACTED] -One staff member is in the process of renewing their OHSS process; on the last step and needs to complete an in person appointment.

Action Items: [REDACTED] -Committee approved adding new permit information to protocol.
[REDACTED] -Committee approved annual renewal.
[REDACTED] -Committee approved the annual renewal.

IACUC Vote

Approval	23
Withhold Approval	0
Abstain	0
Present	23

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable

regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	03-18-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Additional review time requested by reviewer. Additional discussion during the meeting included: a. Approved for designated review.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	23												
2. # [REDACTED]	E	[REDACTED]	03-04-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of training. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>24</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	1	Present	24
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	1												
Present	24												
3. # [REDACTED]	D	[REDACTED]	03-16-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification requested regarding weight loss of obese mice and request to deviate from humane endpoints policy. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	23												
4. # [REDACTED]	D	[REDACTED]	03-04-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding euthanasia methods provided. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>24</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>24</td></tr></table>				IACUC Vote		Approval	24	Withhold Approval	0	Abstain	0	Present	24
IACUC Vote													
Approval	24												
Withhold Approval	0												
Abstain	0												
Present	24												
5. # [REDACTED]	D Y	[REDACTED]	03-04-2021										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. CNPRC SOP incorporates APV guidelines.

IACUC Vote

Approval	22
Withhold Approval	0
Abstain	1
Present	23

6. #	D Y	03-18-2021
------	-----	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification regarding grounding unit and verification of placement verification.

Additional discussion during the meeting included:

a. Amendment tabled.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	24

7. #	D	03-17-2021
------	---	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Request DMR for additional reviewer's question.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	23

8. #	C	03-04-2021
------	---	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. PI worked with TRACS to be able to house 7-8 breeding cages in holding room. All survival procedures will be completed in the shared procedure room.

Additional discussion during the meeting included:

a. Committee approved amendment.

IACUC Vote

Approval	23
Withhold Approval	0
Abstain	0
Present	23

9. #	D	03-04-2021
------	---	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification provided regarding assessment prior to behavioral testing by trained staff. Committee requesting additional adverse effects be added to section 3.

Additional discussion during the meeting included:

a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	23

10. #	D		05-04-2021
-------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. pending PI response request DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	23

11. #	D Y		03-04-2021
-------	-----	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	23
Withhold Approval	0
Abstain	0
Present	23

12. #	D Y		04-15-2021
-------	-----	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. PI clarified incident.

Additional discussion during the meeting included:

a. Tabled pending pathology results.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	23

13. #	D Y		03-04-2021
-------	-----	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. All questions addressed during pre-review.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	23
Withhold Approval	0
Abstain	0
Present	23

14. #	D Y	03-04-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:												
a. Clarification provided regarding timing of acquisition and studying starting points.												
Additional discussion during the meeting included:												
a. Committee approved the amendment.												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>			IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote												
Approval	23											
Withhold Approval	0											
Abstain	0											
Present	23											

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 10-28-2020	
2. 01-27-2021	
3. 01-28-2021	
4. 01-28-2021	
5. 01-29-2021	
6. 01-31-2021	
7. 01-31-2021	
8. 02-04-2021	
9. 02-05-2021	
10. 02-11-2021	
11. 02-11-2021	
12. 02-24-2021	
13. 02-24-2021	
14. 02-25-2021	
15. 02-25-2021	
16. 02-25-2021	
17. 02-26-2021	

Discussion:	3. Room log was missing entries on two dates.										
Action:	3. The PI clarified the animals were checked but the documentation was missed.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>20</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>20</td></tr> </tbody> </table>		IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	20										
Withhold Approval	0										
Abstain	0										
Present	20										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 02-08-2021	LAB	
2. 02-08-2021	LAB	
3. 02-10-2021	LAB	
4. 02-17-2021	LAB	
5. 02-18-2021	LAB	

6. 02-18-2021	LAB	
7. 02-22-2021	LAB	
8. 02-22-2021	LAB	
9. 02-23-2021	LAB	
10. 02-24-2021	LAB	
11. 02-25-2021	LAB	
12. 02-26-2021	LAB	
13. 12-01-2020	PAM	
14. 12-22-2020	PAM	
15. 02-18-2021	PAM	
16. 02-18-2021	PAM	
17. 02-18-2021	PAM	

Discussion:	<p>9. Room log was missing census and entries were not being initialed. One drug being used was non-pharmaceutical grade but not justified in protocol.</p> <p>15. PI contacted CVS the following day.</p> <p>16. Animals were purchased without CVS assessment. Animals were placed on holding protocol.</p> <p>17. PI submitted an amendment to verify start time of behavior testing.</p>										
Action:	<p>9. Lab has corrected form entries to prevent missing information in the future. Lab has ordered pharmaceutical grade drug.</p> <p>15. PI to ensure CVS is contacted right away for all future incidents.</p> <p>16. CVS released animals from holding protocol and transferred them to PI's protocol. PI is informed that these special requests must be entered in the ATS as an import request.</p> <p>17. PI ensures in the future amendments will be submitted and approved first prior to making adjustments to study details.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>23</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>23</td> </tr> </tbody> </table>		IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote											
Approval	23										
Withhold Approval	0										
Abstain	0										
Present	23										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. [REDACTED] status	
Discussion:	PI requests permission for one lab staff to be able to work independently on breeding procedures. PI is still overseeing all lab procedures with staff while he works to hire a lab manager. In interim, the PI request permission for lab staff to be able to complete breeding procedures without his direct supervision. This lab member was observed by CVS performing the genotyping procedure and it was done appropriately.
Action:	IACUC approved one staff member to perform breeding procedures of pairing, separating, genotyping and weaning independently.
2. SAPR	
Discussion:	Reviewed 7/2020 - 12/2020 Animal Care Program events, activities and action plans. Discussed SAPR format plans moving forward with recommendation to adopt OLAW template pending IO's approval.

Action:	None.
3. IACUC member training opportunity - PRIM&R Conference April 14-16, 2021. https://www.eventscribe.com/2021/IACUC21/	
Discussion:	Contact IACUC Director if interested.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

March 18, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M111, M042, A095, M004, M092, A019, M119, M087, A109, M110, M120, A013, M016, M024, M223, M001, M112, M114

Excused:

M222, M102, M090, M093

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1. #	Category: D Y										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding monitoring of equipment and contact with animals. Additional discussion during the meeting included: a. Committee voted to approve.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>		IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	20										
Withhold Approval	0										
Abstain	0										
Present	20										
2. #	Category: D Y										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending pathology report. Additional discussion during the meeting included: a. Tabled.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	20										

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

Action: Location.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending CHEM/EHS			
2. # [REDACTED]	E	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
3. # [REDACTED]	C	[REDACTED]	03-15-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding caging provided. Alternate contact's OHSS renewal is pending due to COVID vaccine and TB testing scheduling conflict. IACUC approves moving forward for OHSS situations of this nature. Additional discussion during the meeting included: a. None.			
4. # [REDACTED]	D Y	[REDACTED]	03-08-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response. Additional discussion during the meeting included: a. None.			
5. # [REDACTED]	D Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Location Clarification			

6. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending ANR protocol discussion.</p>			
7. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Location Clarification</p>			
8. # [REDACTED]	D	[REDACTED]	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI.</p>			
9. # [REDACTED]	D	[REDACTED]	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI.</p>			
10. # [REDACTED]	C	[REDACTED]	03-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of standard-of-care and experimental procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	C	[REDACTED]	03-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of standard-of-care and experimental procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer</p>			
13. # [REDACTED]	C	[REDACTED]	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

14. # [REDACTED]	C	[REDACTED]	03-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
16. # [REDACTED]	C	[REDACTED]	03-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of group numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	03-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending SCRO</p>			
19. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending SCRO</p>			
20. # [REDACTED]	C	[REDACTED]	03-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of exclusion criteria.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	C	[REDACTED]	03-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of exclusion criteria.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

22. # [REDACTED]	D	[REDACTED]	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer</p>			
24. # [REDACTED]	C Y	[REDACTED]	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	D	[REDACTED]	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending reviewer.</p>			
27. # [REDACTED]	D	[REDACTED]	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding monitoring of the animals provided.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. # [REDACTED]	D	[REDACTED]	03-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. # [REDACTED]	C	[REDACTED]	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. # [REDACTED]	C Y	[REDACTED]	03-15-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
31. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of inclusion and exclusion criteria, and adverse effects. Additional discussion during the meeting included: a. Pending reviewer.			
32. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA Additional discussion during the meeting included: a. Remains in DMR			
33. # [REDACTED]	C Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BIO Additional discussion during the meeting included: a. Remains in DMR			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	C	[REDACTED]	03-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
2. # [REDACTED]	D	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures. Additional discussion during the meeting included: a. Pending PI.			
3. # [REDACTED]	C Y	[REDACTED]	03-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Disposition. Additional discussion during the meeting included: a. None.			
4. # [REDACTED]	D Y	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			

Additional discussion during the meeting included: a. Pending PI.			
5. # [REDACTED]	D Y	[REDACTED]	03-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	D Y	[REDACTED]	03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Veterinarian to clarify wording/lay language terminology correction.			
7. # [REDACTED]	D	[REDACTED]	03-09-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. # [REDACTED]	E	[REDACTED]	03-10-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of DMSO grade. Additional discussion during the meeting included: a. None.			
9. # [REDACTED]	C	[REDACTED]	03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of anesthetic risks. Additional discussion during the meeting included: a. None.			
10. # [REDACTED]	D	[REDACTED]	03-17-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
11. # [REDACTED]	D	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Chem			
12. # [REDACTED]	D	[REDACTED]	03-09-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None Additional discussion during the meeting included: a. None.			
13. # [REDACTED]	D	[REDACTED]	03-15-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Removed personal information.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D		03-15-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Removed personal info.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D Y		03-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Faculty reviewer verbal approval at meeting.</p>			
16. #	D		03-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding humane endpoints, weight loss, and documentation for animals.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	C		03-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	C		03-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	E		03-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of dose rationale for acute and control doses.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		03-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #			03-15-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
22. #	C Y		03-17-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
23. #	Y		03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
24. #	C		03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
25. #	C		03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
26. #	D		03-17-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. clarification of when CVS was notified. Additional discussion during the meeting included: a. None.			
27. #	C		03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
28. #	Y		03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Faculty reviewer gave verbal approval at meeting.			
29. #	D		03-09-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
30. #	D		03-17-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Recommendations from the Chemical Hygiene Officer</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. #	D		03-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Chem</p>			
33. #	D		03-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding monitoring of animals and incision sites prior to behavioral testing.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
34. #	Y		03-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
35. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
36. #	D		03-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
37. #	D Y		03-10-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
38. #	E		03-04-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
39. #	D		03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
40. #	D		03-05-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
41. #	C		03-05-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
42. #	D Y		03-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Wording modifications requested for clarity. Additional discussion during the meeting included: a. None.			
43. #	C Y		03-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 156 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. #	D		03-18-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding animals numbers. Chemical safety officer completed review and provided updated VHSS. Additional discussion during the meeting included: a. Committee voted to approve.			

<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
2. #	D		03-18-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
3. #	D		03-18-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification and discussion on adverse effects Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
4. #	D		03-18-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
5. #	D		03-18-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification requested regarding potential adverse effects or toxicities. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0		
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												

Present 21											
6. # [REDACTED]	D Y [REDACTED] 03-18-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding housing of animals, identification procedures and staff expertise provided husbandry care.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>21</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>21</td></tr> </tbody> </table>		IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote											
Approval	21										
Withhold Approval	0										
Abstain	0										
Present	21										

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	C	[REDACTED]	3-28-2019	03-18-2021	03-28-2022
[REDACTED]	C	[REDACTED]	3-28-2019	03-18-2021	03-28-2022
[REDACTED]	D	[REDACTED]	3-21-2019	03-18-2021	03-21-2022
[REDACTED]	D	[REDACTED]	3-20-2019	03-18-2021	03-20-2022
[REDACTED]	D	[REDACTED]	4-01-2019	03-18-2021	04-01-2022
[REDACTED]	D	[REDACTED]	3-21-2019	03-18-2021	03-21-2022
[REDACTED]	D	[REDACTED]	3-21-2019	03-18-2021	03-21-2022
[REDACTED]	C	[REDACTED]	3-21-2019	03-18-2021	03-21-2022
[REDACTED]	C Y	[REDACTED]	3-21-2019	03-18-2021	03-21-2022
[REDACTED]	C	[REDACTED]	3-21-2019	03-18-2021	03-21-2022
[REDACTED]	C	[REDACTED]	3-21-2019	03-18-2021	03-21-2022
[REDACTED]	C	[REDACTED]	3-20-2019	03-18-2021	03-20-2022
[REDACTED]	C	[REDACTED]	3-21-2019	03-18-2021	03-21-2022
[REDACTED]	D	[REDACTED]	3-26-2019	03-18-2021	03-26-2022
[REDACTED]	C Y	[REDACTED]	3-21-2019	03-18-2021	03-21-2022

	C Y		3-21-2019	03-18-2021	03-21-2022
	C Y		3-21-2019	03-18-2021	03-21-2022
	C		3-27-2019	03-18-2021	03-27-2022
			3-21-2019	03-18-2021	03-21-2022
	C		3-28-2019	03-18-2021	03-28-2022
	C		3-28-2019	03-18-2021	03-28-2022
	C		4-02-2019	03-18-2021	04-02-2022
	C		3-25-2019	03-18-2021	03-25-2022
	D		4-02-2020	03-31-2022	04-02-2023
	D		4-01-2020	03-17-2022	04-01-2023
	D		3-24-2020	03-17-2022	03-24-2023
	C		3-19-2020	03-18-2021	03-19-2022
	D Y		4-02-2020	03-31-2022	04-02-2023
	C		4-02-2020	03-31-2022	04-02-2023
	C		4-02-2020	03-31-2022	04-02-2023
	C		3-21-2020	03-17-2022	03-21-2023
	D		3-24-2020	03-17-2022	03-24-2023
	C		3-31-2020	03-17-2022	03-31-2023
	D		4-01-2020	03-17-2022	04-01-2023
	C Y		4-02-2020	03-31-2022	04-02-2023
	E		3-23-2020	03-17-2022	03-23-2023
	D		4-02-2020	03-31-2022	04-02-2023
	C		3-20-2020	03-17-2022	03-20-2023
	C		4-02-2020	03-31-2022	04-02-2023
	C		3-26-2020	03-17-2022	03-26-2023
	C		3-26-2020	03-17-2022	03-26-2023
	D Y		4-02-2020	03-31-2022	04-02-2023

Discussion:	<p>At least one person on the roster is in the process of OHSS renewal and is awaiting an appointment.</p> <p>-Another veterinarian listed in section 11.</p>										
Action Items:	<p>-The committee approved the annual renewals.</p> <p>-AV is looking into MOU status.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D	[REDACTED]	06-22-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Amendment is pending review of new Core facilities SOPs.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
2. # [REDACTED]	D Y	[REDACTED]	03-18-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify which animals/groups this applies to.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
3. # [REDACTED]	C Y	[REDACTED]	03-18-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. CHO verification that VHSS is not needed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr></table>				IACUC Vote									
IACUC Vote													


<table><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			Approval	21	Withhold Approval	0	Abstain	0	Present	21		
Approval	21											
Withhold Approval	0											
Abstain	0											
Present	21											
4. # [REDACTED]	D Y [REDACTED]	03-18-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed extension of care for animals slow to recover.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>			IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	20											
Withhold Approval	0											
Abstain	0											
Present	20											
5. # [REDACTED]	E [REDACTED]	03-18-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	21											
Withhold Approval	0											
Abstain	0											
Present	21											
6. # [REDACTED]	D [REDACTED]	03-23-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewers, requested change of reviewer.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	22											

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 03-03-2021	[REDACTED]
2. 03-11-2021	
3. 03-18-2021	
Discussion:	None.
Action:	None.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

XIII. Laboratory/Study Area Inspections:



Inspection Date	Type	Location or Protocol
1. 02-23-2021	LAB	
2. 02-25-2021	LAB	
3. 02-25-2021	PAM	
4. 02-25-2021	PAM	
5. 02-25-2021	PAM	
6. 02-25-2021	PAM	
7. 02-25-2021	PAM	
8. 03-09-2021	PAM	
9. 03-11-2021	PAM	

Discussion:	3-7= PI findings during a TRACS facility inspection that showed marked improvement in post-op documentation and Hazardous cage card labeling. 8. PI working in non-approved lab space.										
Action:	3-7=Positive PAMs sent to PIs. 8. Amendments have been submitted and a lab inspection is being scheduled.										
<table> <tr> <td colspan="2">IACUC Vote</td></tr> <tr> <td>Approval</td><td>21</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>21</td></tr> </table>		IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote											
Approval	21										
Withhold Approval	0										
Abstain	0										
Present	21										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. PI maintain form.  	
Discussion:	Clarification provided on SOP, room log and PI maintain form regarding staff training and husbandry care.
Action:	Committee voted to approve PI maintain request.
2. Semi-annual program review update	
Discussion:	Will transition to modified OAW template.
Action:	None.
3. ANR update - FYI	
Discussion:	UC Merced will continue to cover through end of year. Recommendation for ANR to form own IACUC. AV and IACUC Director to further discuss with ANR.
Action:	FY - no IACUC action required at this time.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

**University of California, Davis
IACUC Business Administration System**

**April 01, 2021
Meeting Minutes**

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:**Present:**

M009, M097, M005, M222, M102, M090, A095, M004, M092, A019, M119, M087, A109, M110, M120, M093, A013, M223, M001, M114

Excused:

M111, M042, M016, M024, M112

Guests:

M116, A017

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the March 4, 2021, meeting minutes as written.

IACUC Vote

Approval	19
Withhold Approval	0
Abstain	0
Present	19

The IACUC reviewed and approved the March 18, 2021, meeting minutes as written.

IACUC Vote

Approval	19
Withhold Approval	0
Abstain	0
Present	19

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1	Category: D Y								
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending pathology report. Additional discussion during the meeting included: a. Tabled.									
IACUC Vote <table><tbody><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></tbody></table>		Approval	0	Withhold Approval	0	Abstain	0	Present	19
Approval	0								
Withhold Approval	0								
Abstain	0								
Present	19								

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

CNPRC

Action: Escape from SC, recaptured without incident.

Sheep Barn
Action: Predation requiring treatment of one animal; USDA depredation contacted, and they investigated and found no sign of the predators returning.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Chem</p>			
2. [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
3. [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Locations and AV.</p>			
4. [REDACTED]	D Y	[REDACTED]	03-30-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. [REDACTED]	B	[REDACTED]	03-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. [REDACTED]	C	[REDACTED]	03-23-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. [REDACTED]	B	[REDACTED]	04-01-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

8.		C		03-29-2021
----	--	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of breeding scheme.

b. Clarification of euthanasia method

Additional discussion during the meeting included:

a. None.

9.		D		03-23-2021
----	--	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

10.		C		03-29-2021
-----	--	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of standard-of-care, and procedures.

Additional discussion during the meeting included:

a. None.

11		D		03-30-2021
----	--	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

12		C		-
----	--	---	--	---

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending PI and Reviewer

13.		DY		-
-----	--	----	--	---

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending Pl.

14.		C		-
-----	--	---	--	---

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending Pl.

15.		E		04-01-2021
-----	--	---	--	------------

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16.		D	04-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Added VHSS</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17.		D	04-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on anesthesia, drugs administration and VHSS</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18.		C	04-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of standard-of-care, procedures, and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19.		D	04-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of post procedure monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20.		D	03-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding potential adverse effects and updated VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21.		C	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA approved</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22.		C Y	03-31-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

23. [REDACTED]	C	[REDACTED]	03-31-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Reviewers recommended brevity of section 12 for future submissions to prevent confusion of past studies compared with studies in the proposed protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. [REDACTED]	C Y	[REDACTED]	04-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. [REDACTED]	C	[REDACTED]	03-31-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on breeding and terminology</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. [REDACTED]	C	[REDACTED]	04-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. [REDACTED]	C	[REDACTED]	04-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. [REDACTED]	B	[REDACTED]	03-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. [REDACTED]	C	[REDACTED]	03-30-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. [REDACTED]	D	[REDACTED]	-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
2		D	04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3.		D Y	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI. PI may withdraw but remains in DMR.</p>			
4.		D	04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5.		D Y	04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety completed review and verified no VHSS is required.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6.		C	03-25-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7.		D	04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8		C	03-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9		D Y	03-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
10.	C		03-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11.	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending SOPs from PI providing imaging services.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
12.	D		03-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13.	C		04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on proteins being used and procedures</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14.	C Y		04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15.	C		04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed review and provided new VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16.	C Y		04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17.	C		03-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18.	C		03-22-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19.	C		04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20.	C		03-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21.	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer requests additional information (CAS) to complete review.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
22.	E		03-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on Food or Water Regulation, number justification, and euthanasia procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23.	D		03-25-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding euthanasia method provided.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24.	C		03-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Animal numbers clarified as well as entering animals in the animal tracking system as an import request for review by CVS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25.	D Y		03-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

26. [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. [REDACTED]	D Y	[REDACTED]	03-25-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
29. [REDACTED]	C Y	[REDACTED]	04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Reviewer approved at meeting.</p>			
30. [REDACTED]	D Y	[REDACTED]	03-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding the source of the animal provided.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. [REDACTED]	D Y	[REDACTED]	03-31-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. [REDACTED]	D Y	[REDACTED]	03-26-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Typos identified and fixed.</p> <p>b. Clarification of pre-surgical fasting/withholding water.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Request follow-up with Biosafety for clarification. Remains in DMR.</p>			
34. [REDACTED]	D	[REDACTED]	03-23-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:		
a. None.		
Additional discussion during the meeting included:		
a. None.		
35.	C Y	04-01-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:		
a. None.		
Additional discussion during the meeting included:		
a. None.		
36.	C Y	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:		
a. Clarify number of attempts.		
Additional discussion during the meeting included:		
a. Remains in DMR.		
37.	D	03-30-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:		
a. None.		
Additional discussion during the meeting included:		
a. None.		
38.	D	03-30-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:		
a. None.		
Additional discussion during the meeting included:		
a. None.		
39.	C Y	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:		
a. None.		
Additional discussion during the meeting included:		
a. Pending PI/clarification of locations		

VIII. Administrative and Veterinary Verification Amendments:

Total of 153 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. [REDACTED]	C Y	[REDACTED]	04-01-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- Clarification of number of animals affected, age of animals and if age related.
- Sedation over time and experience with aged animals.

c. Clarification on use of Maropitant (Cerenia).													
d. Include potential for corneal ulcers.													
e. Consistency across the exams with the volume of individuals listed on the protocol.													
Additional discussion during the meeting included:													
a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
2.		D Y	07-08-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. Numbers clarification requested.													
Additional discussion during the meeting included:													
a. Approved for DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
3.		D Y	07-08-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. Alternatives.													
b. Surgical fasting.													
c. Surgery timelines.													
d. Supportive care and frequency of weighing.													
e. OHSS delays.													
Additional discussion during the meeting included:													
a. Approved for DMR													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
4.		D Y	04-01-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. Tissue collection clarification.													
Additional discussion during the meeting included:													
a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
5.		D	04-01-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification regarding study design, anesthetic and local analgesic protocol, monitoring protocol, humane endpoints, and VHSS requested by chemical safety officer.

Additional discussion during the meeting included:

- a. Committee voted to approve.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

6. [REDACTED]	D	[REDACTED]	04-01-2021
---------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Discussion on anesthetic procedures, VHSS, Adverse Effects and personnel

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	1
Present	19

7. [REDACTED]	D Y	[REDACTED]	04-05-2021
---------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification requested regarding analgesia protocol and assessment.

Additional discussion during the meeting included:

- a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

8. [REDACTED]	C	[REDACTED]	04-01-2021
---------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

9. [REDACTED]	D Y	[REDACTED]	04-03-2021
---------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Title change recommendation.
- b. Addition of biological sampling.
- c. Additional search recommendation.
- d. SOP reference requests.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D Y		04-04-2019	04-01-2021	04-04-2022
	D		04-03-2019	04-01-2021	04-03-2022
	D		04-04-2019	04-01-2021	04-04-2022
	D		04-10-2019	04-01-2021	04-10-2022
	C		04-04-2019	04-01-2021	04-04-2022
	D		04-03-2019	04-01-2021	04-03-2022
	D		04-04-2019	04-01-2021	04-04-2022
	D		04-04-2019	04-01-2021	04-04-2022
	C		04-03-2019	04-01-2021	04-03-2022
	C		04-04-2019	04-01-2021	04-04-2022
	D		04-15-2019	04-01-2021	04-15-2022
	D		04-03-2019	04-01-2021	04-03-2022
	C Y		04-03-2019	04-01-2021	04-03-2022
	D Y		04-04-2019	04-01-2021	04-04-2022
	C		04-16-2019	04-01-2021	04-16-2022
	D		04-05-2019	04-01-2021	04-05-2022
	D Y		04-04-2019	04-01-2021	04-04-2022

[REDACTED]	C	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	C	[REDACTED]	04-16-2020	04-28-2022	04-16-2023
	E	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	E	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D	[REDACTED]	04-14-2020	04-14-2022	04-14-2023
	D	[REDACTED]	04-07-2020	03-31-2022	04-07-2023
	D	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D Y	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	C	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
[REDACTED]	C	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D	[REDACTED]	04-16-2020	04-01-2021	04-16-2022
	B	[REDACTED]	04-15-2020	03-31-2022	04-15-2023
	C	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	C	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	C Y	[REDACTED]	04-15-2020	04-01-2021	04-15-2022
	D	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D	[REDACTED]	04-03-2020	03-31-2022	04-03-2023
	C	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	C	[REDACTED]	04-16-2020	04-28-2022	04-16-2023
	C	[REDACTED]	04-15-2020	03-31-2022	04-15-2023
	D Y	[REDACTED]	04-16-2020	04-14-2022	04-16-2023
	D Y	[REDACTED]	04-16-2020	04-14-2022	04-16-2023

Discussion: Protocols [REDACTED], [REDACTED], [REDACTED], and [REDACTED] - at least one staff member is in progress of completing their OHSS renewal. Most are pending their in person appt. due to scheduling conflict based on COVID

	vaccine. - Protocol has another veterinarian listed in section 11. - Food regulation included in section 9 for fasting prior to glucose tolerance testing.										
Action Items:	Protocols [REDACTED] [REDACTED] [REDACTED] and [REDACTED] - Committee approved renewals. [REDACTED] AV to review and determine if MOU is needed. [REDACTED] Committee agreed to keep the information in section 9 and review the food regulation policy before making any changes.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>18</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>18</td></tr> </tbody> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. [REDACTED]	D	[REDACTED]	04-01-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. [REDACTED]		[REDACTED]	05-07-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. More information requested on hypothermia and scientific justification for animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
3. [REDACTED]	D	[REDACTED]	04-01-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>													

<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
4.		D	04-01-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
5.		D	04-01-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
6.		D	04-01-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Committee reviewed justification and PI's ability to test the drug for efficacy. Additional discussion during the meeting included: a. Committee voted to approve.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
7.		Y	04-01-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 19 Withhold Approval 0 Abstain 0 Present 19 </div>			
8.		D	04-15-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending reviewer.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	20

9. [REDACTED]	D Y	[REDACTED]	04-01-2021
---------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	20
Withhold Approval	0
Abstain	0
Present	20

10. [REDACTED]	C Y	[REDACTED]	04-01-2021
----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	20
Withhold Approval	0
Abstain	0
Present	20

11. [REDACTED]	D	[REDACTED]	04-01-2021
----------------	---	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	20
Withhold Approval	0
Abstain	0
Present	20

12. [REDACTED]	D	[REDACTED]	04-12-2021
----------------	---	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending PI and reviewer sent to DMR.

<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
13.		D	04-01-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
14.		D	04-15-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Addition of VHSS Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
15.		D Y	04-13-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Necessity of procedure. Additional discussion during the meeting included: a. Adoption policy. b. PI to adopt. c. CVS to perform surgery.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
16.		D Y	04-14-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Biopsy rationale, size and location. Additional discussion during the meeting included: a. Approved for DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0		
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												

	Present	20											
17.	D		04-01-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. None.													
Additional discussion during the meeting included:													
a. None.													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
18.	E		04-01-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. None.													
Additional discussion during the meeting included:													
a. None.													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 12-08-2020	
2. 03-10-2021	
3. 03-10-2021	
4. 03-11-2021	
5. 03-15-2021	
6. 03-17-2021	
7. 03-18-2021	
8. 03-30-2021	
9. 03-31-2021	

Discussion:	#2 and #3- Discussed ensuring documentation for food mill dates and food barrel cleaning are clearly marked on the barrel and room log.										
Action:	#2 and #3-Lab staff have updated their documentation procedures.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
-----------------	------	----------------------

1. 02-28-2021	LAB		
2. 03-18-2021	LAB		
3. 03-18-2021	LAB		
4. 03-19-2021	LAB		
5. 03-22-2021	LAB		
6. 03-25-2021	LAB		
7. 03-25-2021	LAB		
8. 03-30-2021	LAB		
9. 01-28-2021	PAM		
10. 03-17-2021	PAM		

Discussion:	10. Positive PAM report sent to PI for thorough post-op records reviewed during the facility inspection.										
Action:	10. None- FYI										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. IACUC member voting options - abstention reminders	
Discussion:	FYI.
Action:	None.
2. IACUC member training opportunity - PRIM&R Conference April 14-16, 2021. https://www.eventscribe.com/2021/IACUC21/	
Discussion:	FYI.
Action:	None.
3. FYI - Animal Care Leadership Team Task Force member update	
Discussion:	
Action:	None.
4. Sieving lab	
Discussion:	Completed lab inspection for 2 rooms requested by PI for ERG and OTC studies. Amendment to add these rooms will be on the next agenda. Deficiencies noted during the lab inspection were documented on a PAM and will be reviewed at the next committee meeting.
Action:	Inspection reports will be reviewed at the next meeting.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

April 15, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M102, M111, M090, M042, A095, M004, M092, A019, M087, A109, M110, A013, M016, M024, M223, M001, M112, M114

Excused:

M222, M119, M120, M093

Guests:

A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1. [REDACTED], [REDACTED]	Category: D Y										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pathology report indicates an underlying heart condition.											
Additional discussion during the meeting included: a. Committee approved the amendment.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>		IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote											
Approval	21										
Withhold Approval	0										
Abstain	0										
Present	21										

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
[REDACTED]
Action: PAM report discussed self reported by PI.
[REDACTED] [REDACTED]
Action: IACUC director and chair to set up a Zoom meeting with the PI to review approved protocol.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Chem			
2. # [REDACTED]	E	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Chem			
3. # [REDACTED]	D Y	[REDACTED]	04-14-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
4. # [REDACTED]	D Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Additional information requested for number Justification. Additional discussion during the meeting included: a. Pending PI.			
5. # [REDACTED]	D	[REDACTED]	04-13-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of blood collection. Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	D Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Potential adverse effect clarification; ventilator use; timelines. b. Perfusion procedure update. f. Testing cage size and chair clarification. c. MRI location; MRI procedures and intent. Additional discussion during the meeting included: a. Pending PI.			
7. # [REDACTED]	C	[REDACTED]	04-13-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. # [REDACTED]	D Y	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
9. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
10. #	C		04-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of blood collection.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	C Y		04-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
13. #			04-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D		04-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on dose administration, study time, anesthesia and monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	C		04-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal number justification and animal disposition.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

16. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
17. # [REDACTED]	C	[REDACTED]	04-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of objectives.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D Y	[REDACTED]	04-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding analgesia, monitoring and CVS assessment.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	C	[REDACTED]	04-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of parameter used to assess passive transfer.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	C	[REDACTED]	04-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D Y	[REDACTED]	04-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Title update.</p> <p>b. Procedure clarifications and additions, sop references.</p> <p>c. Literature search recommendation.</p> <p>Additional discussion during the meeting included:</p> <p>a. Title update.</p>			
22. # [REDACTED]	D	[REDACTED]	04-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding procedure technique and method.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	C	[REDACTED]	04-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Minor clarification to ensure numbers were consistent through out protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
2. # [REDACTED]		[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA submission.</p> <p>B. Procedure clarification.</p> <p>c. Number justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
3. # [REDACTED]	C Y	[REDACTED]	04-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	Y	[REDACTED]	04-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D	[REDACTED]	04-15-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA and mouse strain clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
7. # [REDACTED]	D	[REDACTED]	04-15-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending lab manager of imaging facility creating SOPs to be managed as a core facility.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
9. # [REDACTED]	D	[REDACTED]	04-15-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
10. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PAM.			
11. #	D		04-12-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
12. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
13. #	D		04-12-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
14. #	D Y		04-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
15. #	D		04-12-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of how defecation will be monitored. Additional discussion during the meeting included: a. None.			
16. #	D		04-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed review and provided and updated VHSS. Additional discussion during the meeting included: a. None.			
17. #	E		04-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:			

a. None.			
18. #	C Y		04-07-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
19. #	D Y		04-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
20. #	E		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. Pending reviewer			
21. #	D Y		04-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
22. #	D		04-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification on tracking neuronal activation			
Additional discussion during the meeting included:			
a. None.			
23. #	D		04-08-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification on blood volume injection and constant rate ICV injection			
Additional discussion during the meeting included:			
a. None.			
24. #	D		04-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
25. #	D		04-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
26. #	D		-

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
27. #	C		04-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
28. #	D Y		04-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Adoption policy consultation. Additional discussion during the meeting included: a. Adoption policy.			
29. #	D		04-14-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
30. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer			
31. #	D		04-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
32. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None Additional discussion during the meeting included: a. Request additional information from EH&S regarding recommendation. b. Remains in DMR.			
33. #	D Y		04-09-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
34. #	C Y		04-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedure. Additional discussion during the meeting included: a. None.			

35. # [REDACTED]	C	[REDACTED]	04-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussion on site selection and variation Additional discussion during the meeting included: a. None.			
36. # [REDACTED]	D Y	[REDACTED]	04-14-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Biopsy size determination and rationale. Additional discussion during the meeting included: a. None.			
37. # [REDACTED]	C Y	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			

VIII. Administrative and Veterinary Verification Amendments:

Total of 141 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	05-05-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal strain, numbers and signs of morbidity.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to send to DMR</p> <table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </tbody> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D	[REDACTED]	04-28-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending chemical safety review and PI's response to questions related to potential toxicities.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </tbody> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												

Approval	0
Withhold Approval	0
Abstain	0
Present	21

3. # [REDACTED] D [REDACTED] 05-11-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Humane endpoints policy requested to be exceeded, committee would like more information project tabled.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

4. # [REDACTED] C Y [REDACTED] 04-15-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

5. # [REDACTED] D [REDACTED] 04-15-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

6. # [REDACTED] D [REDACTED] 04-15-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Replacement protocol. Clarification regarding category E for live feedings. Clarification regarding transportation.

Additional discussion during the meeting included:

a. Committee approved by vote.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		04-30-2019	04-15-2021	04-06-2022
	C		04-18-2019	04-15-2021	04-18-2022
	D		04-18-2019	04-15-2021	04-18-2022
	C		04-18-2019	04-15-2021	04-18-2022
	D		04-18-2019	04-15-2021	04-18-2022
	D		04-18-2019	04-15-2021	04-18-2022
	D		04-22-2019	04-15-2021	04-22-2022
	C		04-23-2019	04-15-2021	04-23-2022
	D		04-29-2019	04-15-2021	04-29-2022
	D		04-29-2019	04-15-2021	04-29-2022
	C Y		04-18-2019	04-15-2021	04-18-2022
	C		04-18-2019	04-15-2021	11-02-2021
	C		04-17-2019	04-15-2021	04-17-2022
	D		04-18-2019	04-15-2021	04-18-2022
	D Y		04-18-2019	04-15-2021	04-18-2022
	C		04-29-2019	04-15-2021	04-29-2022
	C		04-18-2019	04-15-2021	04-18-2022
	C		04-18-2019	04-15-2021	04-18-2022
	D		04-18-2019	04-15-2021	04-18-2022
	C		04-29-2019	04-15-2021	04-29-2022
	D Y		04-30-2020	04-28-2022	04-30-2023
	D Y		04-30-2020	04-28-2022	04-30-2023
	D		04-21-2020	04-15-2021	04-21-2022
	C		04-28-2020	04-14-2022	04-28-2023
			04-21-2020	04-14-2022	04-21-2023

	C		04-24-2020	04-14-2022	04-24-2023
	C		04-30-2020	04-15-2021	04-30-2022
	C		04-21-2020	04-14-2022	04-21-2023
	C		04-20-2020	04-14-2022	04-20-2023
	C		04-21-2020	04-14-2022	04-21-2023
	D		04-30-2020	04-15-2021	04-30-2022
	E		04-17-2020	04-14-2022	04-17-2023
	C		04-16-2020	04-15-2021	04-16-2022
	D		04-17-2020	04-14-2022	04-17-2023
	C		04-29-2020	04-14-2022	04-29-2023
	D		04-30-2020	04-28-2022	04-30-2023
	C Y		04-29-2020	04-14-2022	04-29-2023
	D Y		04-30-2020	04-28-2022	04-30-2023
	D		04-17-2020	04-14-2022	04-17-2023
	D		04-30-2020	04-28-2022	04-30-2023
	D		04-27-2020	04-14-2022	04-27-2023
	D		04-30-2020	04-28-2022	04-30-2023

Discussion: [REDACTED] [REDACTED] [REDACTED] [REDACTED]-at least one staff member is pending completing their in person appointment to complete their OHSS renewal process.
[REDACTED] [REDACTED] and [REDACTED] have expired permits. [REDACTED] is currently not doing any work requiring a permit and it will be renewed before studies resume. The other two protocols provided the updated permit information to add to the protocol.
[REDACTED]-another veterinarian is listed in section 11. AV confirming if an MOU is needed.

Action Items: [REDACTED] [REDACTED] [REDACTED] [REDACTED]-the committee approved the annual renewal.
[REDACTED] [REDACTED] and [REDACTED]-the committee approved the annual renewals and adding the updated permit information to the protocols.
[REDACTED]-the committee approved the annual renewal.

IACUC Vote

Approval 17

Withhold Approval 0

Abstain	0
Present	17

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	C	[REDACTED]	04-15-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Room is already on the inspection schedule and deemed appropriate for overnight dark adaptation. SOPs completed along with room log. Core facility to ensure other users requesting this space have the procedures and room approved on their protocol. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D Y	[REDACTED]	04-15-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
3. # [REDACTED]	C	[REDACTED]	04-15-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on derivation of implanted tissue, mouse strain availability and tumor diameter before euthanasia. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	D Y	[REDACTED]	06-21-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding the number of injections, monitoring and alternatives. Additional discussion during the meeting included:													

a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

5. # [REDACTED] D [REDACTED] 04-15-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Room was seen by an IACUC staff person and CVS and deemed appropriate for overnight dark adaptation. SOPs completed along with room log.

Additional discussion during the meeting included:

a. Committee approved by vote.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

6. # [REDACTED] D [REDACTED] 04-15-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Room was seen by an IACUC staff person and CVS and deemed appropriate for overnight dark adaptation. SOPs completed along with room log.

Additional discussion during the meeting included:

a. Committee approved by vote.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

7. # [REDACTED] C Y [REDACTED] 04-15-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

8. # [REDACTED] E [REDACTED] 04-29-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification on animal numbers.

Additional discussion during the meeting included:

a. Pending Chem

IACUC Vote	
Approval	0
Withhold Approval	0

Abstain	0
Present	20

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 02-25-2021	
2. 03-11-2021	
3. 03-15-2021	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>20</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>20</td></tr> </tbody> </table>		IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	20										
Withhold Approval	0										
Abstain	0										
Present	20										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 02-24-2021	LAB	
2. 03-11-2021	LAB	
3. 03-19-2021	LAB	
4. 04-07-2021	LAB	
5. 03-31-2021	PAM	
6. 04-08-2021	PAM	

Discussion:	<p>#4 - Lab has been on quarterly visits for over a year and has done a great job communicating with IACUC staff, implementing suggestions and improving communication with lab staff.</p> <p>#5 - Housing occurred without approval. Lab inspection revealed other non-compliance issues. All have been resolved.</p> <p>#6 - PI self reported staff member who performed technique not approved on protocol. Re-training has been completed and PI and alternate contact will assess staff's animal work.</p>										
Action:	<p>#4 - Committee approved moving inspections back to semi-annual schedule.</p> <p>#5 - Lab is scheduled to be rechecked next month to ensure they remain in compliance.</p> <p>#6 - IACUC Director to contact granting agency.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
Animals transferred to holding protocol from [REDACTED]	
Discussion:	Animals placed on holding protocol due to expired protocol.
Action:	Animals will be transferred to replacement protocol now that the renewal has been approved.
Animals transferred to holding protocol from [REDACTED]	
Discussion:	None.
Action:	Animals placed on holding protocol due to expired protocol..
SAPR Signature pages (check information and degrees/certifications)	
Discussion:	None.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

April 29, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M222, M102, M042, A095, M004, M092, A019, M119, M087, A109, M110, M120, M093, A013, M024, M223, M001, M114

Excused:

M111, M090, M016, M112

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the April 1, 2021, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

II. Protocols Tabled From Previous Meetings:

1. #		Category: D										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:												
a. Weight loss criteria, PI revised to be within humane endpoints and added additional monitoring criteria												
Additional discussion during the meeting included:												
a. Pending PI response to location questions												
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	20											

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

PETA records request - Email follow-up

Action: FYI.

Action: Discussed facility and possible drain alternatives.
CNPRC
Action: 1)Caging, 2)Field pen foreign object.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	C	[REDACTED]	04-26-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
3. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
4. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. MRI location criteria and transport.</p> <p>b. Pairing criteria.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer response.</p>			
5. # [REDACTED]	D	[REDACTED]	04-26-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of dose, standard of care, and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	C	[REDACTED]	04-29-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal source.</p>			

Additional discussion during the meeting included: a. None.			
7. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures. Additional discussion during the meeting included: a. Pending PI.			
8. # [REDACTED]	C Y	[REDACTED]	04-29-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of numbers justification. Additional discussion during the meeting included: a. None.			
9. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Special procedure justification addition. b. Procedural clarifications, suspension. c. Procedural clarification, sample collections. c. Chem safety review updated VHSSs. Additional discussion during the meeting included: a. Pending Reviewer.			
10. # [REDACTED]	D	[REDACTED]	04-28-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed their review and provided updated VHSS. Additional discussion during the meeting included: a. None.			
11. # [REDACTED]	C	[REDACTED]	04-29-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
12. # [REDACTED]	C	[REDACTED]	04-29-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of blood volume. Additional discussion during the meeting included: a. None.			
13. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
14. # [REDACTED]	C	[REDACTED]	04-27-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	C	[REDACTED]	04-29-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Review of responses</p>			
17. # [REDACTED]	B	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Reviewer</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	04-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	C	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]		[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
4. # [REDACTED]	C	[REDACTED]	04-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

5. # [REDACTED]	C	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer</p>			
6. # [REDACTED]	D Y	[REDACTED]	04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer</p>			
8. # [REDACTED]	D	[REDACTED]	04-26-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	04-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	C Y	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C Y	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	D Y	[REDACTED]	04-28-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending SOPs for facility.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
15. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer</p>			
16. #	D		04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's response to clarify use and duration.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
18. #	C		04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D		04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of analgesia.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of madministration frequency.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

22. #	D		04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	D		04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	E		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer</p>			
25. #	C Y		04-15-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pairing status date clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D		04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer.</p>			
28. #	C		04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal source and anesthesia</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	D		04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D Y		04-26-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

31. # [REDACTED]	D Y	[REDACTED]	04-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. # [REDACTED]	D	[REDACTED]	04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. # [REDACTED]	E	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
34. # [REDACTED]	C	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
35. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's description of procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
36. # [REDACTED]	D Y	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
37. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
38. # [REDACTED]	C	[REDACTED]	04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
39. # [REDACTED]	C	[REDACTED]	04-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

40. # [REDACTED]	C	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
41. # [REDACTED]	C Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer</p>			
42. # [REDACTED]	D Y	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
43. # [REDACTED]	D Y	[REDACTED]	04-15-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 192 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	07-08-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Request further consultation on anesthesia recovery plan.</p> <p>Additional discussion during the meeting included:</p> <p>a. Tabled pending PI response.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D Y	[REDACTED]	04-29-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification of handler numbers.
- b. Clarification of procedures wording.
- c. Clarification of cat care.
- d. Clarification of animal numbers.
- e. Clarification of adoption timing.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

3. # [REDACTED]	D Y	[REDACTED]	04-29-2021
-----------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification of procedure areas.
- b. clarification of antibiotics.
- c. Clarification of anesthesia methods and complications..

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

4. # [REDACTED]	D	[REDACTED]	04-29-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification on weights during sciatic transection and euthanasia procedures.

Additional discussion during the meeting included:

- a. Committee voted to Approve

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

5. # [REDACTED]	D	[REDACTED]	05-27-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Pending PI response to reviewer questions.

Additional discussion during the meeting included:

- a. Committee voted to send to DMR

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	21

6. # [REDACTED]	D	[REDACTED]	04-29-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to Approve.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
7. # [REDACTED]	D	[REDACTED]	05-18-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response to reviewer questions.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to send to DMR</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
8. # [REDACTED]	D Y	[REDACTED]	04-29-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Project reference.</p> <p>b. Wording and treatment clarifications.</p> <p>c. Analgesic administration clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
9. # [REDACTED]	E	[REDACTED]	05-26-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI, request DR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												

10. # [REDACTED]	C	[REDACTED]	05-03-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Reviewer</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to send to DMR</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
11. # [REDACTED]	D	[REDACTED]	05-02-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested regarding rooms used for procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
12. # [REDACTED]	D	[REDACTED]	04-29-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding housing and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved by committee vote.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
13. # [REDACTED]	D	[REDACTED]	04-30-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending RAD</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to send to DMR</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
----------	----------	-------	-------------------	---------------	---------

	D Y		05-02-2019	04-29-2021	05-02-2022
	D		05-09-2019	04-29-2021	05-09-2022
	D		05-01-2019	04-29-2021	05-01-2022
	D		05-06-2019	04-29-2021	05-06-2022
	D		05-02-2019	04-29-2021	05-02-2022
	D		04-18-2019	04-29-2021	04-18-2022
	B		04-18-2019	04-29-2021	04-18-2022
	D		05-03-2019	04-29-2021	05-03-2022
	D		05-02-2019	04-29-2021	05-02-2022
	D Y		05-07-2019	04-29-2021	05-07-2022
	D		05-02-2019	04-29-2021	05-02-2022
	C		05-01-2019	04-29-2021	05-01-2022
	C		05-14-2019	04-29-2021	05-14-2022
	C		05-14-2020	05-12-2022	05-14-2023
	C Y		05-12-2020	04-29-2021	05-12-2022
	C		05-14-2020	05-12-2022	05-14-2023
	C Y		04-16-2020	04-14-2022	04-16-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	D		05-14-2020	05-12-2022	05-14-2023
	C		04-30-2020	04-28-2022	04-30-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	E		05-01-2020	04-28-2022	05-01-2023
	C		05-01-2020	05-12-2022	05-01-2023
	D Y		05-04-2020	04-28-2022	05-04-2023
	E		05-14-2020	05-26-2022	05-14-2023
	E		05-14-2020	05-26-2022	05-14-2023

	C		04-20-2020	04-14-2022	04-20-2023
	D		05-07-2020	04-28-2022	05-07-2023
	C		05-14-2020	05-12-2022	05-14-2023
	C		05-11-2020	04-28-2022	05-11-2023
	C		05-04-2020	04-28-2022	05-04-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	D Y		05-01-2020	04-28-2022	05-01-2023
	E		05-04-2020	04-28-2022	05-04-2023
	Y		05-14-2020	05-12-2022	05-14-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	D Y		05-14-2020	05-12-2022	05-14-2023
	C		05-12-2020	05-12-2022	05-12-2023
	D		05-14-2020	05-12-2022	05-14-2023

Discussion:	<p>one staff member is in the process of completing the OHSS renewal process. Pending completion due to in person appt.</p> <p>-approved amendment to add minor surgery changes category.</p> <p>-section 11 other vet listed. AV reviewing all MOUs.</p> <p>-Clarification requested regarding husbandry procedures.</p>										
Action Items:	<p>committee approved renewal.</p> <p>-committee approved renewal and for IACUC staff to update protocol format and update category.</p> <p>-committee approved renewal.</p> <p>-committee approved renewal.</p> <p>committee approved renewal and IAUC staff working with PI to update section 7.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>16</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
----------	----------	---------	---------------

1. #	E		06-11-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of findings. Additional discussion during the meeting included: a. Voted to send to DR to get Committee member's new question addressed.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
2. #	D		04-29-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Confirmed amendment request was following campus policy. Additional discussion during the meeting included: a. Committee approved by vote.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
3. #	D		04-29-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified maximum encounters. Additional discussion during the meeting included: a. Committee approved by vote.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
4. #	C		04-29-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Confirmed room is already approved for dark adaptation. Additional discussion during the meeting included: a. Committee approved by vote.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
5. #	D		04-29-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Committee concerned there is too much risk to repeat procedure without knowing for sure if animals had been affected by the first time. Additional discussion during the meeting included: a. Committee voted to deny request.													
<table><tr><td colspan="2">IACUC Vote</td></tr></table>				IACUC Vote									
IACUC Vote													

<table><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>21</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				Approval	0	Withhold Approval	21	Abstain	0	Present	21		
Approval	0												
Withhold Approval	21												
Abstain	0												
Present	21												
6. #	D		04-29-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
7. #	C		04-29-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
8. #	D Y		05-10-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Obesity in colony; study animal selection criteria and metabolic ramification. Additional discussion during the meeting included: a. Obesity in colony and metabolic ramification, heterogeneity. b. Weight loss with weighing schedules. c. Locations; animal movements. d. Weight loss in controls. d. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
9. #	D Y		05-02-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification requested regarding the dose. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr></table>				IACUC Vote									
IACUC Vote													

Approval	0
Withhold Approval	0
Abstain	0
Present	21

10. # [REDACTED]	D [REDACTED]	04-29-2021
------------------	--------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Current status of animal clarified as well as anesthetic procedure.

Additional discussion during the meeting included:

a. Committee approved by vote.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 03-17-2021	[REDACTED]
2. 03-29-2021	
3. 03-31-2021	
4. 04-02-2021	
5. 04-19-2021	
6. 04-19-2021	
7. 04-21-2021	
8. 04-21-2021	

Discussion:	5. Despite the minor deficiency resulting in using an expired drug, the IACUC was very impressed with the overall management of the clinic. The organization, thoroughness of records and attention to detail is commended.
Action:	5. Deficiencies have been corrected.

IACUC Vote	
Approval	15
Withhold Approval	0
Abstain	0
Present	15

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 10-27-2020	LAB	[REDACTED]
2. 04-15-2021	LAB	
3. 04-21-2021	LAB	
4. 04-21-2021	LAB	
5. 04-15-2021	PAM	
6. 04-20-2021	PAM	
7. 04-21-2021	PAM	

Discussion:	2. This room is not used for animal work. Discussed combining the inspection in the room that is shared and alternating every 3 months between the two PI's. 5. PI was breeding animals without IACUC approval.										
Action:	2. Room will be removed from the IACUC protocol and this PI's lab inspection will be scheduled at her collaborators lab on a rotating basis. 5. Meeting between PI, IACUC Director and Committee Chair helped clarify to the PI what needs to be included in his protocol and when an amendment is needed. Procedure has now been approved via an amendment.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>20</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>20</td></tr> </tbody> </table>		IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	20										
Withhold Approval	0										
Abstain	0										
Present	20										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
Animals transferred to holding protocol from [REDACTED]	
Discussion:	None.
Action:	None.
PI Maintained Form [REDACTED]	
Discussion:	None.
Action:	Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

May 13, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M222, M102, M111, M042, A095, M092, A019, M119, M087, A109, M110, M120, M093, A013, M016, M024, M223, M001, M114

Excused:

M090, M004, M112

Guests:

M116, A017

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

1. # [REDACTED]	Category: D Y										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI consult with veterinary staff.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	21										

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:	
AMP news alert: SAEN complaint to USDA	
Action: FYI	
[REDACTED]	Action: Surgical prep retraining; self -reported no animal welfare impact.
[REDACTED]	Action: Fracture pending pathology results and inquire to vendor, no experimental procedures.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
Sentinel Program
corynebacterium bovis
Action Items: Pull all current sentinel cages; cull; PCR. PI notification. Evaluate other program options.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
2. # [REDACTED]	C	[REDACTED]	05-11-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D Y	[REDACTED]	05-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal monitoring parameters and animals number justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI review.</p>			
5. # [REDACTED]	C	[REDACTED]	05-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. Pending PI.			
7. # [REDACTED]	D	[REDACTED]	05-06-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of timing for suspension test.</p> <p>Additional discussion during the meeting included:</p> <p>a. Original reviewer unavailable; Substitute reviewer.</p>			
8. # [REDACTED]	D	[REDACTED]	05-11-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Reviewer and BUA</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
10. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Reviewer</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
11. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
12. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending chem.</p>			
13. # [REDACTED]	C	[REDACTED]	05-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	C	[REDACTED]	05-12-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal disposition.</p>			

Additional discussion during the meeting included: a. None.			
15. # [REDACTED]	D	[REDACTED]	05-02-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI was agreeable to updating the protocol to include survival surgeries in the vivarium procedure room and only terminal surgeries in the lab. Additional discussion during the meeting included: a. None.			
16. # [REDACTED]	C	[REDACTED]	05-11-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
17. # [REDACTED]	C Y	[REDACTED]	05-13-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification provided regarding adoption procedures, numbers justification and animals expected to be infected with WT. Additional discussion during the meeting included: a. None.			
18. # [REDACTED]	C Y	[REDACTED]	05-13-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on refinement. Additional discussion during the meeting included: a. None.			
19. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures. Additional discussion during the meeting included: a. None.			
20. # [REDACTED]	B	[REDACTED]	04-30-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
21. # [REDACTED]	C Y	[REDACTED]	05-13-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
22. # [REDACTED]	D	[REDACTED]	04-30-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures, post-operative, potential side effects and animal transportation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Reviewer</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
24. #	C		05-12-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D		05-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	B		05-11-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	B		05-11-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D Y		05-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. #			05-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures and animal numbers.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
3. #	C Y		05-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
4. #	C		05-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
5. #	D		05-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
6. #	D		05-12-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
7. #	D Y		05-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. #	D Y		05-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
9. #	D		05-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
10. #	D		05-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
11. #	C		-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending reviewer</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
12. #	D		05-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer</p>			
13. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending facility SOPs.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
14. #	D		05-11-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	C		05-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D Y		05-10-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #			-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI response to chem question.</p>			
18. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
19. #	D Y		05-10-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Text updated with PI per previous IACUC review.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

20. # [REDACTED]	E	[REDACTED]	05-11-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	E	[REDACTED]	05-12-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	D	[REDACTED]	05-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety clarified no new VHSS was required.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested regarding animal numbers and how animals will be generated to ensure the PI's BUA will not be required to be updated.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	D	[REDACTED]	05-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	B	[REDACTED]	04-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. # [REDACTED]	E	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending chem and reviewer.</p>			
27. # [REDACTED]	C	[REDACTED]	05-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. # [REDACTED]	D	[REDACTED]	05-13-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	D		05-11-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
31. #	D Y		05-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. More details provided on how the procedure will be performed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	D Y		05-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding the dose given to each animal.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending further review with EH&S.</p>			
34. #	C		05-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
35. #	C Y		05-11-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
36. #	C		05-12-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
37. #	D		05-10-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 148 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	C Y	[REDACTED]	05-17-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Numbers clarification. b. Drug dose clarification. c. Social group and colony assignment clarification. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI response, approved for designated review. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>21</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
2. # [REDACTED]	C Y	[REDACTED]	05-27-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Title clarification. b. Clarification of potential adverse effects. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Approved for designated review. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>21</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
3. # [REDACTED]	D	[REDACTED]	05-27-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Voted for DR, pending final reviewer and chemical safety

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	22

4. # [REDACTED] C Y [REDACTED] 05-13-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	21
Withhold Approval	0
Abstain	1
Present	22

5. # [REDACTED] D [REDACTED] 05-13-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	22
Withhold Approval	0
Abstain	0
Present	22

6. # [REDACTED] D Y [REDACTED] 05-13-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	22
Withhold Approval	0
Abstain	0
Present	22

7. # [REDACTED] D [REDACTED] 05-17-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. discussion of pain category.

b. sent to DR for clarification of monitoring/observation frequency.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	21

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		05-20-2019	05-13-2021	05-20-2022
	E		05-16-2019	05-13-2021	05-16-2022
	D Y		05-16-2019	05-13-2021	05-16-2022
	D		05-16-2019	05-13-2021	05-16-2022
	D		05-17-2019	05-13-2021	05-17-2022
	D		05-24-2019	05-13-2021	05-24-2022
	C		05-16-2019	05-13-2021	05-16-2022
	C		05-16-2019	05-13-2021	05-16-2022
	D		05-16-2019	05-13-2021	05-16-2022
	D		05-16-2019	05-13-2021	05-16-2022
	C Y		05-15-2019	05-13-2021	05-15-2022
	D		05-15-2019	05-13-2021	05-15-2022
	D		05-15-2019	05-13-2021	05-15-2022
	D		05-16-2019	05-13-2021	01-11-2022
	D Y		05-15-2019	05-13-2021	05-15-2022
	C		05-16-2019	05-13-2021	05-16-2022
	C		05-27-2019	05-13-2021	05-27-2022
	D Y		05-16-2019	05-13-2021	05-16-2022
	D Y		05-28-2020	05-26-2022	05-28-2023
	D		05-28-2020	05-26-2022	05-28-2023
	C		05-15-2020	05-12-2022	05-15-2023
	E		05-28-2020	05-26-2022	05-28-2023

	C		5-15-2020	05-12-2022	05-15-2023
	C		5-28-2020	05-26-2022	05-28-2023
	C Y		5-28-2020	05-26-2022	05-28-2023
	C		5-13-2020	04-28-2022	05-13-2023
	D		5-28-2020	05-26-2022	05-28-2023
			5-28-2020	05-26-2022	05-28-2023
	D Y		5-28-2020	05-26-2022	05-28-2023
	D		5-28-2020	05-26-2022	05-28-2023
	D		5-28-2020	05-26-2022	05-28-2023
	C		5-28-2020	05-26-2022	05-28-2023
	C		5-28-2020	05-26-2022	05-28-2023
	C		5-19-2020	05-12-2022	05-19-2023
	C		5-19-2020	05-12-2022	05-19-2023
	D		5-28-2020	05-26-2022	05-28-2023
	C		5-28-2020	05-13-2021	10-18-2021
	D Y		5-28-2020	05-26-2022	05-28-2023

Discussion:	██████████ and ██████████ one staff member on each protocol is on the last step of the OHSS renewal process. They are pending their in person appointment at occupational health.										
Action Items:	██████████ and ██████████ -The committee voted and approved the annual renewals.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>18</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>18</td></tr> </tbody> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
----------	----------	---------	---------------

1. #	D		05-13-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												
Present	22												
2. #	E		06-11-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of commercially available sensor/alarm to detect low water level. Additional discussion during the meeting included: a. Committee member with aquatic background to evaluate tanks at Facility Inspection. Committee decided to table the amendment.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
3. #	D		05-13-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Committee appreciated the PI was willing to meet with the chair, vice chair and IACUC director to come up with a new plan to address previous issues. PI consulted with another PI on campus as requested by the IACUC to help guide the success of the study. Additional discussion during the meeting included: a. Committee approved by vote.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												
Present	22												
4. #	D		05-27-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Committee requests further clarification regarding the numbers justification. The original protocol and the additional animal requested in this amendment is quite large. Additional discussion during the meeting included: a. Tabled.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
5. #	D Y		07-02-2021										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Committee requests a literature search and a change in pain category to D. Additional information requested to understand cause of lameness and more thorough plan for prevention.

Additional discussion during the meeting included:

- a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	22

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 04-14-2021	
2. 04-26-2021	
3. 04-28-2021	
4. 05-04-2021	

Discussion:	1. Facility shared by two PI's. On quarterly rotation to ensure both PI's are seen every 6 months.
Action:	1. None at this time. PI is just starting project and everything looked good thus far with their set up.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 04-12-2021	LAB	
2. 04-29-2021	LAB	
3. 04-08-2021	PAM	
4. 04-15-2021	PAM	
5. 05-05-2021	PAM	

Discussion:	None.
Action:	None.

IACUC Vote	
Approval	22
Withhold Approval	0
Abstain	0
Present	22

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. PI Maintain Form	
Discussion:	Previous location for housing was shared between PI and TRACS. New location which is already set up for aquatic housing cannot be accommodated by TRACS staff at this time.
Action:	Committee approved request for PI maintain housing. Protocol, SOP and room log will be reviewed at the next meeting.
2. House keeping reminder - protocol/amendment review availability	
Discussion:	None.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

May 27, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M222, M102, M111, M090, A095, M092, A019, M119, A109, M110, M120, A013, M016, M024, M223, M001, M114

Excused:

M042, M004, M087, M093, M112

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1. #		Category: E										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:												
a. None.												
Additional discussion during the meeting included:												
a. Send to DR to update amendment with plan proposed at Facility Inspection.												
<table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	20											

2. #		Category: D										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:												
a. PI modified numbers justification and total number of animals.												
Additional discussion during the meeting included:												
a. Committee voted to approve.												
<table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>			IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	20											
Withhold Approval	0											
Abstain	0											
Present	20											

IV. Reports of Concern, Events and Incidents:

Action: FYI.

None at this time.

Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	C	[REDACTED]	05-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of animal numbers b. Clarification of procedures c. Clarification of animal ownership d. Confirmation of consent form <p>Additional discussion during the meeting included: a. None.</p>			
7. # [REDACTED]	E	[REDACTED]	05-26-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of housing b. Clarification of pathogens c. Clarification of Protein and adjuvant mixtures <p>Additional discussion during the meeting included: a. None.</p>			
8. # [REDACTED]	C Y	[REDACTED]	05-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.</p> <p>Additional discussion during the meeting included: a. None.</p>			
9. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of cohort start date verbiage b. Explanation of treatment approach purpose d. Clarification of calf husbandry timing <p>Additional discussion during the meeting included: a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	05-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.</p> <p>Additional discussion during the meeting included: a. None.</p>			
11. # [REDACTED]	C Y	[REDACTED]	05-27-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Length of dilation and return time to outside housing.</p> <p>Additional discussion during the meeting included: a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Procedure clarifications.</p> <p>Additional discussion during the meeting included: a. Pending PI.</p>			

13. # [REDACTED]	D	[REDACTED]	05-27-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. SOP Provided.</p>			
14. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of doses, maximum volume, and overnight housing.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Occ Health clearance and review of PI response by reviewer.</p>			
15. # [REDACTED]	C	[REDACTED]	05-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Method of Urine Sampling to be clarified</p> <p>Additional discussion during the meeting included:</p> <p>a. Method clarified</p>			
17. # [REDACTED]	D Y	[REDACTED]	05-24-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on implant apparatus fractures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	C	[REDACTED]	05-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
20. # [REDACTED]	D	[REDACTED]	05-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of pain category</p> <p>b. Clarification of timing for increased monitoring</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

21. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
22. # [REDACTED]	C	[REDACTED]	05-27-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	C	[REDACTED]	05-27-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	D	[REDACTED]	05-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	D	[REDACTED]	05-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of maximum volume and overnight housing.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Biosafety and Occ Health clearance.</p>			
27. # [REDACTED]		[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Reviewer. Alternate reviewer volunteered.</p>			
28. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of numbers and procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Occ Health clearance.</p>			
29. # [REDACTED]	C	[REDACTED]	05-21-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Approved via DR for tracking purposes only.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BIO and CHEM</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in Designated Reviewer</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		05-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. #	D		05-25-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. #	D Y		05-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	D Y		05-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. #			05-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on statistical rationale and animal number justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Reviewer</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in Designated Reviewer</p>			
7. #	D		05-27-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			
Additional discussion during the meeting included: a. None.			
8. #	C		05-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on age of larvae at the experimental endpoint.			
Additional discussion during the meeting included: a. None.			
9. #	D Y		05-26-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			
Additional discussion during the meeting included: a. None.			
10. #	D		05-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			
Additional discussion during the meeting included: a. Numbers clarified by PI			
11. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending facility SOPs.			
Additional discussion during the meeting included: a. Remains in DMR.			
12. #			-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			
Additional discussion during the meeting included: a. Pending PI response to Chem.			
13. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI's response.			
Additional discussion during the meeting included: a. Remains in DMR.			
14. #	D		05-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			
Additional discussion during the meeting included: a. Post procedural question addressed by PI			
15. #			05-26-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			
Additional discussion during the meeting included: a. None.			

16. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final approval from biosafety.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
17. # [REDACTED]	C Y	[REDACTED]	05-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Text clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	E	[REDACTED]	05-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D Y	[REDACTED]	05-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	D	[REDACTED]	05-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D Y	[REDACTED]	05-25-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending further discussion with EH&S.</p>			
23. # [REDACTED]	C	[REDACTED]	05-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	C	[REDACTED]	05-27-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of bleeding technique. Additional discussion during the meeting included: a. None.			
25. #	D Y		05-25-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified saline will be used instead of ultrasound gel. Additional discussion during the meeting included: a. None.			
26. #	C		05-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 86 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	05-27-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on BUA, animal numbers, procedures and adverse effects. Additional discussion during the meeting included: a. Discussion on compliance issue and PAM requested for follow up.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D Y	[REDACTED]	05-27-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. EH&S comments.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

3. # [REDACTED]	D	[REDACTED]	05-27-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. clarification of injection volume and contents.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

4. # [REDACTED]	D Y	[REDACTED]	05-27-2021
-----------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

5. # [REDACTED]	C Y	[REDACTED]	05-27-2021
-----------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

6. # [REDACTED]	C	[REDACTED]	07-07-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Pending final biosafety approval.

Additional discussion during the meeting included:

- a. Voted to send to DMR.

<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
7. #	D		06-14-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending BUA, Voted for DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
8. #	C		06-09-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending final biosafety review and one staff member is in the process of completing the occupational health process. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
9. #	D		05-27-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
10. #	D		06-10-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussion on pain management and pain category Additional discussion during the meeting included: a. Discussion on pain categories and pain management.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0				
IACUC Vote													
Approval	20												
Withhold Approval	0												

	Abstain	0
	Present	20

11. #	C Y		05-27-2021
-------	-----	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Fostering contingency plan.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

12. #	C		05-27-2021
-------	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Biosafety officer and chemical safety officer provided updated VHSS for attachment.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		6-04-2019	05-27-2021	06-04-2022
	C		5-30-2019	05-27-2021	05-30-2022
	D Y		5-30-2019	05-27-2021	05-30-2022
			6-05-2019	05-27-2021	06-05-2022
	D Y		5-30-2019	05-27-2021	05-30-2022
	C		5-30-2019	05-27-2021	05-30-2022
	D		5-30-2019	05-27-2021	05-30-2022
	D		5-30-2019	05-27-2021	05-30-2022
	D		6-03-2019	05-27-2021	06-03-2022
	D		6-03-2019	05-27-2021	06-03-2022

	C		05-30-2019	05-27-2021	05-30-2022
	D Y		05-30-2019	05-27-2021	05-30-2022
	D		06-01-2019	05-27-2021	06-01-2022
	C		06-03-2019	05-27-2021	06-03-2022
	Y		05-30-2019	05-27-2021	05-30-2022
	D		05-30-2019	05-27-2021	05-30-2022
	D		05-30-2019	05-27-2021	05-30-2022
	C		05-30-2019	05-27-2021	05-30-2022
	D Y		05-30-2019	05-27-2021	05-30-2022
	D		05-29-2020	05-26-2022	05-29-2023
	D		06-03-2020	05-26-2022	06-03-2023
	C Y		06-03-2020	05-26-2022	06-03-2023
	D Y		06-01-2020	05-26-2022	06-01-2023
	D		06-01-2020	05-26-2022	06-01-2023
	D Y		06-11-2020	06-09-2022	06-11-2023
	D		05-29-2020	05-26-2022	05-29-2023
	D		06-11-2020	06-09-2022	06-11-2023
	D Y		06-04-2020	06-09-2022	06-04-2023
	D		06-08-2020	05-26-2022	06-08-2023
	C		06-03-2020	05-27-2021	06-03-2022
	D		06-11-2020	06-09-2022	06-11-2023
	C		06-11-2020	06-09-2022	06-11-2023
	D Y		06-11-2020	06-09-2022	06-11-2023
	C		06-11-2020	06-09-2022	06-11-2023
	C		06-11-2020	06-09-2022	06-11-2023

Discussion: [REDACTED] and [REDACTED]-One staff member is in the process of updating their OHSS process; pending in person appointment.

Action Items: [REDACTED] and [REDACTED]-Committee approved annual renewals.											
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>17</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </tbody> </table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D	[REDACTED]	06-07-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending Reviewer Additional discussion during the meeting included: a. Voted to move to Designated Reviewer.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	C	[REDACTED]	05-27-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
3. # [REDACTED]	D	[REDACTED]	05-28-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA Additional discussion during the meeting included: a. Voted to move to Designated Reviewer													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	D Y	[REDACTED]	05-27-2021										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed review and updated VHSS. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
5. #	C		06-24-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Verify veterinarian/vet service plan.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
6. #	D		05-27-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI clarified all measures being taken to ensure adverse effects related to transport is minimized. Study food will be analyzed prior to starting study. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
7. #	D		05-27-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Analgesia regime discussed and verified matches CVS guidelines. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
8. #	D Y		07-02-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Committee requests more information to understand how the adverse effects occurred in the first place and plan for ensuring it does not happen again. Additional discussion during the meeting included:													

a. Tabled												
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	20											
9. # [REDACTED]	D Y [REDACTED]	11-08-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarify steps taken to reduce surgery time. b. Clarify extended support time. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending Path results. Approved for designated review. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	19											
10. # [REDACTED]	D Y [REDACTED]	11-08-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Additional information requested on timeline and justification. b. Clarification on plans moving forward. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending Path results. Approved for designated review. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	19											
11. # [REDACTED]	C Y [REDACTED]	05-27-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>			IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote												
Approval	19											
Withhold Approval	0											
Abstain	0											
Present	19											

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 04-02-2021	[REDACTED]
2. 04-19-2021	[REDACTED]
3. 04-21-2021	[REDACTED]
4. 04-22-2021	[REDACTED]

Discussion:	2. White powder substance in a clear container was being housed in the room however it was not labeled.										
Action:	2. Reviewed labeling criteria with lab staff. Lab staff has since removed the substance and properly disposed it.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 04-22-2021	LAB	
2. 05-13-2021	LAB	
3. 05-13-2021	LAB	
4. 05-13-2021	LAB	
5. 05-18-2021	LAB	
6. 05-20-2021	LAB	
7. 05-20-2021	LAB	
8. 05-24-2021	PAM	

Discussion:	None.
Action:	None.

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
2021-2022 IACUC Membership	
Discussion:	Please notify IACUC Director if any plans to step down.
Action:	None.
Animals transferred to holding protocol from [REDACTED] ([REDACTED])	
Discussion:	None.
Action:	None.
Future meeting format	
Discussion:	Please notify IACUC Director if strong preference to resume in-person or continue Zoom format in Fall.
Action:	TBD.
PI Maintained Form [REDACTED]	
Discussion:	None.
Action:	Approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

June 10, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M005, M222, M111, M042, A095, M004, M092, M119, M087, A109, M110, M120, M093, A013, M016, M024, M223, M001, M114

Excused:

M102, M090, M112

Guests:

M116

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1. #	Category: D Y										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification still needed regarding in vivo trials and dose/prep.											
Additional discussion during the meeting included: a. Tabled. Will invite PI to next meeting.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	22										

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:	
	Action: Pending pathology results.
	Action: Long term anesthesia evaluation for source and project moving forward.
	Action: Veterinary consult for fish. MS22 and water drainage.
WCW emails targeting VA	

Action: FYI

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	E	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
2. # [REDACTED]	D Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer. Remains in DMR.			
3. # [REDACTED]	C	[REDACTED]	06-10-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarifying drug table Additional discussion during the meeting included: a. None.			
4. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Remains in Designated Member Review			
5. # [REDACTED]	C	[REDACTED]	05-28-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of what part of study occurred on preceding protocol. b. Clarification of treatment approach. c. Clarification of formula to estimate energy. d. Removal of reference to Table 1. e. Clarification of age and post-procedure monitoring for castration and dehorning. Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI response. Remains in DMR.			

7. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending controlled drug account approval.</p>			
8. # [REDACTED]	C	[REDACTED]	06-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of drug volume and overnight housing.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	C	[REDACTED]	06-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
11. # [REDACTED]	D	[REDACTED]	06-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of lit search, adverse effects, and staff roster.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending BUA</p>			
13. # [REDACTED]	C	[REDACTED]	06-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Biosafety confirmed BUA approval and provided updated VHSS. All occupational health status were updated.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	C	[REDACTED]	06-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of cystocentesis and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

15. # [REDACTED]	C	[REDACTED]	06-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Add composition of diet additive to protocol.</p>			
16. # [REDACTED]	C	[REDACTED]	06-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of drug volume and overnight housing.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D	[REDACTED]	06-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in Designated Member Review</p>			
18. # [REDACTED]		[REDACTED]	05-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. clarification of endpoints from disposition added to section 14.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	C	[REDACTED]	06-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed review and provided an updated VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	C	[REDACTED]	05-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of standard-of-care procedures and numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	C	[REDACTED]	06-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	C	[REDACTED]	06-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
23. #	C		06-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		06-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		06-07-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Add how dose was calculated.</p>			
26. #	C		06-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure and terminology.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	D		06-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed review and provided updated VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	C		06-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	C		06-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of methods for determining death vs deep anesthesia.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BIO</p> <p>Additional discussion during the meeting included:</p>			

a. Remains in Designated Member Reviewer			
31. #	D		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Pending chemical safety review and final BUA approval.			
Additional discussion during the meeting included:			
a. Remains in DMR.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		06-07-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
2. #	C		06-10-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
3. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Pending BIO			
Additional discussion during the meeting included:			
a. Remains in Designated Member Review			
4. #	D		06-07-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
5. #	C		05-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
6. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Pending approval of SOPs.			
Additional discussion during the meeting included:			
a. Remains in DMR.			
7. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Pending CHEM			
Additional discussion during the meeting included:			
a. Remains in Designated Member Review			
8. #	D		05-28-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #			-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending chem</p>			
10. #	D Y		06-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending clarification from PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
12. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Verify veterinarian or service with PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI, Remains in DMR.</p>			
13. #	E		06-05-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	C		06-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
16. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending path results.</p>			
17. #	D Y		-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending path results.</p>			
18. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending follow-up with EH&S.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
19. #	D		06-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on organism and pilot experiment.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D Y		06-10-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D Y		06-10-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Duplicate entry.</p>			
22. #	D		06-10-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	C		06-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	C		06-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C Y		06-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 203 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	06-24-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer. Approved for DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
2. # [REDACTED]	C Y	[REDACTED]	06-10-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed review and verified no VHSS was required. Adverse effects clarified. Additional discussion during the meeting included: a. Committee voted to approve protocol.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												
Present	22												
3. # [REDACTED]	D	[REDACTED]	06-10-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed review and provided updated VHSS. Pending final biosafety approval. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
4. # [REDACTED]	D	[REDACTED]	06-14-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Voted for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	21

5. #	D	06-10-2021
------	---	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Analgesia regime updated, surgery room inspected and reviewed with PI.

Additional discussion during the meeting included:

a. Committee voted to approve protocol.

IACUC Vote	
Approval	22
Withhold Approval	0
Abstain	0
Present	22

6. #	D Y	06-24-2021
------	-----	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending reviewers. Approved for DMR.

IACUC Vote	
Approval	21
Withhold Approval	0
Abstain	0
Present	21

7. #	D	06-10-2021
------	---	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Chemical safety officer verified no VHSS is required.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	22
Withhold Approval	0
Abstain	0
Present	22

8. #	D	06-10-2021
------	---	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification on BUA and literature search

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	22

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		6-17-2019	06-10-2021	06-17-2022
	D		6-13-2019	06-10-2021	06-13-2022
	D		6-14-2019	06-10-2021	06-14-2022
	C		6-12-2019	06-10-2021	06-12-2022
	D		6-19-2019	06-10-2021	06-19-2022
	C		6-12-2019	06-10-2021	06-12-2022
	D		6-13-2019	06-10-2021	06-13-2022
	D		6-13-2019	06-10-2021	06-13-2022
	C		6-13-2019	06-10-2021	06-13-2022
	D		6-14-2019	06-10-2021	06-14-2022
	D Y		6-13-2019	06-10-2021	06-13-2022
	D		6-13-2019	06-10-2021	06-13-2022
	D		6-13-2019	06-10-2021	06-13-2022
	C		6-13-2019	06-10-2021	06-13-2022
	C		6-19-2019	06-10-2021	06-19-2022
	D		6-13-2019	06-10-2021	06-13-2022
	C Y		6-13-2019	06-10-2021	06-13-2022
			6-14-2019	06-10-2021	06-14-2022
	D		6-13-2019	06-10-2021	06-13-2022
	D		6-13-2019	06-10-2021	06-13-2022
	D		6-12-2019	06-10-2021	06-12-2022
	D Y		6-13-2019	06-10-2021	06-13-2022

	C Y		06-25-2019	06-10-2021	06-25-2022
	D		06-17-2020	06-09-2022	06-17-2023
	D		06-25-2020	06-23-2022	06-25-2023
	D Y		06-22-2020	06-09-2022	06-22-2023
	C		06-22-2020	06-09-2022	06-22-2023
	C Y		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	C		06-18-2020	06-09-2022	06-18-2023
	C		06-22-2020	06-09-2022	06-22-2023
			06-24-2020	06-09-2022	06-24-2023
	D Y		06-25-2020	06-23-2022	06-25-2023
	E		06-25-2020	06-23-2022	06-25-2023
	C Y		06-25-2020	06-23-2022	06-25-2023
	D		06-25-2020	06-23-2022	06-25-2023
	C		06-25-2020	06-23-2022	06-25-2023
	C		06-25-2020	06-23-2022	06-25-2023
	D Y		06-25-2020	06-23-2022	06-25-2023

Discussion:	<p>-one staff member is in the process completing the OHSS renewal process and just needs to complete the in person appointment.</p> <p>-the permit on the protocol is expired.</p>										
Action Items:	<p>-the committee approved the annual renewals</p> <p>-the committee approved the annual renewals and approved updating permit information on the protocols.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	E	[REDACTED]	06-11-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of plan.</p> <p>Additional discussion during the meeting included:</p> <p>a. Discussed facility options with CABA Director. Voted to send to DR to edit plan.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
2. # [REDACTED]	D Y	[REDACTED]											
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer. Approved for DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
3. # [REDACTED]	D Y	[REDACTED]	06-24-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Committee requests clarification as to how many animals are being affected.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to send to DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
4. # [REDACTED]	D	[REDACTED]	06-10-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed PAM associated with amendment under inspection section. PI to report adverse events to CVS first and seek assessment for issues not covered under the protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve amendment.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0		
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												

	Present	22											
5. #	C		06-10-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI Additional discussion during the meeting included: a. Voted to Designated Member Review													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
6. #	C		06-10-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Committee voted to approve amendment.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												
Present	22												
7. #	D		06-10-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on animal numbers and second surgery Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	1	Present	22
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	1												
Present	22												
8. #	C Y		06-10-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Committee voted to approve amendment.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												
Present	22												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
-----------------	----------

1. 04-28-2021	
2. 05-06-2021	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>22</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>22</td></tr> </tbody> </table>		IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote											
Approval	22										
Withhold Approval	0										
Abstain	0										
Present	22										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 05-24-2021	LAB	
2. 05-27-2021	LAB	
3. 05-27-2021	LAB	
4. 05-27-2021	LAB	
5. 06-01-2021	PAM	

Discussion:	5. PI is now aware they must contact CVS for all actions requiring care that are not covered in the protocol and submit an amendment for approval to complete procedures in the future.										
Action:	5. Committee approved the proposed plan.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>22</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>22</td></tr> </tbody> </table>		IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote											
Approval	22										
Withhold Approval	0										
Abstain	0										
Present	22										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. [REDACTED] protocol	
Discussion:	Replacement protocol was approved during the meeting.
Action:	Animals will be transferred to the replacement protocol after the meeting.
2. Guest - CVS resident [REDACTED]	
Discussion:	None.
Action:	None.
3. IACUC Office staffing update	
Discussion:	Assistant Director appointment.
Action:	None.
4. Guest - [REDACTED]	
Discussion:	Discuss potential options for CABA tanks.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

June 24, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M097, M005, M222, M102, M111, M042, A095, M092, A019, M119, M087, A109, M110, M093, A013, M024, M001, M112, M114

Excused:

M009, M090, M004, M120, M016, M223

Guests:

M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1. # [REDACTED]	Category: D Y										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI attended meeting to provide clarification of changes proposed and concerns about not doing a cohort of 4 animals at a time.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee discussed PI's responses and proposed to suggest PI either complete 1 animal for proof of concept or add an additional animal to the protocol for the proof of concept and if no adverse occur, proceed with cohort of n=4. Voted to send the DMR. Chair or Director to contact PI to review plan and suggest modifications to amendment for approval.</p> <table border="1"><thead><tr><th colspan="2">IACUC Vote</th></tr></thead><tbody><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></tbody></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	20										

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:	
[REDACTED]	
[REDACTED]	Action: Pathology results inconclusive for cause of fractures.
[REDACTED]	
[REDACTED]	Action: No deficiencies by PI. CVS made an error in volume of one of the two analgesics. PAM report at the end of the agenda discussed.

		Action: Protocol includes peritonitis as an adverse effect however the incident has exceeded 10 %. The PI will be submitting a Care Update report and plans to decrease incidents.
		Action: PI/vet staff timely communication. Blood from food source mistaken as injury.
		Action: Discussed lower dose of analgesic being given and poor documentation.
		Action: Discussion of event and amendment to follow.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
2. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer. Remains in DMR,</p>			
3. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Recommendation to withdraw protocol. Waiting for PI to respond.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remaining in DMR</p>			
4. # [REDACTED]	C	[REDACTED]	06-23-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Procedural clarifications.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D	[REDACTED]	06-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Controlled drug approval still pending. Removed controlled drug and left veterinarian approved alternative.</p>			

Additional discussion during the meeting included: a. None.			
6. #	D Y		06-24-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.Remains in DMR.			
7. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA approval. Additional discussion during the meeting included: a. Remains in DMR.			
8. #			06-23-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of animal sources. Additional discussion during the meeting included: a. None.			
9. #	D		06-14-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. BUA Approved.			
10. #	D		06-10-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
11. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI's response to clarifying questions. Additional discussion during the meeting included: a. Remains in DMR.			
12. #	D		06-23-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
13. #	D		06-10-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety and biosafety reviews completed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED]	06-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Procedures and numbers questions addressed by PI</p>			
15. # [REDACTED]	D Y	[REDACTED]	06-24-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	D	[REDACTED]	06-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Update on drug table.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D	[REDACTED]	06-24-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	06-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	06-23-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical and bio reviews completed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	D	[REDACTED]	06-24-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's responses to chemical safety officer.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remained in DMR.</p>			
21. # [REDACTED]	C	[REDACTED]	06-24-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. None.			
22. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending Reviewer Additional discussion during the meeting included: a. Remaining in DMR			
23. #	D		06-23-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarificaiton on timepoints. Additional discussion during the meeting included: a. None.			
24. #	B		06-11-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
25. #	D Y		06-24-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarificaiton on animals being received. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	E		06-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Revision of plan based on IACUC discussion. Additional discussion during the meeting included: a. None.			
2. #	C		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Approved by second reviewer.			
3. #	D Y		06-14-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
4. #	D Y		06-14-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
5. #	D		06-17-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Verification with BUA Additional discussion during the meeting included: a. None.			
6. #	D Y		06-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
7. #	C		06-17-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. #	D		06-23-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Dosage determination was added.			
9. #	D		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
10. #	C Y		06-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
11. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending further discussion with PI.			
12. #	D Y		06-22-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
13. #	C		06-24-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D Y		06-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	C		06-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D		06-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D		06-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI removed imaging studies and will submit another amendment in the future when SOPs are approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	D		06-11-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #			06-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		06-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D		06-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. None.			
22. #	D		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
23. #	D Y		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Incident of adverse effects clarified. Additional discussion during the meeting included: a. None.			
24. #	D Y		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Incident of adverse effects clarified. Additional discussion during the meeting included: a. None.			
25. #	D Y		06-21-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Monitoring procedures clarified. Additional discussion during the meeting included: a. None.			
26. #	C		06-23-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
27. #	E		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Verified groups amendment applies to			
28. #	C		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
29. #	C		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
30. #	D Y		06-22-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. #	D Y		06-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. #	D		06-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
34. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
35. #	C Y		06-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on recombinant antibody, species origin and potential for allergic reaction or neutralization.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
36. #	C		06-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
37. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Chem</p>			
38. #	D		06-23-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
39. #	D		06-23-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
40. #	C		06-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
41. #	C		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
42. #	E		06-23-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
43. #	C		06-23-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
44. #	D		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
45. #	C		06-10-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarificaion on thermal perch temperatures and potential adverse effects. Additional discussion during the meeting included: a. None.			
46. #	C		06-24-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
47. #	C		06-21-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
48. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending path results.			
49. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending path results.			
50. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending further discussion with EH&S.			
51. #	C		06-23-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 143 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	08-05-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Pending PI and reviewer. Voted to send to DR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0

	Present	20											
2. #	C		07-01-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. Clarifications requested for final approval.													
Additional discussion during the meeting included:													
a. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
3. #	D		07-01-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. Pending final chemical safety review.													
Additional discussion during the meeting included:													
a. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
4. #	C Y		06-28-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. None.													
Additional discussion during the meeting included:													
a. Pending reviewer. Approved for DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
5. #	C Y		06-24-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:													
a. Reviewed PI status and maintenance of colony.													
Additional discussion during the meeting included:													
a. Committee voted to approve with PI status confirmed.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
6. #	D		06-24-2021										

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Reviewed protocol content and discussed space will be set up for PI maintain. PI maintain form discussed first and approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. Protocol approved. IACUC staff to schedule a time to meet with PI and review space set up and congruency of SOP and room log.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
7. # [REDACTED]	D	[REDACTED]	08-05-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to DMR</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
8. # [REDACTED]	D Y	[REDACTED]	06-24-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>1</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	1	Present	20
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	1												
Present	20												
9. # [REDACTED]	D	[REDACTED]	06-24-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>1</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	1	Present	20
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	1												
Present	20												
10. # [REDACTED]	D Y	[REDACTED]	06-25-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Pending PI response.

Additional discussion during the meeting included:

a. Voted to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		06-27-2019	06-24-2021	06-27-2022
	D		06-26-2019	06-24-2021	06-26-2022
	D		07-02-2019	06-24-2021	07-02-2022
	D		06-27-2019	06-24-2021	06-27-2022
	C		07-09-2019	06-24-2021	07-09-2022
			07-05-2019	06-24-2021	07-05-2022
	C		07-01-2019	06-24-2021	07-01-2022
	C		06-26-2019	06-24-2021	06-26-2022
	D		06-27-2019	06-24-2021	06-27-2022
	D		06-27-2019	06-24-2021	06-27-2022
	D Y		06-27-2019	06-24-2021	06-27-2022
	C		07-02-2019	06-24-2021	07-02-2022
	D		07-02-2019	06-24-2021	07-02-2022
	B		07-03-2019	06-24-2021	07-03-2022
	D		06-27-2019	06-24-2021	06-27-2022
	D		06-27-2019	06-24-2021	06-27-2022
	D		07-01-2019	06-24-2021	07-01-2022
	C		06-27-2019	06-24-2021	06-27-2022
	D Y		06-27-2019	06-24-2021	06-27-2022

	C		06-27-2019	06-24-2021	06-27-2022
	C		06-26-2019	06-24-2021	06-26-2022
	C		07-05-2019	06-24-2021	07-05-2022
	C		06-27-2019	06-24-2021	06-27-2022
	D Y		06-27-2019	06-24-2021	06-27-2022
	C Y		06-27-2019	06-24-2021	06-27-2022
	D		07-08-2020	06-23-2022	07-08-2023
	C		06-23-2020	06-09-2022	06-23-2023
	D Y		06-29-2020	06-23-2022	06-29-2023
	D		06-25-2020	06-23-2022	06-25-2023
	C		07-07-2020	06-24-2021	04-06-2022
	C		07-09-2020	07-07-2022	07-09-2023
			07-09-2020	07-07-2022	07-09-2023
	C		07-09-2020	07-07-2022	07-09-2023
	C Y		07-09-2020	07-07-2022	07-09-2023
	C Y		07-09-2020	07-07-2022	07-09-2023
	C		07-05-2020	06-24-2021	07-05-2022
	C		07-06-2020	06-23-2022	07-06-2023
	D		07-09-2020	07-07-2022	07-09-2023
	D		07-09-2020	07-07-2022	07-09-2023
	C Y		07-09-2020	07-07-2022	07-09-2023
	C		07-09-2020	07-07-2022	07-09-2023
	C		07-09-2020	07-07-2022	07-09-2023

Discussion:	None.
Action Items:	None.

IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	C Y	[REDACTED]	06-24-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Criteria for evaluating and assessing effect of night time separation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	1	Present	20
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	1												
Present	20												
2. # [REDACTED]	C Y	[REDACTED]	06-24-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	1	Present	20
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	1												
Present	20												
3. # [REDACTED]	D Y	[REDACTED]	06-24-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding maximum volume.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	D	[REDACTED]	06-24-2021										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Potential adverse effects clarified. Chemical safety officer provided updated VHSS.

Additional discussion during the meeting included:

- a. Committee voted to approve.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

5. #	C		06-24-2021
------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	1
Present	20

6. #	C Y		06-24-2021
------	-----	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	1
Present	20

7. #	C		06-24-2021
------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	1
Present	20

8. #	D		06-30-2021
------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Pending clarification of study endpoint and animal source from AV.

IACUC Vote	
------------	--

Approval	0
Withhold Approval	0
Abstain	0
Present	19

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 06-14-2021	

Discussion:	No deficiency of the PI's staff. CVS provides the post-op care and miscalculated one of the analgesia doses. The animal had no signs of pain and was being covered by two analgesics.
Action:	Response to deficiency approved.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 01-20-2021	LAB	
2. 01-26-2021	LAB	
3. 06-10-2021	LAB	
4. 03-22-2021	PAM	
5. 03-22-2021	PAM	
6. 04-22-2021	PAM	
7. 04-26-2021	PAM	
8. 05-04-2021	PAM	
9. 05-18-2021	PAM	
10. 06-01-2021	PAM	
11. 06-01-2021	PAM	
12. 06-01-2021	PAM	
13. 06-01-2021	PAM	
14. 06-13-2021	PAM	

Discussion:	None.
Action:	None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:

Inspection Date	Agency	Location	Summary	Discussion
1. 06-23-2021	USDA	site 2; focused	None.	None.

XV. Other Discussion Items:

Topic	
1) [REDACTED]	PI Maintained form
Discussion:	All CABA PI areas are now being required to have a PI maintain form on file.
Action:	Committee approved the PI maintain request form.
2) Imaging SOP for [REDACTED]	
Discussion:	None.
Action:	None.
3) Retiring Committee Member(s).	
Discussion:	Dedicated career service .
Action:	None.
Guest- [REDACTED]	
Discussion:	See notes at top of agenda under tabled amendments.
Action:	See notes at top of agenda under tabled amendments.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

July 08, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M102, M111, A095, M092, A019, M119, M087, M110, M120, M093, A013, M016, M024,
M223, M001, M114

Excused:

M222, M090, M042, M004, M100, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the April 15, 2021, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

The IACUC reviewed and approved the April 29, 2021, meeting minutes as written.

IACUC Vote	
Approval	13
Withhold Approval	0
Abstain	0
Present	1

The IACUC reviewed and approved the May 13, 2021, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

The IACUC reviewed and approved the May 27, 2021, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
The Physicians Committee for Responsible Medicine, pursuant to the California Public Records Act, requests copies of the following: Period: October 10, 2020 to present Scope: 1. The current version of all Institutional Animal Care and Use Committee (IACUC) protocols and protocol reviews related to the training of the University of California Davis' general surgery residents. 2. IACUC annual reports, reviews, meeting minutes, and other IACUC documentation related to the use of animals for training general surgery residents. 3. Documents that include training schedules that involve animal use for training general surgery residents. 4. Documents related to the purchase or acquisition of animals for use in training general surgery residents. 5. All photographs and video footage related to the items above.
Action: None.
Action: Sturgeon found out of outdoor tank; presumed spooked by fireworks activity. Sturgeon euthanized. Tank shade cover repaired and re-aligned.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	E	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
2. # [REDACTED]	D Y	[REDACTED]	07-08-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Animal numbers. b. Transportation. Additional discussion during the meeting included: a. None.			
3. # [REDACTED]	D Y	[REDACTED]	06-24-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

4. # [REDACTED]	C	[REDACTED]	07-07-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Final review and approval of BUA. IACUC director working with PI on CDFW requirements. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
5. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending PI responses to chemical safety officer. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
6. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of Consent Form, drug volume and drug route, group, and adverse effects. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI. 			
7. # [REDACTED]	C	[REDACTED]	07-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. PI clarified drugs dosages and maximum volume of samples. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
8. # [REDACTED]	C	[REDACTED]	07-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. correction of ANS student numbers b. uploaded SOP. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
9. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI 			
10. # [REDACTED]	D	[REDACTED]	07-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Final review completed by chemical safety officer. Verified no VHSS are required. Recommended statement put in section 7. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
11. # [REDACTED]	D	[REDACTED]	06-24-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. PI provided clarification about protentional adverse effects. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			

12. # [REDACTED]	C	[REDACTED]	07-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided to PI about MOU vs. TAF process and requirements. AV discussed with PI that a protocol was not required for this study but the PI requested the review for publication.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C Y	[REDACTED]	06-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
15. # [REDACTED]	D Y	[REDACTED]	07-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	07-07-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on BUA, transportation and drug administration.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending BUA. Remains in DMR</p>			
18. # [REDACTED]	C Y	[REDACTED]	07-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on treatment options for pain and itch as well as breeding.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending CHEM. Remains in DMR.</p>			
20. # [REDACTED]	D	[REDACTED]	07-02-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D Y	[REDACTED]	06-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	C	[REDACTED]	07-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on personnel training.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	D	[REDACTED]	06-27-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on disposition.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	C	[REDACTED]	07-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified breed</p> <p>b. Clarification of husbandry responsibilities between investigator and vivarium</p> <p>c. Clarification of study timing</p> <p>d. Clarification of adverse effects</p> <p>e. Correction of dairy parlor type</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	B	[REDACTED]	07-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	D	[REDACTED]	07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final BUA approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
3. # [REDACTED]	C	[REDACTED]	07-01-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending reviewer.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
5. #	B		07-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #			06-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	D		07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	C		06-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	D		07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	D		07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on habituation</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Revoewer. Remains in DMR.</p>			

12. # [REDACTED]	D	[REDACTED]	07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	D	[REDACTED]	07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on drugs</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED] with [REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of endpoints</p> <p>b. Clarification of drug formulation.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
15. # [REDACTED]	Y	[REDACTED]	07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	D Y	[REDACTED]	07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Neither acetyl choline nor GABA require a VHSS.</p>			
17. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final approval of BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
18. # [REDACTED]	D	[REDACTED]	07-06-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Chem</p>			
20. # [REDACTED]	D Y	[REDACTED]	07-02-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI modified amendment to meet committee recommendations. PI to start with an n of 1 for proof of concept and work with CVS regarding outcomes before proceeding with next cohort of 4.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D		07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Seven day shedding period for AAV. b. Remains in DMR.</p>			
23. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Keep in DMR until necropsy results are available (second pending amendment).</p>			
24. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Neurological findings are consistent with inflammation; possible foreign body reaction and device compatibility. b. Future mitigation methods. c. Antibiotic use. d. Mitigation measures to prevent potential infection. e. Device sterilization techniques.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
25. #	D Y		06-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D		07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	C Y		07-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

28. # [REDACTED]	D	[REDACTED]	06-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. # [REDACTED]	D Y	[REDACTED]	07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Potential risk of aspiration and management.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer. Remains in DMR</p>			
30. # [REDACTED]	C Y	[REDACTED]	07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 164 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	07-08-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Additional information on alternatives and mitigation methods requested.b. Clarification on fasting prior to surgery.c. Clarification on surgical and anesthesia timeline and anesthesia support, clarification and frequency of assessment, .d. Frequency of weight monitoring.e. Personnel OHSS renewals.f. MRI location confirmed.g. Drug and procedure clarification.h. Testing cage clarification.i. Additional consultation with vets recommended for anesthesia recovery plan. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. IACUC staff noted IT error in protocol review tracking history. Did not track properly on agendas or minutes across meetings. IT recovery was required. Previously discussed items now all summarized above. <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
2. # [REDACTED]	D	[REDACTED]	07-14-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending Chem, voted for DMR

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	17

3. # [REDACTED]	D	[REDACTED]	08-18-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending reviewers. Voted to send to DR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	17

4. # [REDACTED]	C	[REDACTED]	07-12-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification requested maintenance and training procedures.

Additional discussion during the meeting included:

a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	17

5. # [REDACTED]	D	[REDACTED]	08-09-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. pending PI and reviewer. Request DR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	17

6. # [REDACTED]	D	[REDACTED]	07-08-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Biosafety and chemical safety officers completed their reviews and provided updated VHSS. Extra cage changes removed from section 9 and included in section 7.

Additional discussion during the meeting included:

a. Committee voted to approve.

<div style="border: 1px solid black; padding: 5px;"> IACUC Vote Approval 17 Withhold Approval 0 Abstain 0 Present 17 </div>			
7. #	D		07-08-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed review and provided an updated VHSS. Additional discussion during the meeting included: a. Committee voted to approve.			
<div style="border: 1px solid black; padding: 5px;"> IACUC Vote Approval 16 Withhold Approval 0 Abstain 1 Present 17 </div>			

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D Y		7-11-2019	07-08-2021	07-11-2022
	C		7-12-2019	07-08-2021	07-12-2022
	C		7-11-2019	07-08-2021	07-11-2022
	C		7-10-2019	07-08-2021	07-10-2022
	D		7-11-2019	07-08-2021	07-11-2022
	C		7-11-2019	07-08-2021	07-11-2022
	C		7-11-2019	07-08-2021	07-11-2022
	D		7-11-2019	07-08-2021	07-11-2022
	E		7-15-2019	07-08-2021	07-15-2022
	C Y		7-22-2019	07-08-2021	07-22-2022
	C		7-11-2019	07-08-2021	07-11-2022
	C		7-11-2019	07-08-2021	07-11-2022
	C Y		7-10-2019	07-08-2021	07-10-2022
	D		7-10-2019	07-08-2021	07-10-2022
	D		7-18-2019	07-08-2021	07-18-2022

	D Y		07-20-2020	07-07-2022	07-20-2023
	D Y		07-17-2020	07-07-2022	07-17-2023
	C		07-23-2020	07-08-2021	07-23-2022
	C		07-13-2020	07-07-2022	07-13-2023
	D		07-23-2020	07-08-2021	07-23-2022
	C		07-17-2020	07-07-2022	07-17-2023
	D		07-23-2020	07-08-2021	07-23-2022
	C		07-23-2020	07-08-2021	07-23-2022
	C		07-23-2020	07-08-2021	07-23-2022
	D		07-23-2020	07-08-2021	07-23-2022
	C		07-08-2020	06-23-2022	07-08-2023
	E		07-23-2020	07-08-2021	07-23-2022
	D		07-23-2020	07-08-2021	07-23-2023
	D		07-23-2020	07-08-2021	07-23-2022
	D		07-23-2020	07-08-2021	07-23-2022

Discussion:	<p>██████████, ██████████, ██████████, ██████████, ██████████, ██████████, ██████████ and ██████████-one staff member is in progress to update their OHSS status. All are either pending their in person appointment or awaiting lab results.</p> <p>██████████-Categorized as D however PI provided video demonstrating the procedure does not cause more than momentary pain or distress.</p> <p>██████████-Section 9 of the protocol was missed during the original final approval process and content that was no longer accurate remains. Section 15 clarifies the Humane Endpoints Policy is followed.</p> <p>██████████-Clarification is needed regarding monitoring of animals, endpoints and analgesic regime.</p>										
Action Items:	<p>██████████, ██████████, ██████████, ██████████, ██████████, ██████████, ██████████ and ██████████ committee voted to approve annual renewals.</p> <p>██████████-Committee voted to change category to C.</p> <p>██████████-Committee voted to remove wording in section 9 and updated category to D.</p> <p>██████████-Annual renewal tabled. IACUC staff to work with PI to update protocol via an amendment.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>17</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </tbody> </table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	C	[REDACTED]	07-26-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending edits by reviewer. Voted to send to DR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>16</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	16												
2. # [REDACTED]	D	[REDACTED]	07-08-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
3. # [REDACTED]	D	[REDACTED]	07-08-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Adjusted POV of wording. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
4. # [REDACTED]	D	[REDACTED]	07-08-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed review and provided updated VHSS. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>16</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr></table>				IACUC Vote		Approval	16	Withhold Approval	0	Abstain	1		
IACUC Vote													
Approval	16												
Withhold Approval	0												
Abstain	1												

	Present	17											
5. #	D Y		07-10-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Treatment criteria determination and consideration of pilot study.b. Induction model species comparison. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. Approved for DMR. <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
6. #	C Y		07-08-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
7. #	D Y		07-08-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 02-25-2021	
2. 03-02-2021	
3. 03-02-2021	
4. 03-11-2021	
5. 03-15-2021	
6. 03-18-2021	
7. 03-25-2021	
8. 04-09-2021	

9. 04-13-2021		
10. 04-27-2021		
11. 04-28-2021		
12. 05-07-2021		
13. 05-12-2021		
14. 05-17-2021		
15. 05-21-2021		
16. 05-21-2021		
17. 05-24-2021		
18. 06-02-2021		
19. 07-01-2021		

Discussion:	17. Animals were housed at the facility however the location was not approved on the PI's protocol.										
Action:	17. Facility will perform a better review process to ensure animals are not transferred to their facility if the location has not been approved by IACUC.										
<table border="1"> <thead> <tr><th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr><td>Approval</td><td>14</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>14</td></tr> </tbody> </table>		IACUC Vote		Approval	14	Withhold Approval	0	Abstain	0	Present	14
IACUC Vote											
Approval	14										
Withhold Approval	0										
Abstain	0										
Present	14										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 12-30-2020	LAB	
2. 01-26-2021	LAB	
3. 02-01-2021	LAB	
4. 02-02-2021	LAB	
5. 02-04-2021	LAB	
6. 03-11-2021	LAB	
7. 03-18-2021	LAB	
8. 03-19-2021	LAB	
9. 03-19-2021	LAB	
10. 03-22-2021	LAB	
11. 04-01-2021	LAB	
12. 04-02-2021	LAB	
13. 04-02-2021	LAB	
14. 04-16-2021	LAB	
15. 04-19-2021	LAB	
16. 04-19-2021	LAB	
17. 04-19-2021	LAB	
18. 04-26-2021	LAB	
19. 04-28-2021	LAB	
20. 04-28-2021	LAB	
21. 04-28-2021	LAB	
22. 04-28-2021	LAB	
23. 04-28-2021	LAB	
24. 04-28-2021	LAB	

25. 05-03-2021	LAB	
26. 05-05-2021	LAB	
27. 05-07-2021	LAB	
28. 05-07-2021	LAB	
29. 05-20-2021	LAB	
30. 05-25-2021	LAB	
31. 05-25-2021	LAB	
32. 05-28-2021	LAB	
33. 06-29-2021	LAB	
34. 06-30-2021	LAB	
35. 06-30-2021	LAB	
36. 06-30-2021	LAB	
37. 06-01-2021	PAM	
38. 06-18-2021	PAM	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr><th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr><td>Approval</td><td>16</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1) Introduce IACUC Office Specialist [REDACTED]	
Discussion:	None.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

July 22, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M222, M102, M111, M042, A095, M100, M092, A019, M119, M087, A109, M110, M120, A013, M024, M223, M001, M114

Excused:

M090, M004, M093, M016, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the June 10, 2021, meeting minutes as written.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

The IACUC reviewed and approved the June 24, 2021, meeting minutes as written.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

██████ ██████ review of protocol and post-op record revealed confusion in how the protocol was written regarding analgesia doses and frequency as well as when CVS will be contacted.

Action: Reviewed PAM responses and post-op record documentation. Committee agreed the PI's staff assessment was in line with the study model. All deficiencies noted were minor. PI is working on submitting an amendment to clarify the protocol.

		Action: Committee heard concerns expressed by two VMTH clinicians regarding anesthesia project study design, potential adverse effects, length of anesthesia, and drugs being studied. PI presented summary of project to date, potential future mitigation measures, number of animals required, and value of this model. IACUC members discussed risk/benefit. IACUC appointed subcommittee for further review.
		Action: Tabled to next meeting.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI, To be withdrawn for non-response</p>			
2. # [REDACTED]	D	[REDACTED]	07-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
4. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of funding, hazards, monitoring, and transmission.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
5. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of standard of care.</p> <p>Additional discussion during the meeting included:</p>			

a. Pending PI.			
6. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
7. # [REDACTED]	C	[REDACTED]	07-12-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding housing and maintenance procedures provided by PI and husbandry staff. Director working with PI to amend CDFW permit.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	C	[REDACTED]	07-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending remaining veterinary questions.</p>			
10. # [REDACTED]	C	[REDACTED]	07-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of husbandry.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	C	[REDACTED]	07-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. IACUC member suggested wording change.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	07-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C	[REDACTED]	07-22-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on locations for housing and procedures. Clarification on potential adverse effects from neuroblastoma.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending BUA.</p>			
15. #	D		07-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures regarding itch and animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D Y		07-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety review and addition of VHSS's.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	C Y		07-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of urine collection and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
19. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
20. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending clarification regarding collaboration and BUA amendment approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
2. #	C		-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
3. #	C		07-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding sample collection.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #			-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final review by chemical safety.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
5. #	C		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #	D		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	C		07-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	D Y		07-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	C		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of study design.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	C		07-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

	a. None.		
11. #	D		07-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Suggestion to increase habituation in behavioral room.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		07-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Room will be set up as a lab inspection.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	D		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D		07-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of euthanasia criteria.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
16. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
17. #	D Y		07-10-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Optimal treatment interval and potential pilot study.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	E		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D		07-22-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		07-20-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. correction of mouse strain name typo.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	D Y		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Biosafety officer confirmed approval of BUA amendment.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	E		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	E		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending CHEM.</p>			
25. #	D		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	C		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	D		07-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	D		07-16-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chem safety review and recommendations for Vancomycin use.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Seven day shedding period for AAV.</p> <p>b. Recommend further discussion with Biosafety officer and IBC.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
30. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Keep in DMR until necropsy results are available (second pending amendment).</p>			
31. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Neurological findings are consistent with inflammation; possible foreign body reaction and device compatibility.</p> <p>b. Future mitigation methods.</p> <p>c. Antibiotic use.</p> <p>d. Mitigation measures to prevent potential infection.</p> <p>e. Device sterilization techniques.</p> <p>Additional discussion during the meeting included:</p> <p>a. Additional path result consultation required.</p>			
32. #	D		07-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified source and numbers justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. #	D Y		07-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Aspiration risk and management.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
34. #	D		07-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
35. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
36. #	C		07-22-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
37. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.			
38. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 346 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	07-22-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	E	[REDACTED]	07-22-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

3. #	D	08-18-2021
------	---	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending PI. Voted to send to DR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		07-25-2019	07-22-2021	07-25-2022
	D		07-29-2019	07-22-2021	07-29-2022
	C		07-09-2019	07-22-2021	07-09-2022
	C		07-09-2019	07-22-2021	07-09-2022
			07-24-2019	07-22-2021	07-24-2022
	D		07-25-2019	07-22-2021	07-25-2022
	C		07-25-2019	07-22-2021	07-25-2022
	C		07-31-2019	07-22-2021	07-31-2022
	C		07-24-2019	07-22-2021	07-24-2022
	D Y		07-25-2019	07-22-2021	07-25-2022
	D		07-24-2019	07-22-2021	07-24-2022
			07-24-2019	07-22-2021	07-24-2022

	D		07-30-2019	07-22-2021	07-30-2022
	C		07-25-2019	07-22-2021	07-25-2022
	C		07-25-2019	07-22-2021	07-25-2022
	D		08-05-2019	07-22-2021	08-05-2022
	C		07-10-2019	07-22-2021	07-10-2022
	C Y		08-05-2019	07-22-2021	08-05-2022
	D Y		07-25-2019	07-22-2021	07-25-2022
	C		07-26-2019	07-22-2021	07-26-2022
	C		07-24-2019	07-22-2021	07-24-2022
	D		08-02-2019	07-22-2021	08-02-2022
	C		08-05-2019	07-22-2021	08-05-2022
	C		08-02-2019	07-22-2021	08-02-2022
	C		08-05-2019	07-22-2021	08-05-2022
	E		08-06-2020	07-22-2021	08-06-2022
	C		07-20-2020	07-22-2021	07-22-2022
	D		08-06-2020	07-22-2021	08-06-2022
	D		07-31-2020	07-22-2021	07-31-2022
	C		07-28-2020	07-22-2021	07-28-2022
	C		07-28-2020	07-22-2021	07-28-2022
	D		07-23-2020	07-22-2021	07-23-2022
	D Y		08-06-2020	07-22-2021	08-06-2022
	D		08-06-2020	07-22-2021	08-06-2022
	D		08-06-2020	07-22-2021	08-06-2022
	C		07-21-2020	07-07-2022	07-21-2023
	C		08-04-2020	07-22-2021	08-04-2022
	C Y		08-06-2020	07-22-2021	08-06-2022
	C		08-06-2020	07-22-2021	08-06-2022

40. #	C		08-05-2020	07-22-2021	08-05-2022
----------	---	--	------------	------------	------------

Discussion:	<p>-PI is on last step of OHSS renewal process.</p> <p>-IACUC staff is working with PI to amend protocol to update the alternate contact.</p> <p>-PI submitted an amendment clarifying monitoring procedures and study endpoints and will be reviewed under the FC amendments.</p>										
Action Items:	<p>-Committee approved the annual renewal.</p> <p>-Committee approved the annual renewal.</p> <p>-Committee approved the annual renewal.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>18</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>18</td></tr> </tbody> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D	[REDACTED]	07-26-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI response.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	C Y	[REDACTED]	07-22-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
3. # [REDACTED]	D	[REDACTED]	07-22-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Reviewers agreed the additional wording clarify the scoring system and endpoints categories the study as D.</p> <p>Additional discussion during the meeting included:</p>													

a. Committee voted to approve.												
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>			IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	20											
Withhold Approval	0											
Abstain	0											
Present	20											
4. # [REDACTED]	E [REDACTED]	07-22-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>			IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	20											
Withhold Approval	0											
Abstain	0											
Present	20											
5. # [REDACTED]	D Y [REDACTED]	07-22-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified CVS to perform adoption exams per policy and will make the final determination when animals are ready to leave.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>			IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	20											
Withhold Approval	0											
Abstain	0											
Present	20											

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 03-23-2021	[REDACTED]
2. 03-24-2021	
3. 03-30-2021	
4. 04-06-2021	
5. 04-20-2021	
6. 04-22-2021	
7. 04-30-2021	
8. 05-06-2021	
9. 05-07-2021	
10. 05-20-2021	
11. 05-26-2021	
12. 07-16-2021	
Discussion:	None.
Action:	None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 04-23-2021	LAB	
2. 04-23-2021	LAB	
3. 06-29-2021	LAB	
4. 06-29-2021	LAB	
5. 06-30-2021	LAB	
6. 06-30-2021	LAB	
7. 06-30-2021	LAB	
8. 06-18-2021	PAM	
9. 07-12-2021	PAM	

Discussion:	9. Review of post-op records and protocol revealed confusion and inconsistencies.										
Action:	9. PI to modify surgery records and submit an amendment to the protocol to clarify monitoring and analgesia.										
<table> <tr> <td colspan="2">IACUC Vote</td></tr> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic
1. Guests to discuss [REDACTED] protocol [REDACTED]
Discussion: See above section 4.
Action: IACUC appointed subcommittee for further review.
2. IACUC Chair and Vice-Chair appointments
Discussion: Appointment letter sent from VCR.
Action: None.
3. 2021-2022 IACUC appointment letter and meeting dates
Discussion: Appointment letters sent from VCR.
Action: None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

August 05, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M102, M111, M090, M042, A095, M100, M092, A019, M119, M087, A109, M110, M120, M093, A013, M016, M024, M223, M001, M112, M114

Excused:

M222, M004

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

<div style="background-color: black; width: 100px; height: 1.2em; display: inline-block;"></div>
--

Action: 2.9% fish mortality; aging infrastructure

<div style="background-color: black; width: 100px; height: 1.2em; display: inline-block;"></div>
--

Action: IACUC updated on subcommittee approach to engage external subject matter reviewers.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # <div style="background-color: black; width: 40px; height: 1.2em; display: inline-block;"></div>	C	<div style="background-color: black; width: 340px; height: 40px; display: inline-block;"></div>	-
<div>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:<div>a. Pending PI's responses.</div>Additional discussion during the meeting included:</div>			

a. Remains in DMR.			
2. # [REDACTED]	D	[REDACTED]	08-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of experimental procedures versus standard of care.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending.</p>			
4. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of experimental procedures versus standard of care.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending.</p>			
5. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI response</p>			
6. # [REDACTED]	C	[REDACTED]	07-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	08-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on location for BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of numbers and stem cell concentration.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
9. # [REDACTED]	C	[REDACTED]	08-02-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	D		08-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarification of single housing and controls.</p>			
11. #			-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Request update on OHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI response.</p>			
12. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
13. #	D Y		08-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer</p>			
14. #	C Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
15. #	C		08-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Monitoring of parameters.</p>			
16. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending approval of BUA amendment.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
17. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. Pending Reviewer			
18. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Reviewer			
19. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. pending reviewer			
20. #	C		07-29-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Suggestions on wording in the protocol. Additional discussion during the meeting included: a. None.			
21. #	B		07-27-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
22. #	B		07-27-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
23. #	D		08-05-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed review and provided updated VHSS. Additional discussion during the meeting included: a. None.			
24. #	C		08-05-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on procedure. Additional discussion during the meeting included: a. None.			
25. #	C		08-05-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
26. #	C		08-02-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	C	[REDACTED]	07-26-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
2. # [REDACTED]	C Y	[REDACTED]	07-27-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
3. # [REDACTED]	C Y	[REDACTED]	08-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
4. # [REDACTED]	D	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. Remains in DMR.			
5. # [REDACTED]	C	[REDACTED]	08-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
6. # [REDACTED]	C	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. Remains in DMR.			
7. # [REDACTED]	C	[REDACTED]	08-05-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification of statistics.			
Additional discussion during the meeting included:			
a. None.			
8. # [REDACTED]	D	[REDACTED]	08-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			

9. # [REDACTED]	D	[REDACTED]	08-05-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D Y	[REDACTED]	07-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]		[REDACTED]	08-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed final review and provided updated VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	08-05-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
13. # [REDACTED]	D	[REDACTED]	08-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED]	08-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	C	[REDACTED]	08-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	D	[REDACTED]	07-26-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	C	[REDACTED]	08-04-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	D		08-05-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer completed final review and provided updated VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D		08-05-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of drug preparation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		08-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		08-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	D		08-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	D		08-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Endpoint clarification.</p> <p>b. Cholestyramine administration and diet prep clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
25. #	C		08-05-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

26. # [REDACTED]	D	[REDACTED]	08-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Mouse strain clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. # [REDACTED]	E	[REDACTED]	08-05-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. # [REDACTED]	D	[REDACTED]	08-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. # [REDACTED]	C Y	[REDACTED]	08-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. # [REDACTED]	C	[REDACTED]	08-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. # [REDACTED]	C	[REDACTED]	07-21-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
33. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
34. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. Remains in DMR			
35. #	E		08-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
36. #	D Y		07-30-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
37. #	D		08-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Reference request for dosing. b. Value of Serum chemistries. c. Add blood glucose and azo as proposed. Additional discussion during the meeting included: a. None.			
38. #	D		08-05-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
39. #	D		07-30-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
40. #	D		08-05-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Maximum imaging and anesthesia episodes. Additional discussion during the meeting included: a. None.			
41. #	C Y		07-30-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
42. #	C		08-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
43. #	D		08-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:			

a. None.			
44. #	C		08-05-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
45. #	C Y		08-05-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
46. #	D		08-03-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
47. #	D		08-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification requested regarding SOP.			
Additional discussion during the meeting included:			
a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 253 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	08-19-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Pending Chem safety review.
- b. Updated literature search requested.
- c. Dosing and duration clarifications.
- d. Frequency of AST/ALT assessment.
- f. Animal number justification.
- g. Potetial ART reaction/mitigation.
- h. Pairing.

Additional discussion during the meeting included:

- a. Pending PI, remains in DMR..

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	23

2. #	D Y		10-28-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chairing timeline.</p> <p>b. Alternate Contact status clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. Logistical and procedural information in protocol requires revision. Recommend return to PI for editing. Committee voted to send to DMR.</p>													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	23												
3. #	D Y		08-05-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	0												
Present	23												
4. #	D		08-12-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification requested regarding training of TAs and students.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p>													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	23												
5. #	D Y		08-05-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding fluid administration and femoral catheters.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p>													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	0												
Present	23												
6. #	E		12-02-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification on medications.

Additional discussion during the meeting included:

- a. Discussion regarding pain relief and pain management.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	23

7. #

E

08-05-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote

Approval	23
Withhold Approval	0
Abstain	0
Present	23

8. #

D Y

08-05-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Minor edit to summary of procedures provided.

Additional discussion during the meeting included:

- a. Committee voted to approve.

IACUC Vote

Approval	23
Withhold Approval	0
Abstain	0
Present	23

9. #

D

08-05-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Committee voted to approve.

IACUC Vote

Approval	23
Withhold Approval	0
Abstain	0
Present	23

10. #

D

08-05-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification regarding adding sucrose to the water clarified. Chemical safety officer completed final review and provided a VHSS.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	23
Withhold Approval	0
Abstain	0
Present	23

11. #	D Y	08-06-2021
-------	-----	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Reference requested

Additional discussion during the meeting included:

a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	22

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		08-08-2019	08-05-2021	08-08-2022
	D Y		08-08-2019	08-05-2021	08-08-2022
	D		08-08-2019	08-05-2021	08-08-2022
	D		08-09-2019	08-05-2021	08-09-2022
	D		08-08-2019	08-05-2021	08-08-2022
	C		08-14-2019	08-05-2021	08-14-2022
	D		08-08-2019	08-05-2021	08-08-2022
	C		08-20-2019	08-05-2021	08-20-2022
	D		08-08-2019	08-05-2021	08-08-2022
	D		08-08-2019	08-05-2021	08-08-2022
	D		08-19-2019	08-05-2021	08-19-2022
	C Y		08-08-2019	08-05-2021	08-08-2022

	D Y		08-08-2019	08-05-2021	08-08-2022
	C		08-17-2020	08-05-2021	08-17-2022
	D		08-20-2020	08-05-2021	08-20-2022
	D		08-19-2020	08-05-2021	08-19-2022
	C		08-13-2020	08-05-2021	08-13-2022
	C		08-20-2020	08-05-2021	08-20-2022
	C		08-20-2020	08-05-2021	08-20-2022
	C		08-20-2020	08-05-2021	08-20-2022
	D		08-20-2020	08-05-2021	08-20-2022
	D		08-18-2020	08-05-2021	08-18-2022
	D Y		08-20-2020	08-05-2021	08-20-2022
	D		08-10-2020	08-05-2021	08-10-2022
	C		08-17-2020	08-05-2021	08-17-2022
	D		08-20-2020	08-05-2021	08-20-2022
	D		08-20-2020	08-05-2021	08-20-2022
	C		08-20-2020	08-05-2021	08-20-2022
	D Y		08-20-2020	08-05-2021	08-20-2022

Discussion:	<p>One staff member on each protocol is awaiting their MA from OHSS to be able to complete their renewal process.</p> <p>and permit information is expired. Both PI's provided the updated permit information.</p> <p>-Section 9 was not clear as to how long animals are singly housed. PI provided wording that was presented to the committee.</p>
Action Items:	<p>Committee approved annual renewals.</p> <p>and -Committee approved the permit information being updated on the protocol and approved the annual renewals.</p> <p>-Committee approved adding the wording to the protocol and approval of the renewal.</p>

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	09-07-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Request for clarification regarding monitoring of animals. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
2. # [REDACTED]	D	[REDACTED]	08-19-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Housing clarification. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	22												
3. # [REDACTED]	D Y	[REDACTED]	08-05-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	0												
Present	22												
4. # [REDACTED]	D Y	[REDACTED]	08-30-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. AV recommended rewording to better clarify request and justification. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0		
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												

	Present	22											
5. #	D Y		08-05-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	0												
Present	23												
6. #	D		08-05-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	0												
Present	23												
7. #	Y		08-05-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Recommended adding bupivacaine infiltration around the incision site and a single dose of an NSAID. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>22</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	22	Withhold Approval	0	Abstain	1	Present	23
IACUC Vote													
Approval	22												
Withhold Approval	0												
Abstain	1												
Present	23												
8. #	D Y		09-16-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on signs, symptoms and monitoring of adverse effects. Additional discussion during the meeting included: a. Pending PI.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	23												
9. #	C Y		08-05-2021										

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Amendment was put on agenda because it was time sensitive to study start date and would usually not require full committee review.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	0												
Present	23												
10. #		D Y	08-05-2021										

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	0												
Present	23												
11. #		D	08-05-2021										

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Study is finished and colony is being culled. Committee approved other options for disposition if PI is able to find alternatives.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>23</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>23</td></tr></table>				IACUC Vote		Approval	23	Withhold Approval	0	Abstain	0	Present	23
IACUC Vote													
Approval	23												
Withhold Approval	0												
Abstain	0												
Present	23												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 05-20-2021	
2. 07-22-2021	
3. 07-28-2021	
4. 07-28-2021	

Discussion:	None.								
Action:	None.								
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>22</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> </tbody> </table>		IACUC Vote		Approval	22	Withhold Approval	0	Abstain	0
IACUC Vote									
Approval	22								
Withhold Approval	0								
Abstain	0								

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 07-23-2021	LAB	
2. 01-20-2021	PAM	
3. 03-22-2021	PAM	

Discussion:	None.
Action:	None.

IACUC Vote	
Approval	22
Withhold Approval	0
Abstain	0
Present	22

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic
1. New SIC and Chair for Animal Science.
Discussion: None.
Action: Approved.
2. Guest: [REDACTED]
Discussion: Attendance of 1st committee meeting.
Action: None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

**University of California, Davis
IACUC Business Administration System**

**August 19, 2021
Meeting Minutes**

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:**Present:**

M009, M097, M102, M111, M090, M004, M100, M092, A019, M087, A109, M110, M120, M093, A013, M024, M223, M001, M114

Excused:

M222, M042, A095, M119, M016, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

1. # [REDACTED]	Category: E										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussion on PAM and Post Operative monitoring. Additional discussion during the meeting included: a. Voted to sent to DMR.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	18										

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
PETA records request
Action: Notification.
SAEN records request
Action: Notification.
PCRM lawsuit
Action: Notification.
[REDACTED]
Action: PAM; mice unattended, procedural retraining.
Update [REDACTED]
Action: Recommended modifications successful.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	08-19-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI addressed all previously identified questions.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	08-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of standard of care versus experimental procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	D	[REDACTED]	08-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of standard of care versus experimental procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D	[REDACTED]	08-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending veterinary review questions were answered regarding sterilization.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D	[REDACTED]	08-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of standard of care versus experimental procedures and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	08-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]		[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Needed to complete OHSS.</p>			

Additional discussion during the meeting included: a. Remains in DMR.			
9. # [REDACTED]	C	[REDACTED]	08-17-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Further clarification of standard of care versus experimental procedures. Additional discussion during the meeting included: a. None.			
10. # [REDACTED]	C Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
11. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. pending BUA			
12. # [REDACTED]	C	[REDACTED]	08-06-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
13. # [REDACTED]	C	[REDACTED]	08-06-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
14. # [REDACTED]	D	[REDACTED]	08-12-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI provided updated information regarding training of TAs and students prior to survival surgeries. Additional discussion during the meeting included: a. None.			
15. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
16. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

17. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending bio and chem review.</p>			
18. # [REDACTED]	C	[REDACTED]	08-10-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further clarification of standard of care versus experimental procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D Y	[REDACTED]	08-06-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	C	[REDACTED]	08-19-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on terminology and euthanasia method.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D	[REDACTED]	08-19-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on animal source and euthanasia method.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	C Y	[REDACTED]	08-11-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	C	[REDACTED]	08-19-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	C	[REDACTED]	08-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
2. # [REDACTED]	D	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Rat weight discussed. Additional discussion during the meeting included: a. None.			
3. # [REDACTED]	D Y	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
4. # [REDACTED]	D	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of justification. Additional discussion during the meeting included: a. None.			
5. # [REDACTED]	C	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	C	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
7. # [REDACTED]		[REDACTED]	08-17-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
8. # [REDACTED]	D	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
9. # [REDACTED]	D	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:			

	a. None.		
10. #	D Y		08-10-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
11. #	D		08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
12. #	D		08-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
13. #	D		08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
14. #	D		08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
15. #	C		08-09-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
16. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending recommended rewording for clarity. Remains in DMR.			
17. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response. Additional discussion during the meeting included: a. Remains in DMR.			
18. #	C		-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
19. #	E		08-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		08-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending path. Remains in DMR.</p>			
22. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Request time reevaluation by Bio.</p> <p>Additional discussion during the meeting included:</p> <p>a. Request time reevaluation by Bio; including references. Remains in DMR.</p>			
23. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
24. #	D		08-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		08-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of standard of care versus experimental procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Requested specification of breeding lines and total offspring.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	C		-

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending Reviewer. Additional discussion during the meeting included: a. Remains in DMR.			
28. # [REDACTED]	C	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
29. # [REDACTED]	C Y	[REDACTED]	08-12-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
30. # [REDACTED]	D	[REDACTED]	08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Grammar correction. Additional discussion during the meeting included: a. None.			
31. # [REDACTED]	D	[REDACTED]	-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending chem.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 196 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	12-17-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification on hazardous material and procedure.

Additional discussion during the meeting included:

- a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0

	Present	18											
2. #	D Y		11-01-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on pairing exemption wording.</p> <p>b. Clarification on housing (renovation).</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
3. #	D Y		01-18-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted for DR</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
4. #	D Y		08-19-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures, analgesics, and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
5. #	E		08-19-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedure and adverse events.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
6. #	E		08-23-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Adverse effects and caging discussed.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

7. # [REDACTED]	D	[REDACTED]	09-02-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. correction of typo.

Additional discussion during the meeting included:

- a. Pending health coordinator review.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

8. # [REDACTED]	B	[REDACTED]	08-19-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Group number and procedure clarification

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

9. # [REDACTED]	D	[REDACTED]	09-07-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Pending Reviewer, Bio and CHEM

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

10. # [REDACTED]	D	[REDACTED]	09-07-2021
------------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Pending reviewer and Bio

<table border="1"> <tr><th colspan="2">IACUC Vote</th></tr> <tr><td>Approval</td><td>0</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>18</td></tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
11. #	C Y		08-19-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr><th colspan="2">IACUC Vote</th></tr> <tr><td>Approval</td><td>19</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>19</td></tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
12. #	D		09-02-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Rationale for course significance.</p> <p>b. Verification IACUC Rodent Survival Surgery course material included.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table border="1"> <tr><th colspan="2">IACUC Vote</th></tr> <tr><td>Approval</td><td>0</td></tr> <tr><td>Withhold Approval</td><td>0</td></tr> <tr><td>Abstain</td><td>0</td></tr> <tr><td>Present</td><td>18</td></tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C Y		08-22-2019	08-19-2021	08-22-2022
	C		08-14-2019	08-19-2021	08-14-2022
	D		08-22-2019	08-19-2021	08-22-2022
	D		08-27-2019	08-19-2021	08-27-2022
	C		08-22-2019	08-19-2021	08-22-2022
	C		08-09-2019	08-19-2021	08-09-2022
	D		08-29-2019	08-19-2021	08-29-2022
	D		08-22-2019	08-19-2021	08-22-2022
	D		08-22-2019	08-19-2021	08-22-2022

	C		08-22-2019	08-19-2021	08-22-2022
	C		08-22-2019	08-19-2021	08-22-2022
	C Y		08-26-2019	08-19-2021	08-26-2022
	D Y		08-22-2019	08-19-2021	08-22-2022
	D		08-22-2019	08-19-2021	08-22-2022
	C		08-22-2019	08-19-2021	08-22-2022
	D		08-22-2019	08-19-2021	08-22-2022
	C		08-23-2019	08-19-2021	08-23-2022
	C		08-28-2019	08-19-2021	08-28-2022
	D		08-30-2019	08-19-2021	08-30-2022
	D		09-03-2020	08-19-2021	09-03-2022
	D		09-02-2020	08-19-2021	09-02-2022
	C		09-03-2020	08-19-2021	09-03-2022
	D		08-26-2020	08-19-2021	08-26-2022
	D Y		09-03-2020	08-19-2021	09-03-2022
	D		09-03-2020	08-19-2021	09-03-2022
	C		09-02-2020	08-19-2021	09-02-2022
	D Y		09-03-2020	08-19-2021	09-03-2022
	C		09-03-2020	08-19-2021	09-03-2022
	C		09-03-2020	08-19-2021	09-03-2022
	D Y		09-03-2020	08-19-2021	09-03-2022
	C Y		09-03-2020	08-19-2021	09-03-2022
	C		09-02-2020	08-19-2021	09-02-2022
	C		09-03-2020	08-19-2021	09-03-2022
	D Y		09-03-2020	08-19-2021	09-03-2022
	C Y		08-28-2020	08-19-2021	08-28-2022

	C		09-02-2020	08-19-2021	09-02-2022
	C		09-03-2020	08-19-2021	09-03-2022
	C		09-03-2020	08-19-2021	09-03-2022

Discussion:	Lit search amendment needed for [REDACTED]										
Action Items:	Moved protocol to next agenda.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>17</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </tbody> </table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	08-19-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
2. # [REDACTED]	D Y	[REDACTED]	08-19-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
3. # [REDACTED]	D Y	[REDACTED]	08-19-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													

<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 18 Withhold Approval 0 Abstain 0 Present 18 </div>			
4. #	Y		08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 17 Withhold Approval 0 Abstain 0 Present 17 </div>			
5. #	E		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending Reviewer. Additional discussion during the meeting included: a. Voted to send to DMR.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 18 </div>			
6. #	Y		08-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 18 Withhold Approval 0 Abstain 0 Present 18 </div>			
7. #	D Y		09-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 </div>			

	Present	18											
8. #	D		08-19-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
9. #	C		08-19-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 07-14-2021	
2. 07-19-2021	
3. 07-26-2021	
4. 08-09-2021	
5. 08-09-2021	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>17</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>17</td> </tr> </tbody> </table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 07-14-2021	LAB	
2. 07-14-2021	LAB	
3. 07-14-2021	LAB	
4. 07-14-2021	LAB	

5. 07-14-2021	LAB		
6. 07-26-2021	LAB		
7. 08-03-2021	LAB		
8. 08-11-2021	LAB		
9. 08-12-2021	LAB		
10. 08-18-2021	LAB		
11. 08-18-2021	LAB		
12. 08-09-2021	PAM		
13. 08-16-2021	PAM		

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>18</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>18</td></tr> </tbody> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic
2nd quarter fluid report
Discussion: All compliant.
Action: None.
Animals moved from # [REDACTED] to holding protocol.
Discussion: None.
Action: None.
Guest [REDACTED]
Discussion: 2nd meeting attended. Can now serve as an alternate member.
Action: None.
UC Exemption form and training policy
Discussion: Recommended modification to broaden to non-UC Davis.; Require UCD ACU101.
Action: Changes approved.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

September 02, 2021 Meeting Minutes

Attendance:

M009, M097, M222, M102, M111, M090, M042, M004, M100, M092, A019, M119, M087, A109, M110, M120, M093, A013, M001, M114

A095, M016, M024, M223, M112

M224, M116, A017, A018

There are no previous meeting minutes for discussion.

There were no tabled protocols for discussion.

There were no tabled amendments for discussion.

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

Action: FYI - Courtesy notification.

Action: PAM, amendment

There are no Attending Veterinarian updates for this agenda.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending PI. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
2. # [REDACTED]	C	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
3. #			08-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Some personnel had expired OHSS or ACU 101</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. #	C Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
5. #	C		09-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Verbiage has been changed from CAT imaging to CT scans.</p> <p>b. Chem safety clearance.</p> <p>c. Dosage change.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending location inspection following renovation. Remains in DMR.</p>			
7. #	C		08-26-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI</p>			
9. #	C		09-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	D		08-31-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D		08-31-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Updated title.</p> <p>b> Additional Eh&S review.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
13. #	C		09-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	E		08-23-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed analgesia and animal housing.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D		09-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Dosage clarification.</p> <p>B. Wording edits.</p> <p>c. Animal movement/biosecurity</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D		09-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	D		-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	C		09-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		09-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of numbers and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending review of PI's response.</p>			
23. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending review of PI response.</p>			
24. #	C		09-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
2. # [REDACTED]		[REDACTED]	08-31-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D Y	[REDACTED]	08-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	C	[REDACTED]	09-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending review of response</p>			
5. # [REDACTED]	C	[REDACTED]	09-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	E	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
7. # [REDACTED]	D Y	[REDACTED]	08-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Amendment wording updated per AV.</p>			
8. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
9. # [REDACTED]	C	[REDACTED]	09-02-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
11. #	D Y		09-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Frequency of weighing.</p> <p>b. Methods to control spillage.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		09-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed dose-finding and biosafety.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	D		08-26-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Specified breeding lines and disposition.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	C		09-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D		09-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify who will be handling the PLX3397 chow.</p> <p>b. Include VHSS.</p> <p>c. PLX3397 dosing.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
16. #	D		09-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify who will be handling the PLX3397 chow.</p> <p>b. Include VHSS.</p> <p>c. PLX3397 dosing.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 178 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	10-28-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending revision.</p> <p>Additional discussion during the meeting included:</p> <p>a. Request by IACUC Member to move back to full committee review.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	E	[REDACTED]	10-14-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. The IACUC committee would like you to work with the IACUC staff and CVS to clarify the procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Protocol was tabled until next meeting.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
3. # [REDACTED]	E	[REDACTED]	12-02-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussion on pain management, surgeries and post op monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. The Committee discussed your responses and would like more information on pain management and to have CVS and an IACUC member present for the first few surgeries and post op monitoring. The committee has invited the PI to the next meeting. The protocol was tabled until the next meeting.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	D	[REDACTED]	09-16-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to be assigned DMR.</p>													

<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 20 </div>			
5. # [REDACTED]	D	[REDACTED]	09-09-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI responses. Additional discussion during the meeting included: a. Voted to be assigned DMR.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 20 </div>			
6. # [REDACTED]	C Y	[REDACTED]	09-02-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 20 Withhold Approval 0 Abstain 0 Present 20 </div>			
7. # [REDACTED]	D	[REDACTED]	09-02-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed biosafety. Additional discussion during the meeting included: a. None.			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> IACUC Vote Approval 21 Withhold Approval 0 Abstain 0 Present 21 </div>			

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	D	[REDACTED]	9-04-2019	09-02-2021	09-04-2022
[REDACTED]	D	[REDACTED]	9-17-2019	09-02-2021	09-17-2022
[REDACTED]	C	[REDACTED]	9-12-2019	09-02-2021	09-12-2022

	C		9-05-2019	09-02-2021	09-05-2022
	C		9-05-2019	09-02-2021	09-05-2022
	C		9-06-2019	09-02-2021	09-06-2022
	Y		9-05-2019	09-02-2021	09-05-2022
	C		9-05-2019	09-02-2021	09-05-2022
	C		9-05-2019	09-02-2021	09-05-2022
	D		9-04-2019	09-02-2021	09-04-2022
	C		9-16-2019	09-02-2021	09-16-2022
	C		9-17-2019	09-02-2021	09-17-2022
	C Y		9-04-2019	09-02-2021	09-04-2022
	D		9-05-2019	09-02-2021	09-05-2022
	C		9-17-2019	09-02-2021	01-18-2022
	C		9-12-2019	09-02-2021	09-12-2022
	C Y		9-17-2020	09-02-2021	09-17-2022
	Y		9-04-2020	09-02-2021	09-04-2022
	D Y		9-03-2020	09-02-2021	09-03-2022
	C		9-17-2020	09-02-2021	09-17-2022
	D		9-17-2020	09-02-2021	09-17-2022
	D Y		9-17-2020	09-02-2021	09-17-2022
	C		9-17-2020	09-02-2021	09-17-2022
	C Y		9-17-2020	09-02-2021	09-17-2022
	C		9-16-2020	09-02-2021	09-16-2022
	C		9-16-2020	09-02-2021	09-16-2022
	C		9-17-2020	09-02-2021	09-17-2022
	C		9-15-2020	09-02-2021	09-15-2022

	E		09-17-2020	09-02-2021	09-17-2022
	D		09-17-2020	09-02-2021	09-17-2022
	D		09-11-2020	09-02-2021	09-11-2022
	D Y		09-17-2020	09-02-2021	09-17-2022
	D		09-17-2020	09-02-2021	09-17-2022
	C		09-17-2020	09-02-2021	09-17-2022

Discussion:	None.										
Action Items:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>20</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>20</td></tr> </tbody> </table>		IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	20										
Withhold Approval	0										
Abstain	0										
Present	20										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	09-02-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D	[REDACTED]	09-03-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												

3. # [REDACTED]	D	[REDACTED]	09-16-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to be assigned DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	D	[REDACTED]	09-16-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to assigned to DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
5. # [REDACTED]	D Y	[REDACTED]	09-02-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. EH&S re-reviewed.</p> <p>Additional discussion during the meeting included:</p> <p>a. EH&S re-reviewed and confirmed 7-day single housing adequate for this application.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>2</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	2	Present	20
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	2												
Present	20												
6. # [REDACTED]	D Y	[REDACTED]	11-08-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Request by IACUC Member to move back to full committee review.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending resolution of path result interpretation.</p> <p>b. Approved for DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
7. # [REDACTED]	D Y	[REDACTED]	11-08-2021										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. PI and veterinary staff interpret path results differently. Recommend phone consultation with AV.

b. Approved for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 04-22-2021	
2. 08-20-2021	
3. 08-23-2021	
4. 08-25-2021	

Discussion:	General update on inspection logistics and options with consideration of current COVID restrictions and precautions.										
Action:	None.										
<table> <tr> <th colspan="2">IACUC Vote</th></tr> <tr> <td>Approval</td><td>17</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 07-30-2021	LAB	
2. 07-30-2021	LAB	
3. 08-23-2021	LAB	
4. 08-25-2021	LAB	
5. 08-25-2021	LAB	
6. 08-25-2021	LAB	
7. 08-26-2021	LAB	
8. 08-26-2021	LAB	
9. 08-26-2021	LAB	
10. 09-01-2021	LAB	
11. 07-23-2021	PAM	
12. 08-23-2021	PAM	

Discussion:	None.
Action:	None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

There are no other discussion topics for this agenda.

XVI. Program Updates:

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

September 16, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M097, M102, M111, M090, M042, A095, M004, M100, M092, A019, M119, M087, A109, M110, M093, A013, M016, M024, M001, M112, M114

Excused:

M009, M222, M223

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

1. # [REDACTED]	Category: E										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending Reviewers review of PI response. Additional discussion during the meeting included: a. Voted to DMR											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>		IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote											
Approval	20										
Withhold Approval	0										
Abstain	0										
Present	20										
2. # [REDACTED]	Category: E										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response to questions. Additional discussion during the meeting included: a. PI presented and discussed pain management and procedures in more detail. Voted to DMR.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>		IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote											
Approval	21										
Withhold Approval	0										
Abstain	0										
Present	21										

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

(Y) [REDACTED]
Action: Net capture and section 15 recommendation.
[REDACTED]
Action: Potential actions going forward; provide consult feedback; suspend additional work under current proposal

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. IACUC staff will work with PI on modifications and editing.</p> <p>Additional discussion during the meeting included:</p> <p>a. IACUC staff will work with PI on modifications and editing.</p>			
2. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
3. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
4. # [REDACTED]	C	[REDACTED]	09-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarify breeding scheme</p>			
5. # [REDACTED]	C Y	[REDACTED]	09-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarify Procedures</p>			
6. # [REDACTED]	D Y	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending location renovation.</p> <p>b. Remains in DMR.</p>			
7. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
8. # [REDACTED]	D	[REDACTED]	09-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. correction to title.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. # [REDACTED]	D	[REDACTED]	09-07-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Biosafety officer confirmed BUA has been approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	09-07-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Biosafety officer confirmed BUA has been approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D	[REDACTED]	09-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	09-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	D	[REDACTED]	09-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	C	[REDACTED]	09-07-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	C		09-07-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D		09-09-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. clarification of retinography timing.</p> <p>b. clarification of post procedure housing</p> <p>c. Clarification of training requirements.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
18. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
19. #	C Y		09-07-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarify methods and dosing</p>			
21. #	C		09-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified collection times.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

22. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified housing and feed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	C	[REDACTED]	09-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Reviewed facility SOPs.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	09-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI provided clarification regarding monitoring of animals and feeding.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	D Y	[REDACTED]	09-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	C	[REDACTED]	09-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarify animal size and add other supportive methods</p>			
4. # [REDACTED]	D	[REDACTED]	09-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D	[REDACTED]	09-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
6. #	D		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
7. #	D Y		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Pending BIO.			
Additional discussion during the meeting included:			
a. Remains in DMR.			
8. #	D		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			
9. #	D		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarified injection volume.			
Additional discussion during the meeting included:			
a. None.			
10. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. Pending Reviewer.			
11. #	E		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Pending PI.			
Additional discussion during the meeting included:			
a. Remains in DMR.			
12. #	D		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification on changes and procedures.			
Additional discussion during the meeting included:			
a. None.			
13. #	D		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. Clarification on changes.			
Additional discussion during the meeting included:			
a. None.			
14. #	D Y		-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
15. #	D		09-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D Y		09-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on incident and monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D		09-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Removal of TRDRP number.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	C		09-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on treatment and procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	E		09-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		09-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D		09-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending revisions following AV consultation.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending revisions following AV consultation.</p>			
23. #	D Y		-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Reopening amendment to PI following phone consultation with Attending Veterinarian.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending revisions following AV consultation.</p>			
24. #	C		09-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI response to Biosafety reviewer's question.</p>			
26. #	C		09-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	D		09-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed statistical analysis of animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	C Y		09-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	E		09-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 128 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
----------	----------	-------	---------------

1. # [REDACTED]	D Y [REDACTED]	09-17-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Facility name.b. Imaging clarifications.c. CSF volume.d. CMV shedding clarification. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	21											
2. # [REDACTED]	D [REDACTED]	09-21-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Pending Review of responses. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. Voted to DMR. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	21											
3. # [REDACTED]	D [REDACTED]	11-18-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Mouse strain clarification. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. Pending new room inspection. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	22											
4. # [REDACTED]	D Y [REDACTED]	09-17-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Pending review of responses. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. Voted to DMR. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	21											

5. # [REDACTED]	D [REDACTED]	09-20-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Occ health clearance, voted for DMR</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	21											
6. # [REDACTED]	D [REDACTED]	09-16-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	21											
Withhold Approval	0											
Abstain	0											
Present	21											
7. # [REDACTED]	D [REDACTED]	09-30-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Unanswered questions regarding euthanasia, housing, and pain evaluation.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI response.</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>22</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	22
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	22											

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	D	[REDACTED]	9-18-2019	09-16-2021	09-18-2022
[REDACTED]	C	[REDACTED]	9-19-2019	09-16-2021	09-23-2021
[REDACTED]	D	[REDACTED]	9-20-2019	09-16-2021	09-20-2022
[REDACTED]	C Y	[REDACTED]	9-19-2019	09-16-2021	09-19-2022
[REDACTED]	D Y	[REDACTED]	9-05-2019	09-16-2021	09-05-2022
[REDACTED]	D	[REDACTED]	9-19-2019	09-16-2021	09-19-2022

	D		09-23-2019	09-16-2021	09-23-2022
	D		09-20-2019	09-16-2021	09-20-2022
	D		09-19-2019	09-16-2021	09-19-2022
	D		09-05-2019	09-16-2021	09-05-2022
	D Y		09-19-2019	09-16-2021	09-19-2022
	D Y		09-19-2019	09-16-2021	09-19-2022
	D		09-29-2019	09-16-2021	09-29-2022
	C		09-11-2019	09-16-2021	09-11-2022
	E		09-19-2019	09-16-2021	09-19-2022
	D Y		09-20-2019	09-16-2021	09-20-2022
	D		09-19-2019	09-16-2021	09-19-2022
	C		09-19-2019	09-16-2021	09-19-2022
			09-18-2019	09-16-2021	09-18-2022
	C		09-19-2019	09-16-2021	09-19-2022
	D		10-01-2020	09-16-2021	10-01-2022
	D		09-21-2020	09-16-2021	09-21-2022
	D		10-01-2020	09-16-2021	10-01-2022
	C		09-30-2020	09-16-2021	09-30-2022
	C		10-01-2020	09-16-2021	10-01-2022
	E		09-17-2020	09-16-2021	09-17-2022
	D Y		09-17-2020	09-16-2021	09-17-2022
	C		09-30-2020	09-16-2021	09-30-2022
	C		09-25-2020	09-16-2021	09-25-2022
	D		09-29-2020	09-16-2021	09-29-2022
	D		10-01-2020	09-16-2021	10-01-2022
	C		09-29-2020	09-16-2021	09-29-2022
	C		10-01-2020	09-16-2021	10-01-2022

	C		09-17-2020	09-16-2021	09-17-2022
	C		10-01-2020	09-16-2021	10-01-2022
	C		09-29-2020	09-16-2021	09-29-2022
	C		10-01-2020	09-16-2021	10-01-2022
	C		09-24-2020	09-16-2021	09-24-2022
	D		09-17-2020	09-16-2021	09-17-2022
	C		09-30-2020	09-16-2021	09-30-2022
	D		09-28-2020	09-16-2021	09-28-2022
	C		09-25-2020	09-16-2021	09-25-2022
	C		09-24-2020	09-16-2021	09-24-2022
	C		09-24-2020	09-16-2021	09-24-2022
	C		10-01-2020	09-16-2021	10-01-2022
	C		10-01-2020	09-16-2021	10-01-2022
	D		10-01-2020	09-16-2021	10-01-2022

Discussion:	<p>██████████ and ██████████ - One staff member is at the final step of the OHSS renewal process.</p> <p>██████████ PI provided IACUC staff with updated literature search in reference to recently approved amendment.</p> <p>██████████ IACUC staff working with PI to clarify terminal procedure and/or euthanasia technique.</p>										
Action Items:	<p>██████████ and ██████████ - Committee approved moving forward with annual renewals.</p> <p>██████████ - Committee approved staff adding the updated literature search to the original protocol.</p> <p>██████████ Committee approved IACUC staff to update the original protocol.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>19</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>19</td></tr> </tbody> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
----------	----------	---------	---------------

1. #	D	10-13-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. incidence of previous occurrence.</p> <p>b. clarification of criteria for removal form study.euthanasia.</p> <p>Additional discussion during the meeting included:</p> <p>a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.</p>												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	21											
2. #	D	09-16-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Amendment was submitted in response to a PAM and recommendations from IACUC to ensure protocols were clear and consistent.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committed voted to approve.</p>												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	21											
Withhold Approval	0											
Abstain	0											
Present	21											
3. #	D	09-16-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. incidence of previous occurrence.</p> <p>b. clarification of criteria for removal form study.euthanasia.</p> <p>Additional discussion during the meeting included:</p> <p>a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.</p>												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	21											
Withhold Approval	0											
Abstain	0											
Present	21											
4. #	D	09-16-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Amendment was submitted in response to a PAM and recommendations from IACUC to ensure protocols were clear and consistent.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p>												
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>			IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote												
Approval	21											
Withhold Approval	0											
Abstain	0											
Present	21											
5. #	D	10-13-2021										

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. incidence of previous occurrence. b. clarification of criteria for removal form study.euthanasia. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>21</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
6. #	C		10-13-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. incidence of previous occurrence. b. clarification of criteria for removal from study/euthanasia. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>21</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
7. #	D		09-23-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Request edit to remove personal names. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>21</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
8. #	C		10-13-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. incidence of previous occurrence. b. clarification of criteria for removal form study.euthanasia. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia. <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>21</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												

9. # [REDACTED]	D	[REDACTED]	11-03-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of Consent Form, and number of kittens affected, and total that received the transplant.</p> <p>Additional discussion during the meeting included:</p> <p>a. Discussed further collaboration with CTRB, altering source of animals, and experimental design. Tabled.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	21												
10. # [REDACTED]	D	[REDACTED]	09-16-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Amendment was submitted in response to a PAM and recommendations from IACUC to ensure protocols were clear and consistent.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
11. # [REDACTED]	D	[REDACTED]	09-16-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Amendment was submitted in response to a PAM and recommendations from IACUC to ensure protocols were clear and consistent.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>21</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	21	Withhold Approval	0	Abstain	0	Present	21
IACUC Vote													
Approval	21												
Withhold Approval	0												
Abstain	0												
Present	21												
12. # [REDACTED]	C	[REDACTED]	09-16-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on location, chambers and objective.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>1</td></tr><tr><td>Present</td><td>21</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	1	Present	21
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	1												
Present	21												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 01-08-2021	
2. 08-04-2021	
3. 08-30-2021	
4. 09-09-2021	
5. 09-09-2021	
6. 09-14-2021	
7. 09-15-2021	

Discussion: 2. Facility is working with FM to have fire damage/debris removed from the outside of the facility. IACUC director to discuss in next leadership meeting to help assist PI. The front door lock has been repaired and the inside of the facility is very clean.

Action: 2. Committee approved inspection updates and PI moving forward with ordering animals.

IACUC Vote

Approval	19
Withhold Approval	0
Abstain	0
Present	19

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 08-11-2021	LAB	
2. 08-25-2021	LAB	
3. 08-30-2021	LAB	
4. 08-30-2021	LAB	
5. 08-30-2021	LAB	
6. 08-31-2021	LAB	
7. 09-01-2021	LAB	
8. 09-02-2021	LAB	
9. 09-13-2021	LAB	
10. 09-14-2021	LAB	
11. 06-01-2021	PAM	
12. 06-14-2021	PAM	
13. 07-27-2021	PAM	
14. 08-09-2021	PAM	
15. 09-08-2021	PAM	

Discussion: 1. PI has hired a new lab manager who used to work for another lab. One out of four protocols was missed updating the animal numbers this past quarter. Otherwise, records looked good.
14. During facility inspection, noted post-op records in the animal room. Documentation was not clear leading to confusion of whether there were protocol deficiencies. After further review with the lab it was identified as a record deficiency and not a protocol deficiency. Re-training provided for clear record documentation.

Action: 1. No further action at this time other than to remain on quarterly inspection until new manager is fully trained.
14. Committee approved the lab's plan to prevent the deficiency in the future.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:				
Inspection Date	Agency	Location	Summary	Discussion
1. 09-08-2021	USDA	Site 1	Inspection dates for Site 1 (routine) and Site 2 (focused): 9/8/21, 9/9/21, 9/10/21 No non-compliant items.	Zero non-compliant items documented. b. Pending final report.

XV. Other Discussion Items:

Topic	
1. Guest: PI [REDACTED]	
Discussion:	Reviewed protocol objectives and pain management plan.
Action:	None.
2. [REDACTED] PI maintain request form.	
Discussion:	Discussed preliminary inspection attended by AV, Aquatics IACUC member and IACUC staff. Facility is appropriate for study. PI will be working with other aquatic users on campus to ensure proper set up and consistent SOPs. Once the facility is completely set up, another inspection will be completed prior to approval of the IACUC protocols.
Action:	Committee approved PI to maintain the facility.
3. Semi Annual Program Review	
Discussion:	None.
Action:	Deferred to next meeting.
4. [REDACTED]	
Discussion:	None.
Action:	See section 4.
5. FYI - [REDACTED] - Animals moved to holding protocol	
Discussion:	None.
Action:	None.
6. FYI - [REDACTED] - Animals moved to holding protocol.	
Discussion:	None.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

September 30, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M102, M111, M090, M042, A095, M004, M100, M092, A019, M119, A109, M110, M093, A013, M024, M223, M001, M114

Excused:

M222, M087, M016, M112

Guests:

M224, A017

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the July 8, 2021, meeting minutes as written.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

The IACUC reviewed and approved the July 22, 2021, meeting minutes as written.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

1. # [REDACTED]	Category: D								
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.									
Additional discussion during the meeting included: a. CTRB ad-hoc meeting occurring 9/30/21. Will prepare a report to IACUC. Amendment tabled.									
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0
IACUC Vote									
Approval	0								
Withhold Approval	0								
Abstain	0								

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

[REDACTED]

Action: None.

[REDACTED]

Action: PAM.

Records request: PRCM follow-up requests for Neuralink

Action: Notification of additional information requested.

[REDACTED]

Action: Root cause analysis to be performed

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. IACUC Office working with PI on protocol modifications.</p> <p>Additional discussion during the meeting included:</p> <p>a. IACUC Office working with PI on protocol modifications.</p>			
2. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
3. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending completion of OHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
4. # [REDACTED]	D Y	[REDACTED]	09-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D Y	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. numbers justification. b. analgesia criteria. c. clarification of number of procedures. d. clarification of clinical vs teaching procedures <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI. 			
6. #	E		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending Reviewers review of responses. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
7. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR until location renovation is complete and inspected. 			
8. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending PI's responses regarding procedures. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
9. #	E		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending PI response. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
10. #	D		09-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification on animal numbers and procedure. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
11. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending room approval. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
12. #	D Y		09-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
13. #	C Y		09-30-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BIO.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
15. # [REDACTED]	D	[REDACTED]	09-30-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. # [REDACTED]	C	[REDACTED]	09-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. # [REDACTED]	D	[REDACTED]	09-20-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	D	[REDACTED]	09-30-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of endpoints.</p> <p>b. clarification of housing density.</p> <p>c. Clarification of pain.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D Y	[REDACTED]	09-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. Pending PI response to reviewers questions.			
21. # [REDACTED]	C	[REDACTED]	09-28-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
22. # [REDACTED]	C	[REDACTED]	09-24-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified timeline and significance of study. Additional discussion during the meeting included: a. None.			
23. # [REDACTED]	C	[REDACTED]	09-24-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified adverse effects and staff roster. Additional discussion during the meeting included: a. None.			
24. # [REDACTED]	C	[REDACTED]	09-23-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Reviewed referenced SOPs. Additional discussion during the meeting included: a. None.			
25. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of animal source. b. clarification of drug dosing range Additional discussion during the meeting included: a. Pending PI response.			
26. # [REDACTED]	C	[REDACTED]	09-30-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures and adverse effects. Additional discussion during the meeting included: a. None.			
27. # [REDACTED]	D	[REDACTED]	09-30-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
28. # [REDACTED]	C	[REDACTED]	09-30-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			

Additional discussion during the meeting included: a. None.			
29. #	C		09-30-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified animal feed and housing. Additional discussion during the meeting included: a. None.			
30. #	B		09-30-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. clarification of previous occurrence. b. clarification of when animals will be excluded from the study and/or humanely euthanized. Additional discussion during the meeting included: a. Request further clarification of when animals will be excluded from the study and/or humanely euthanized.			
2. #	D Y		09-29-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
3. #	D Y		09-30-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
4. #	D		09-29-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer confirmed no VHSS was required. Additional discussion during the meeting included: a. None.			
5. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response. Additional discussion during the meeting included: a. Remains in DMR.			
6. #	D		09-16-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	C		09-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	C		09-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	D		09-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	C		09-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D Y		09-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on using genetically modified organisms.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of frequency of monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. pending PI.</p>			
13. #	E		09-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify how this relates to the current objectives in the parent protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarification of when animals should be excluded from the study and/or humanely euthanized.</p>			
15. #	D		09-16-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D Y		09-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	D		09-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D Y		09-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D Y		09-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
22. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarification of when animals should be excluded from the study and/or humanely euthanized.</p>			
23. #	D Y		09-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D Y		09-20-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D		09-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA amendment approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending BUA amendment approval confirmation</p>			
27. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Clarification of when animals should be excluded from the study and/or humanely euthanized.</p>			
28. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI responses.</p>			
29. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending approval following revision of second amendment per PI/Alternate Contact/AV phone consultation.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending approval following revision of second amendment per PI/Alternate Contact/AV phone consultation.</p>			
30. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending revision following PI/Alternate Contact/AV phone consultation.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending revision following PI/Alternate Contact/AV phone consultation.</p>			
31. #	D		09-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	D Y		09-21-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
33. #	D		09-30-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
34. #	C		09-17-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
35. #	D Y		09-30-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
36. #			-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending Reviewer review of responses . Additional discussion during the meeting included: a. Remains in DMR.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 238 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	12-02-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Procedure clarifications including drug name, choice and dosing information, SOP procedures and references, procedure frequencies.

Additional discussion during the meeting included:

- a. Tabled for further review following clarifications.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0

	Present	20											
2. #	D Y		10-11-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarifications requested for : numbers and doing; IL10Ra-FC source and previous use, half-life; immunoadhesion; SOP verification; use of non-pharmaceutical grade; potential vaccine systemic effects. Additional discussion during the meeting included: a. Approved for DMR follow-up review and approval pending clarifications.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
3. #	D		10-05-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
4. #	C Y		10-10-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify if blood collection is under anesthesia/sedation. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
5. #	D		09-30-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												

6. #	D		10-13-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BIO and CHEM. Additional discussion during the meeting included: a. Voted to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
7. #	D		09-30-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
8. #	E		09-30-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed adverse effects. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
9. #	D Y		10-06-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pair and single housing clarifications. b. Confirmation of funding source. c. Alternatives search terms. d. Use of Telazol. e. Numbers clarification. f. AAV clarifications. g. Procedural clarifications. h. Use of non-pharmaceutical grade agents. i. Immune responses. j. Dosing. Additional discussion during the meeting included: a. Additional information requested. Approved for DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr></table>				IACUC Vote		Approval	0						
IACUC Vote													
Approval	0												

<table><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				Withhold Approval	0	Abstain	0	Present	19				
Withhold Approval	0												
Abstain	0												
Present	19												
10. #	D		09-30-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
11. #	D		09-30-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of food and water regulation policy. b. fixed typo regarding weight loss c. clarification of when mice would be separated d. clarification of behavioral testing frequency. e. clarification o weighing frequency. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
12. #	D Y		10-05-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Replacement protocol. Pending clarifying questions regarding procedures and monitoring. Additional discussion during the meeting included: a. Committee voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
13. #	C Y		10-08-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:													

a. Approved for DMR pending reviewer.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

14. #

C

09-30-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	C		10-03-2019	09-30-2021	10-03-2022
	B		09-27-2019	09-30-2021	09-27-2022
	D		09-19-2019	09-30-2021	09-19-2022
	C Y		10-08-2019	09-30-2021	10-08-2022
	B		10-07-2019	09-30-2021	10-07-2022
	C		10-10-2019	09-30-2021	10-10-2022
	D		10-10-2019	09-30-2021	10-10-2022
	D		10-10-2019	09-30-2021	10-10-2022
	D		10-03-2019	09-30-2021	10-03-2022
	D		10-10-2019	09-30-2021	10-10-2022
	C		10-10-2019	09-30-2021	10-10-2022
	C Y		09-19-2019	09-30-2021	09-19-2022
	C		10-08-2019	09-30-2021	10-08-2022

	C		0-09-2019	09-30-2021	10-09-2022
	C		0-07-2019	09-30-2021	10-07-2022
	C		0-08-2019	09-30-2021	10-08-2022
	C		0-10-2019	09-30-2021	10-10-2022
	C		0-08-2019	09-30-2021	10-08-2022
	C		0-09-2019	09-30-2021	10-09-2022
	C		0-15-2020	09-30-2021	10-15-2022
	D		9-30-2020	09-30-2021	09-30-2022
	E		0-06-2020	09-30-2021	10-06-2022
	D		0-06-2020	09-30-2021	10-06-2022
	C Y		9-17-2020	09-30-2021	09-17-2022
	E		0-11-2020	09-30-2021	10-11-2022
	D		0-15-2020	09-30-2021	10-15-2022
	C		0-15-2020	09-30-2021	10-15-2022
	C		0-15-2020	09-30-2021	10-15-2022
	D		0-02-2020	09-30-2021	10-02-2022
	D		9-30-2020	09-30-2021	09-30-2022
	C		0-12-2020	09-30-2021	10-12-2022
	D		0-13-2020	09-30-2021	10-13-2022

Discussion: [REDACTED] Section 9 was missing maximum duration of time animals would be restrained.
[REDACTED] & [REDACTED]-at least one person on each protocol is in the process of completing their OHSS renewal process. IACUC staff is working with the PI's to ensure these are completed ASAP.

Action Items: [REDACTED]-Committee approved adding the maximum duration of time provided by the PI.
[REDACTED] & [REDACTED]-Committee approved the annual renewals.

IACUC Vote

Approval	19
Withhold Approval	0
Abstain	0

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	09-30-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
2. # [REDACTED]	D Y	[REDACTED]	09-30-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of imaging session frequency, purpose and timeline for procedures. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
3. # [REDACTED]	D Y	[REDACTED]	10-15-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Animal numbers. b. Potential for immune responses; graft evaluation and criteria. c. Mitigation measures. d. Potential impact on immunosuppression. e. Failure rate. Additional discussion during the meeting included: a. Tabled for additional information; PI response.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
4. # [REDACTED]	D	[REDACTED]	09-30-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													

<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
5. #	D Y		09-30-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Efficacy pilot study for procedures already described in original protocol. Additional discussion during the meeting included: a. Committee voted to approve.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
6. #	D		09-30-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on numbers. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
7. #	D Y		09-30-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
8. #	C Y		10-07-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
9. #	D		10-04-2021										

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. clarification of piston adjustment procedures.
- b. clarification of force used and how it will be determined.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

10. #	C		09-30-2021
-------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. Request clarification of why animals need to be transported and who will be transporting them.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 07-28-2021	
2. 08-26-2021	
3. 08-26-2021	
4. 09-22-2021	
5. 09-23-2021	
6. 09-23-2021	
7. 09-23-2021	
8. 09-29-2021	
9. 09-29-2021	
10. 09-29-2021	

Discussion: 10. Study is complete and colony has been disbanded.

Action: 10. This facility will be taken off the IACUC semi-annual inspection schedule.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
-----------------	------	----------------------

1. 07-15-2021	LAB	
2. 07-15-2021	LAB	
3. 09-13-2021	LAB	
4. 09-21-2021	LAB	
5. 09-23-2021	LAB	
6. 09-23-2021	LAB	
7. 09-27-2021	LAB	
8. 09-27-2021	LAB	
9. 09-23-2021	PAM	

Discussion: None.

Action: None.

IACUC Vote

Approval 20

Withhold Approval 0

Abstain 0

Present 20

XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:				
Inspection Date	Agency	Location	Summary	Discussion
1. 09-08-2021	USDA	Site 1 - Routine	FYI - Inspection report received. No non-compliant items.	
2. 09-30-2021	USDA	Site 2 - Focused	FYI - Inspection report received. No non-compliant items.	

XV. Other Discussion Items:

Topic	
2. FYI - [REDACTED] - Animals moved to holding protocol	
Discussion: None.	
Action: None.	
1. FYI - [REDACTED] - Animals moved to holding protocol	
Discussion: None.	
Action: None.	
3. FYI - (Chemical Safety) Standard of Care Medications and Potential Exposure Notification	
Discussion: FYI - new notification procedural annual review.	
Action: None.	
4. SAPR	
Discussion: Reviewed subcommittee recommendations and notes.	
Action: Approved.	
5. [REDACTED] PI Maintain form	
Discussion: PI and collaborator have been using this facility for several years but had not completed the PI maintain form after the policy had been instituted. PI's renewal protocols will be on the 10/14/21 agenda.	
Action: Committee approved the request to remain PI maintained.	

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

October 14, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M097, M222, M102, M090, A095, M100, M092, A019, M119, A109, M110, M093, A013, M016, M024, M223, M001

Excused:

M009, M111, M042, M004, M087, M112, M114

Guests:

M224, M116, A017

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the August 5, 2021, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

The IACUC reviewed and approved the August 19, 2021, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

The IACUC reviewed and approved the September 2, 2021, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

The IACUC reviewed and approved the September 16, 2021, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

The IACUC reviewed and approved the September 30, 2021, meeting minutes as written.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

II. Protocols Tabled From Previous Meetings:

1. # [REDACTED]	Category: D Y										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Procedure clarifications including drug name, choice and dosing information, SOP procedures and references, procedure frequencies. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Tabled, pending PI response. <table border="1"> <tr> <td colspan="2">IACUC Vote</td></tr> <tr> <td>Approval</td><td>0</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	17										

III. Amendments Tabled From Previous Meetings:

1. # [REDACTED]	Category: D Y										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarify if subset or all of animals. b. Clarify historic rates and anticipated future rates. c. Clarify impact on the immunosuppression protocol. d. Clarifying recent graft losses do not appear to be due to lack of material. e. Clarify failure definition and timeline. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI, remains in DMR. <table border="1"> <tr> <td colspan="2">IACUC Vote</td></tr> <tr> <td>Approval</td><td>0</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	17										
2. # [REDACTED]	Category: D										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Discussed CTRB recommendations. Voted to send to DR for PI edits. <table border="1"> <tr> <td colspan="2">IACUC Vote</td></tr> <tr> <td>Approval</td><td>0</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> </table>		IACUC Vote		Approval	0	Withhold Approval	0				
IACUC Vote											
Approval	0										
Withhold Approval	0										

Abstain	0
Present	17

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

CARU Break in.

Action: FYI. No animal welfare impact. Request increase patrols.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Doxycycline requires a VHSS. b. IACUC staff working with PI to remove unnecessary text, edit and rearrange text for clarity. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. IACUC staff working with PI to remove unnecessary text, edit and rearrange text for clarity. Remains in DMR. 			
2. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending PI. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
3. # [REDACTED]	C	[REDACTED]	10-04-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. PI clarified potential adverse effects and monitoring during studies. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
4. # [REDACTED]	D Y	[REDACTED]	10-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Animal numbers clarification. b. Analgesia clarification. c. Clarification of procedures including clinical vs teaching. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
5. # [REDACTED]	E	[REDACTED]	10-14-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on: Hazardous material, Cage dimensions, Animal numbers, Pain/stress hormones, Tail clipping and Adverse effects</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending space renovation and approval. Remains in DMR.</p>			
7. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's responses. PI was contacted to see if he still wants to pursue the project and he responded he does and will get to responses soon.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
8. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI Response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
9. # [REDACTED]	D Y	[REDACTED]	10-11-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. SOP verification.</p> <p>b. NPG vaccine clarification.</p> <p>c. Potential vaccine side effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending updated BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. # [REDACTED]	D	[REDACTED]	10-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Include power calculation. Clarify euthanasia.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. # [REDACTED]	C	[REDACTED]	10-06-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Terminology clarification (floor/ground).</p>			

Additional discussion during the meeting included: a. None.			
13. #	C Y		10-10-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify blood collection sedation. Additional discussion during the meeting included: a. None.			
14. #	C		10-01-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on CRISPR and gene modification. Additional discussion during the meeting included: a. None.			
15. #	D		10-13-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on monitoring of the animals, animal number justification, humane endpoints, staffing and adverse effect. Additional discussion during the meeting included: a. None.			
16. #	C		10-14-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
17. #	D		10-13-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of animal sources/farms and breeds. b. Clarification of farm staff and investigator responsibilities. c. Question about relevance to caustic paste disbudding. d. Clarification of assessment period. e. Clarification of long term follow up responsibilities. Additional discussion during the meeting included: a. None.			
18. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Request for clarification of drug dosing. b. Question about animal source. Additional discussion during the meeting included: a. Pending PI.			
19. #	C		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures.			

Additional discussion during the meeting included: a. Study is exempt per IACUC policy. Pending additional Committee member questions.			
20. # [REDACTED]	C	[REDACTED]	10-14-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of EH&S review, numbers, and procedures. Additional discussion during the meeting included: a. Pending reviewer.			
21. # [REDACTED]	C	[REDACTED]	10-14-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
22. # [REDACTED]	D Y	[REDACTED]	10-06-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Viral status and housing clarifications. b. Clarify funding. c. Clarify literature search for alternatives. d. Telazol use. e. Numbers clarifications. f. rAAV contaminant testing and route of administration. g. Confirmation of pharmaceutical grade; to follow policy if NPG. h. Procedural clarifications. i. Pairing deferral confirmation j. Key word search. k. Alternatives and references. l. Clarify most locations to variants versus serotypes. Additional discussion during the meeting included: a. None.			
23. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
24. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI's responses regarding breeding lines. Additional discussion during the meeting included: a. Remains in DMR.			
25. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Clarification of housing and mortality			

26. # [REDACTED]	D Y	[REDACTED]	10-05-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided for group 3 and transferring options.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. # [REDACTED]	C	[REDACTED]	10-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. # [REDACTED]	C Y	[REDACTED]	10-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. # [REDACTED]	C	[REDACTED]	10-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified if VHSS was needed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. # [REDACTED]	C	[REDACTED]	10-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify breeding procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending clarification of numbers justification.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
2. # [REDACTED]	C	[REDACTED]	10-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	10-14-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
4. #	D		10-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. clarification of previous occurrences. b. Clarification of exclusion/euthanasia criteria. Additional discussion during the meeting included: a. None.			
5. #	C		10-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
6. #	C		10-14-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on acclimation. Additional discussion during the meeting included: a. None.			
7. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response. Additional discussion during the meeting included: a. Remains in DMR.			
8. #	D Y		10-04-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification maximum lidocaine dose. Additional discussion during the meeting included: a. None.			
9. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. clarification of qualifications and responsibilities of new PI. Additional discussion during the meeting included: a. Pending PI.			
10. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.			
11. #	C		10-14-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
12. #	C		10-14-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	C		10-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. #	C		10-06-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of post procedure monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. #	D Y		10-12-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D		10-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of exclusion/euthanasia criteria.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	E		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending BUA amendment</p>			
18. #	D		10-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D		10-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D		10-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D Y		10-01-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Request for more literature search.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		10-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of exclusion/euthanasia criteria.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI response.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
24. #	D		10-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer confirmed no VHSS is required.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D Y		10-11-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA amendment confirmation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	D Y		10-12-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	C		10-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of exclusion/euthanasia criteria.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
29. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending revision following PI/Alternate Contact/AV phone consultation.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending revision following PI/Alternate Contact/AV phone consultation.</p>			
30. #22096	D Y	Amendment clarification on length of surgery time on protocol	-

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending approval following revision of second amendment per PI/Alternate Contact/AV phone consultation.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending approval following revision of second amendment per PI/Alternate Contact/AV phone consultation.</p>			
31. #	D		10-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. #	C Y		10-07-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. #	B Y		09-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
34. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. clarification of qualifications and responsibilities of new PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
35. #	D		10-04-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of force determination calculations.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
36. #	C		09-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. clarification of scientific reason for transportation.</p> <p>b. Clarification of who will provide the transportation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
37. #	D Y		10-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
38. #	D		10-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. None.			
39. #			10-07-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on procedure. Additional discussion during the meeting included: a. None.			
40. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. clarification of adverse effects and how they will be addressed. b. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 242 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	11-19-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted for DMR pending revision and review</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
2. # [REDACTED]	D	[REDACTED]	10-25-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Mortality reducing measures voted for DMR</p> <table border="1"><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												

3. # [REDACTED]	C	[REDACTED]	02-10-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA approval, final inspection of housing room, and minor clarifications.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
4. # [REDACTED]	C	[REDACTED]	02-10-2022										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA approval, final inspection of housing room, and minor clarifications.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
5. # [REDACTED]	D	[REDACTED]	10-14-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on analgesia and pain in post-surgical animals.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
6. # [REDACTED]	D Y	[REDACTED]	10-14-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers.</p> <p>b. Clarification of why cadavers cannot replace live animals</p> <p>c. Clarification of Anesthesia SOP.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												

7. # [REDACTED]	E	[REDACTED]	11-17-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Clarifications of numbers justification.b. Clarification of euthanasia criteria.c. Clarification of testing frequency.d. Clarification of AAV injection procedures. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. pending further review. Requested DR. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
8. # [REDACTED]	D Y	[REDACTED]	10-20-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Clarify the anticipated contraceptive failure rate. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
9. # [REDACTED]	D	[REDACTED]	10-21-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Pending PI response. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. Voted to DMR. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	17												
10. # [REDACTED]	C Y	[REDACTED]	10-14-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none">a. Frequency of monitoring.b. Clarify pairing exemption request. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none">a. None. <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>16</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	16												

11. # [REDACTED]	C Y [REDACTED]	10-14-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of future event vs. past tense.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>			IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote												
Approval	17											
Withhold Approval	0											
Abstain	0											
Present	17											
12. # [REDACTED]	D Y [REDACTED]	10-20-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify rationale for sequential culls at multiple timepoints.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>			IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote												
Approval	17											
Withhold Approval	0											
Abstain	0											
Present	17											
13. # [REDACTED]	C [REDACTED]	10-14-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Updated SOP approved.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>			IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote												
Approval	17											
Withhold Approval	0											
Abstain	0											
Present	17											
14. # [REDACTED]	C Y [REDACTED]	10-14-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>15</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>15</td></tr></table>			IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote												
Approval	15											
Withhold Approval	0											
Abstain	0											
Present	15											
15. # [REDACTED]	C Y [REDACTED]	12-02-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification on tissue collection requirements including type, number of animals and age of animals.
- b. Clarification of personnel and timing for euthanasia procedures.
- c. Clarification of purpose.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	17

16. #	C	10-14-2021
-------	---	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. remnants from previous protocol removed.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D Y		10-16-2019	10-14-2021	10-16-2022
	D		10-17-2019	10-14-2021	10-17-2022
	C		10-18-2019	10-14-2021	10-18-2022
	D		10-21-2019	10-14-2021	10-21-2022
	C Y		10-17-2019	10-14-2021	10-17-2022
	C		10-17-2019	10-14-2021	10-17-2022
	C		10-17-2019	10-14-2021	10-17-2022
	E		10-17-2019	10-14-2021	10-17-2022
	D		10-17-2019	10-14-2021	10-17-2022
	C		10-17-2019	10-14-2021	10-17-2022
	C		10-03-2019	10-14-2021	10-03-2022
	C		10-22-2019	10-14-2021	10-22-2022

	D		10-19-2020	10-14-2021	10-19-2022
	D		10-21-2020	10-14-2021	10-21-2022
	C		10-19-2020	10-14-2021	10-19-2022
	D		10-28-2020	10-14-2021	10-28-2022
	C		10-16-2020	10-14-2021	10-16-2022
	C		10-15-2020	10-14-2021	10-15-2022
	D		10-22-2020	10-14-2021	10-22-2022
	C		10-28-2020	10-14-2021	10-28-2022
	D Y		10-22-2020	10-14-2021	10-22-2022
	D		10-29-2020	10-14-2021	10-29-2022
	C		10-28-2020	10-14-2021	10-28-2022
	D Y		10-29-2020	10-14-2021	10-29-2022
	C		10-29-2020	10-14-2021	10-29-2022
	E		10-29-2020	10-14-2021	10-29-2022
	C Y		10-29-2020	10-14-2021	10-29-2022
	C		10-29-2020	10-14-2021	10-29-2022
	D		02-16-2021	02-03-2022	02-16-2023

Discussion:	<p> - at least one staff member is in process of completing their OHSS renewal; pending appt. PI has prior experience in euthanasia methods. </p>										
Action Items:	<p> - committee approved moving forward with annual renewals. IACUC to observe technique with intent to certify as a campus trainer. </p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>18</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>18</td></tr> </tbody> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D	[REDACTED]	10-14-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding study endpoint</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												
2. # [REDACTED]	D	[REDACTED]	10-14-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding anesthetic protocol clarified.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>17</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	0												
Present	17												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 07-29-2021	[REDACTED]
2. 08-20-2021	[REDACTED]
3. 09-27-2021	[REDACTED]
4. 09-27-2021	[REDACTED]
5. 09-29-2021	[REDACTED]

Discussion:	4. Minor deficiency for yearly eyewash/shower check. Monthly checks have been consistently completed.										
Action:	4. Facility staff to receive training/certification to complete annual checks.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>18</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>18</td> </tr> </tbody> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 09-23-2021	LAB	[REDACTED]
2. 09-24-2021	PAM	[REDACTED]

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>17</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </tbody> </table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. IACUC CEU- ALL course GUIDE FOR THE CARE AND USE OF AGRICULTURAL ANIMALS IN RESEARCH AND TEACHING (4TH EDITION)	
Discussion:	4th edition of the AG Guide adopted by AAALAC council. Voted to add this training for IACUC members.
Action:	Committee approved adding this ALL training module for CE of all members to be completed by 12/31/21.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

October 28, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M222, M102, M111, M042, A095, M004, M100, M092, A019, A109, M110, M093, A013, M016, M024, M001, M114

Excused:

M090, M119, M087, M223, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

1. # [REDACTED]	Category: D Y										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Procedure clarifications including drug name, choice and dosing information, SOP procedures and references, procedure frequencies. Additional discussion during the meeting included: a. Reviewer requested additional time to review responses to previous clarification requests. Approved for designated member review.											
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>		IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	0										
Withhold Approval	0										
Abstain	0										
Present	19										

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
CABA Trees
Action: Grounds following up.
Records Request from "US Right to Know"
Action: Request for old records no longer available due to retention policy.
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
Action: PI maintained form to address housekeeping, room, records.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR</p>			
2. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Protocol needs revision</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending re-review and Chem</p>			
3. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending completion of space renovation and approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending completion of space renovation and approval. Remains in DMR</p>			
4. # [REDACTED]	D	[REDACTED]	10-25-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
6. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
7. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final BUA approval and facilities approval of room.</p> <p>Additional discussion during the meeting included:</p>			

a. Remains in DMR.			
8. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending final BUA approval and facilities approval of room.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
9. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending updated BUA.</p>			
10. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pair housing criteria clarification.</p> <p>b. Pending EH&S review</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved for DMR.</p>			
11. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Source of animals.</p> <p>b. Drug dose clarification</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
12. # [REDACTED]	C Y	[REDACTED]	10-27-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Lab frequency clarified.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarifications of numbers justification.</p> <p>b. Clarification of euthanasia criteria.</p> <p>c. Clarification of testing frequency.</p> <p>d. Clarification of AAV pharmaceutical grade and injection procedure.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending more questions from reviewer.</p>			
14. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures, consent, and roster.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending reviewer.</p>			
15. # [REDACTED]	C	[REDACTED]	10-14-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
16. #	D Y		10-20-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify contraceptive failure rate.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D		10-21-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on blood loss in procedures section and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	C Y		10-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify exam frequency.</p> <p>b. Clarify pairing exemption.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	C		10-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	C		10-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. one DR reviewer confirmed approval during the meeting.</p>			
21. #	C		10-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification provided regarding animal numbers and groups.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	D Y		10-20-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on timepoints.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	C		10-27-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Housing questions addressed.</p>			
24. #	B		10-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		10-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	C Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify age range.</p> <p>b. Clarify requested tissue collection and purpose.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
27. #	C		10-27-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified timing.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. #	D		10-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	D		10-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Updated VHSSs.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
31. #	C		10-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified breeding procedures.</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
32. #	C Y		10-28-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Fixed inconsistency in numbers. Additional discussion during the meeting included: a. None.			
33. #	C		10-15-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified numbers added VHSS. Additional discussion during the meeting included: a. None.			
34. #	C		10-28-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
35. #	B Y		10-25-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		10-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of animal numbers. Additional discussion during the meeting included: a. None.			
2. #	D		10-20-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification regarding breeding procedures, group sizes and publication of strain. Additional discussion during the meeting included: a. None.			
3. #	C		10-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified numbers. Additional discussion during the meeting included: a. None.			
4. #	D Y		10-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
5. #	D Y		10-15-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarify if subset or blanket request. b. Clarify potential for immune response. c. Clarify graft failure determination process. d. Clarify graft cell health and decision to graft. e. Clarify statement regarding spillage or contamination. g. Clarify any impact on immunosuppression protocol. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
6. #	D		10-12-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Added VHSS. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
7. #	D		10-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
8. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of procedures. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending PI. 			
9. #	D Y		10-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification on anesthesia and recovery procedures. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
10. #	D Y		10-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
11. #	C Y		10-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification regarding can food and dry food feedings. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
12. #	D Y		10-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
13. #	C		10-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. addition of new PI to protocol with qualifications requested by reviewer. 			

Additional discussion during the meeting included: a. None.			
14. #	C		10-27-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
15. #	D Y		10-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified which surgery needed the update. Additional discussion during the meeting included: a. None.			
16. #	D		10-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
17. #	D		10-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
18. #	E		10-25-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
19. #	D		10-14-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Minor wording changes made for clarity of intent. Additional discussion during the meeting included: a. None.			
20. #	D Y		10-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
21. #	D Y		10-27-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
22. #	D		10-27-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on the animal model and weight.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	D Y		10-26-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		10-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of the objectives as it relates to original protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
26. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI/Alternate Contact following phone consultation with AV.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI/Alternate Contact following phone consultation with AV.</p>			
27. #	D Y		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI/Alternate Contact following phone consultation with AV.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI/Alternate Contact following phone consultation with AV.</p>			
28. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
29. #	C		10-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D		10-27-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. addition of new PI to protocol with qualifications requested by reviewer.</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
31. #	C		10-20-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. CLarification of possible adverse effects and prevention methods requested.			
Additional discussion during the meeting included:			
a. None.			
32. #	D		10-28-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
a. None.			
Additional discussion during the meeting included:			
a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 188 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	10-28-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. IACUC staff working with PI to remove unnecessary text, edit and rearrange text for clarity. Additional discussion during the meeting included: a. Discussed completed text modifications and wording semantics.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>17</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>2</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	17	Withhold Approval	0	Abstain	2	Present	19
IACUC Vote													
Approval	17												
Withhold Approval	0												
Abstain	2												
Present	19												
2. # [REDACTED]	C Y	[REDACTED]	12-02-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discuss and recommend removal of unnecessary references to euthanasia. Additional discussion during the meeting included: a. Approved for DMR.													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
3. # [REDACTED]	D Y	[REDACTED]	12-02-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification of numbers rationale and groups.
- b. Further describe exam procedures, sedation, and special positioning.
- c. Housing post AAV administration.
- d. Animal ages.

Additional discussion during the meeting included:

- a. Approved for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

4. # [REDACTED] D Y [REDACTED] 10-28-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarify transfer evaluation wording.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

5. # [REDACTED] D Y [REDACTED] 10-29-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. clarity the housing of the animals after AAV administration.

Additional discussion during the meeting included:

- a. Approved for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	19

6. # [REDACTED] D [REDACTED] 01-12-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification of species typo.
- b. Clarification of terms.
- c. Reference for studies in numbers justification requested.
- d. Clarification of surgeons and surgical training.
- e. Clarification of euthanasia method.

Additional discussion during the meeting included:

- a. Pending PI.
- b. Explanation of microwave fixation as a euthanasia method given as this is the first time this has been used at UCD.

IACUC Vote	
Approval	0
Withhold Approval	0

		<table border="1"> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>	Abstain	0	Present	19							
Abstain	0												
Present	19												
7. # [REDACTED]	D	[REDACTED]	11-10-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of enrollment and adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI. Voted to send to DR.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
8. # [REDACTED]	D	[REDACTED]	10-28-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. clarify grant and species justification, clarify to report back if greater than 10 percent reaction is observed</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>18</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>1</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	1	Present	19
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	1												
Present	19												
9. # [REDACTED]	D	[REDACTED]	10-28-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Chemical safety officer finalized review and provided an updated VHSS. PI clarified potential adverse effects.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
10. # [REDACTED]	D Y	[REDACTED]	11-18-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> </table>				IACUC Vote		Approval	0						
IACUC Vote													
Approval	0												

		<div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 19</div> </div>	
11. #	D		10-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI clarified potential adverse effects and morbidity and mortality in past studies. Biosafety confirmed BUA approval and VHSS attached to protocol.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <div> <div>IACUC Vote</div> <div> <div>Approval 19</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 19</div> </div> </div>			
12. #	C Y		10-28-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <div> <div>IACUC Vote</div> <div> <div>Approval 19</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 19</div> </div> </div>			
13. #			11-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. More information provide on the source of the polymer material and how it is monitored.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <div> <div>IACUC Vote</div> <div> <div>Approval 0</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 19</div> </div> </div>			

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		11-13-2019	10-28-2021	11-13-2022
	C Y		10-31-2019	10-28-2021	10-31-2022
	C Y		10-31-2019	10-28-2021	10-31-2022

	D		11-15-2019	10-28-2021	11-15-2022
	D Y		10-31-2019	10-28-2021	10-31-2022
	D		11-14-2019	10-28-2021	11-14-2022
	C		11-13-2019	10-28-2021	11-13-2022
	D		10-31-2019	10-28-2021	10-31-2022
	D		11-02-2019	10-28-2021	11-02-2022
	D Y		10-31-2019	10-28-2021	10-31-2022
	D		11-19-2019	10-28-2021	11-19-2022
	C		11-14-2019	10-28-2021	11-14-2022
	B		10-31-2019	10-28-2021	10-31-2022
	C		11-12-2019	10-28-2021	11-12-2022
	C		10-31-2019	10-28-2021	10-31-2022
	C		11-12-2019	10-28-2021	11-12-2022
	C		10-30-2019	10-28-2021	10-30-2022
	C Y		11-14-2019	10-28-2021	11-14-2022
	C		11-14-2019	10-28-2021	11-14-2022
	D Y		11-12-2020	10-28-2021	11-12-2022
	D		11-19-2020	10-28-2021	11-19-2022
	D		11-17-2020	10-28-2021	11-17-2022
	C		10-30-2020	10-28-2021	10-30-2022
	D		11-02-2020	10-28-2021	11-02-2022
	D		11-12-2020	10-28-2021	11-12-2022
	C		11-12-2020	10-28-2021	11-12-2022
	D		11-04-2020	10-28-2021	11-04-2022
	D		11-02-2020	10-28-2021	11-02-2022

	C		0-23-2020	10-28-2021	10-23-2022
	D Y		11-12-2020	10-28-2021	11-12-2022
	D		11-12-2020	10-28-2021	11-12-2022
	C		11-06-2020	10-28-2021	11-06-2022
	D		11-12-2020	10-28-2021	11-12-2022
	D Y		1-12-2020	10-28-2021	11-12-2022
	E		0-29-2020	10-28-2021	10-29-2022
	C Y		1-09-2020	10-28-2021	11-09-2022
	C		11-19-2020	10-28-2021	11-19-2022
	C		11-12-2020	10-28-2021	11-12-2022

Discussion:	<p>-one person has expired OHSS and is in process of completing their in person appt.</p> <p>-one person has expired OHSS but is on sabbatical and will complete the process when they return.</p> <p>-one person has completed the OHSS process but has not been cleared. Staff member working with occupational health to have Sacramento results added to Davis records.</p> <p>-PI confirmed fasting is only for a few hours and does not require section 9 to be populated.</p> <p>-PI clarified animals are not being transported to VMTH and remain at CEH for studies.</p> <p>-no permit listed in section 3. PI clarified working on federal land under federal permit.</p>										
Action Items:	<p>-committee approved renewal.</p> <p>-committee approved renewal.</p> <p>-committee approved renewal.</p> <p>-committee approved renewal and updating section 7 and 9 of the protocol.</p> <p>-committee approved the renewal and adding the PI's update to section 14a of the protocol.</p> <p>-committee approved renewal and adding PI's response to section 14a of the protocol.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>16</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	D	[REDACTED]	12-09-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA approval and responses to clarifying questions regarding routes of administration and potential adverse effects. Chemical safety officer completed review and provided and updated VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to send to DMR.</p> <table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </tbody> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
2. # [REDACTED]	D Y	[REDACTED]	10-28-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </tbody> </table>				IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
3. # [REDACTED]	D Y	[REDACTED]	11-18-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify timeframes and duration.</p> <p>b. Address potential for pairing failure.</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved for DMR.</p> <table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th> </tr> </thead> <tbody> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </tbody> </table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 09-21-2021	[REDACTED]
2. 09-22-2021	[REDACTED]
3. 09-23-2021	[REDACTED]
4. 09-29-2021	[REDACTED]
5. 09-29-2021	[REDACTED]
6. 10-15-2021	[REDACTED]
7. 10-21-2021	[REDACTED]
8. 10-26-2021	[REDACTED]

Discussion:	1. Facilities noted some bulbs out. 2. Several minor deficiencies noted: roster included people who had left the lab, QA testing of equipment was overdue, lab staff wearing shorts, and CVS not contacted when last trial was in P building. 3. Yearly eyewash check was not scheduled and some rooms needed touch up painting. 4. Anteroom trash was overflowing. 5. Annual eyewash check and hood check were overdue. Rooms needed touch up painting.										
Action:	1. W/O placed to relamp lights. 2. PI corrected all deficiencies and provided plan to prevent them in the future. 3. W/O submitted for both deficiencies. 4. PI corrected deficiency and will implement removing trash more frequently. 5. W/O submitted to correct deficiencies.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>16</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 09-13-2021	LAB	
2. 09-23-2021	LAB	
3. 09-29-2021	LAB	
4. 10-11-2021	LAB	
5. 10-13-2021	LAB	
6. 10-18-2021	LAB	
7. 10-20-2021	LAB	
8. 10-27-2021	LAB	
9. 10-27-2021	LAB	
10. 07-29-2021	PAM	
11. 07-29-2021	PAM	
12. 07-29-2021	PAM	
13. 09-02-2021	PAM	
14. 09-23-2021	PAM	
15. 09-27-2021	PAM	
16. 10-13-2021	PAM	
17. 10-13-2021	PAM	
18. 10-14-2021	PAM	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>17</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>17</td></tr> </tbody> </table>		IACUC Vote		Approval	17	Withhold Approval	0	Abstain	0	Present	17
IACUC Vote											
Approval	17										
Withhold Approval	0										
Abstain	0										
Present	17										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. End of year meeting date reminder: 11/18/21; 12/2/21, 12/16/21. Resume January 6, 2022.	
Discussion:	FYI reminder.
Action:	None.
2. Core and Facility SOP's and IACUC Review	
Discussion:	FYI for future application.
Action:	None.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

**University of California, Davis
IACUC Business Administration System**

**November 18, 2021
Meeting Minutes**

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M102, M111, M042, A095, M100, M092, A019, M119, M087, A109, M110, A013, M016, M024, M223, M001, M114

Excused:

M222, M090, M004, M093, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
<div><div></div><div></div><div></div></div>
Action: Discussed non-compliance, PAM, and action plan moving forward.
FYI - VA public records request courtesy review
Action: None; FYI
FYI - Dart capture (CNPRC)
Action: lameness, under veterinary observation.
FYI - Public Records Request (PETA) CNPRC necropsy records
Action: None; FYI
Additional FYI on notification of SAEN's request to USDA re coyote activity

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
----------	----------	-------	---------------

1. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
2. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending re-review, BIO and Chem</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending Bio and Chem</p>			
3. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding Dex treatment.</p> <p>b. Clarify Aqueous Humor (AH) Outflow facility measurements.</p> <p>c. Clarify stated purpose of the Simbadol use.</p> <p>d. Inclusion of ocular hypertension as potential adverse effect.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remain in DMR.</p>			
4. # [REDACTED]	D Y	[REDACTED]	11-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Change in lab space to remove hold posed by renovation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
6. # [REDACTED]	E	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
7. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending further clarification of numbers with PI.</p>			
8. # [REDACTED]	C	[REDACTED]	-

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA and VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
9. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA and VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
10. #	D		11-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Room approval and BUA approval.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D Y		10-29-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Added new VHSS's provided by Chem Safety.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	C Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Euthanasia procedures not part of this study to be removed. Remains in DMR.</p>			
13. #	D Y		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of numbers rationale and groups.</p> <p>b. Further describe exam procedures, sedation, and special positioning.</p> <p>c. Housing post AAV administration.</p> <p>d. Animal ages..</p> <p>Additional discussion during the meeting included:</p> <p>a. Disposition location pending. Continue in DMR.</p>			
14. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
15. #	E		11-17-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal number calculations.</p> <p>b. Clarification of euthanasia criteria.</p> <p>c. clarification of testing frequency.</p> <p>d. Clarification of non-pharmaceutical compound status.</p>			

e. Clarification of injection types and procedures. Additional discussion during the meeting included: a. None.			
16. # [REDACTED]	C	[REDACTED]	10-29-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of rabies requirement via email. Additional discussion during the meeting included: a. None.			
17. # [REDACTED]	D Y	[REDACTED]	10-29-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify housing location after AAV administration. Additional discussion during the meeting included: a. None.			
18. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
19. # [REDACTED]	D	[REDACTED]	11-10-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of post-surgical monitoring. Additional discussion during the meeting included: a. None.			
20. # [REDACTED]	C Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify age range. b. Clarify tissue requirements within stated objective. Additional discussion during the meeting included: a. Remains in DNR.			
21. # [REDACTED]	D	[REDACTED]	11-16-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified Animal disposition, dosages, wording, and occupational health and safety. Additional discussion during the meeting included: a. None.			
22. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI. Additional discussion during the meeting included: a. Remains in DMR.			
23. # [REDACTED]	D Y	[REDACTED]	11-18-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarify disposition, modify study endpoint and disposition. b. AAV and disposition review by CNPRC. c. VHSS clarification. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
24. #			11-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification on materials to be implanted. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
25. #	B		11-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
26. #	C		-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Pending Chem 			
27. #	C		11-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
28. #	D		11-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification on retro-orbital sinus injections. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
29. #	C Y		11-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification of teaching colony animal care. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
30. #	C Y		11-18-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			

31. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. # [REDACTED]	C	[REDACTED]	11-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
33. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed diet change and animal breed.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
2. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussion on enrichment for frogs.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
4. # [REDACTED]	D Y	[REDACTED]	11-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D	[REDACTED]	11-08-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
6. #			11-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. #	C		11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. #	D Y		11-15-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
9. #	D Y		11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarify length of time, maximum duration, groups, options.</p> <p>b. Address potential repairing issues.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. #	C		11-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
11. #	D		11-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
12. #	D		11-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. #	D		10-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

14. # [REDACTED]	D Y [REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed occupational health, subjective behavior evaluations, and analgesia specifics.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>		
15. # [REDACTED]	D [REDACTED]	11-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>		
16. # [REDACTED]	[REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>		
17. # [REDACTED]	C [REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>		
18. # [REDACTED]	D [REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>		
19. # [REDACTED]	D [REDACTED]	10-28-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>		
20. # [REDACTED]	D [REDACTED]	11-03-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Further edits to Consent Form.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>		
21. # [REDACTED]	D Y [REDACTED]	11-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Request further consultation with AV.</p> <p>Additional discussion during the meeting included:</p> <p>a. Phone consultation occurred with AV; amendment revised.</p>		
22. # [REDACTED]	D Y [REDACTED]	11-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Request further consultation with AV.</p> <p>Additional discussion during the meeting included:</p> <p>a. Phone consultation occurred with AV; amendment revised.</p>		

23. # [REDACTED]	C	[REDACTED]	10-29-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers and ATS.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. # [REDACTED]	D	[REDACTED]	11-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. # [REDACTED]	D	[REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Resiquimod requires a VHSS was attached.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. # [REDACTED]	D	[REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. # [REDACTED]	D	[REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. # [REDACTED]	D Y	[REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. # [REDACTED]	E	[REDACTED]	11-17-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. # [REDACTED]	D	[REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
31. # [REDACTED]	C Y	[REDACTED]	11-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding maximum duration of sedation.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

32. # [REDACTED]	D	[REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 279 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D	[REDACTED]	12-02-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
2. # [REDACTED]	D	[REDACTED]	11-18-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
3. # [REDACTED]	D	[REDACTED]	11-19-2021										
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0				
IACUC Vote													
Approval	0												
Withhold Approval	0												

	Abstain	0
	Present	18

4. # [REDACTED]	D	[REDACTED]	12-02-2021
-----------------	---	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Additional information requested re effects of suspension on sleep, stress, grooming, feeding. Additional discussion during the meeting included:
 - a. Approved for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

5. # [REDACTED]	D Y	[REDACTED]	11-24-2021
-----------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Title verification.
- b. Animal numbers clarification.
- c. BUA verification.
- d. Address previous subject matter publication.

Additional discussion during the meeting included:

- a. Approved for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

6. # [REDACTED]	D Y	[REDACTED]	11-18-2021
-----------------	-----	------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarified numbers justification, transportation practices, and transfer of animals to other approved protocols.

Additional discussion during the meeting included:

- a. Committee voted and approved.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
[REDACTED]	E	[REDACTED]	11-20-2019	11-18-2021	11-20-2022
[REDACTED]	E	[REDACTED]	11-25-2019	11-18-2021	11-25-2022

	D Y		11-20-2019	11-18-2021	11-20-2022
	D Y		11-27-2019	11-18-2021	11-27-2022
	E		11-22-2019	11-18-2021	11-22-2022
	C		11-13-2019	11-18-2021	11-13-2022
	C		11-25-2019	11-18-2021	11-25-2022
			11-26-2019	11-18-2021	11-26-2022
	C		12-02-2019	11-18-2021	12-02-2022
	C		12-02-2019	11-18-2021	12-02-2022
	C		11-27-2019	11-18-2021	11-27-2022
	E		12-03-2020	11-18-2021	12-03-2022
	D		12-03-2020	11-18-2021	12-03-2022
	D		11-12-2020	11-18-2021	11-12-2022
	C		11-25-2020	11-18-2021	11-25-2022
	D Y		12-03-2020	11-18-2021	12-03-2022
	D Y		12-03-2020	11-18-2021	12-03-2022
	C		11-30-2020	11-18-2021	11-30-2022
	C		12-01-2020	11-18-2021	12-01-2022
	D		12-02-2020	11-18-2021	12-02-2022
	C		12-03-2020	11-18-2021	12-03-2022
	D Y		12-03-2020	11-18-2021	12-03-2022
	C		12-02-2020	11-18-2021	12-02-2022
	D Y		12-03-2020	11-18-2021	12-03-2022
	E		12-03-2020	11-18-2021	12-03-2022
	D Y		12-02-2020	11-18-2021	12-02-2022
	D		11-23-2020	11-18-2021	11-23-2022
	C		12-03-2020	11-18-2021	12-03-2022
	D		12-03-2020	11-18-2021	12-03-2022

	C		12-03-2020	11-18-2021	12-03-2022
	D		2-03-2020	11-18-2021	12-03-2022
	C Y		2-03-2020	11-18-2021	12-03-2022
	D Y		12-03-2020	11-18-2021	12-03-2022

Discussion:	<p>_____ and _____ = At least one staff member is pending their OHSS renewal process. Must complete in person appointment.</p> <p>_____ - Literature search inadvertently missing from original protocol. PI submitted amendment on other protocol for same search criteria.</p> <p>_____ Reviewed amendments for jealousy study and boxing. Committee confirmed any distress in jealousy study is momentary and animals in box have normal postural movement.</p>										
Action Items:	<p>_____ and _____ = Committee voted to approve renewals.</p> <p>_____ - Committee approved adding literature search results to original protocol.</p> <p>_____ Committee approved adding wording to clarify momentary distress and animals having normal postural movement.</p>										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>14</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>14</td></tr> </tbody> </table>		IACUC Vote		Approval	14	Withhold Approval	0	Abstain	0	Present	14
IACUC Vote											
Approval	14										
Withhold Approval	0										
Abstain	0										
Present	14										

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved										
1. # [REDACTED]	C Y	[REDACTED] mals	11-18-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Anesthesia, analgesic clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <table border="1"><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
2. # [REDACTED]	D	[REDACTED]	11-18-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Confirmation for reviewer that changes will be added to the protocol.</p> <p>Additional discussion during the meeting included:</p>													

a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

3. # [REDACTED]	D Y	[REDACTED]	04-28-2022
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Additional scientific justification requested for transfer.
 - b. Clarify relation of request and potential mitigation measures with previously obtained pathology.
- New surgeon training.

Additional discussion during the meeting included:

- a. Approved for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

4. # [REDACTED]	D	[REDACTED]	11-18-2021
-----------------	---	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Reviewed procedure differences and lab inspection report.

Additional discussion during the meeting included:

- a. Committee approved clarification.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

5. # [REDACTED]	D Y	[REDACTED]	11-18-2021
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

6. # [REDACTED]	D Y	[REDACTED]	11-18-2021
-----------------	-----	------------	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. None.

Additional discussion during the meeting included:

- a. None.

IACUC Vote	
Approval	18

		<div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 18</div> </div>	
7. #	D Y		01-06-2022
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Cautey procedure clarification.</p> <p>Additional discussion during the meeting included:</p> <p>a. Approved for DMR.</p> <div> <div>IACUC Vote</div> <div> <div>Approval 0</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 18</div> </div> </div>			
8. #	E		11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. BUA for project clarified.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee approved by vote.</p> <div> <div>IACUC Vote</div> <div> <div>Approval 18</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 18</div> </div> </div>			
9. #	D		11-22-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI's responses.</p> <p>Additional discussion during the meeting included:</p> <p>a. Voted to send to DMR.</p> <div> <div>IACUC Vote</div> <div> <div>Approval 0</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 18</div> </div> </div>			
10. #	D		11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p> <div> <div>IACUC Vote</div> <div> <div>Approval 18</div> <div>Withhold Approval 0</div> <div>Abstain 0</div> <div>Present 18</div> </div> </div>			
11. #22094	C	Increase Maximum Temperature to 65degC	01-12-2022

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Pending PI.

Additional discussion during the meeting included:

a. Voted to DMR.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

12. #	D Y		11-18-2021
-------	-----	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

13. #	D Y		11-18-2021
-------	-----	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. PI provided clarification regarding animal numbers.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

14. #	D		11-18-2021
-------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. PI provided clarification regarding animal numbers.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 07-20-2021	
2. 08-11-2021	
3. 10-21-2021	

4. 10-22-2021	
5. 10-26-2021	
6. 10-27-2021	

Discussion:	3. The facility will be completely retrofitted so some work orders may remain open until the renovation begins. 6. One staff member on the roster had an expired OHSS. One door is not shutting properly.										
Action:	3. The IACUC will re-evaluate timelines for facility repairs at the next semi-annual inspection. 6. The staff member had left months ago and it was missed they had not been taken off the roster. Work order submitted for the door.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>15</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>15</td></tr> </tbody> </table>		IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote											
Approval	15										
Withhold Approval	0										
Abstain	0										
Present	15										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 05-19-2021	LAB	
2. 08-11-2021	LAB	
3. 10-01-2021	LAB	
4. 10-07-2021	LAB	
5. 10-12-2021	LAB	
6. 10-18-2021	LAB	
7. 10-18-2021	LAB	
8. 10-18-2021	LAB	
9. 10-25-2021	LAB	
10. 11-02-2021	LAB	
11. 11-04-2021	LAB	
12. 11-08-2021	LAB	
13. 11-10-2021	LAB	
14. 07-29-2021	PAM	
15. 10-21-2021	PAM	
16. 10-25-2021	PAM	
17. 10-29-2021	PAM	
18. 11-04-2021	PAM	

Discussion:	9. Amendment discussed under FC section. Clarified analgesia for all procedures on protocol and added room inadvertently left off previous amendment.										
Action:	9. Committee approved changes.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>16</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>16</td></tr> </tbody> </table>		IACUC Vote		Approval	16	Withhold Approval	0	Abstain	0	Present	16
IACUC Vote											
Approval	16										
Withhold Approval	0										
Abstain	0										
Present	16										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. Policies ready for review: -04 "IACUC Laboratory/Study Area Inspection Program" -19 "Laboratory Housing for Research Animals" -45 "IACUC Semi-Annual Program Review (SAPR)" -55 "Food and Fluid Regulation Policy for Rodents" -56 "Non-affiliated Member Recruitment and Appointment Process"	
Discussion:	04 returns to sub committee 19 Approved 45 Approved 55 Approved 56 Approved
Action:	None.
2. IACUC 101 Plus Workshop (Zoom Dec 1-2, 10AM-2PM) Register by Nov 30.	
Discussion:	Online opportunity for IACUC 101 course.
Action:	Interested Committee members to contact IACUC office by 11/30/21.
3. Complete ALL course by 12/31/21.	
Discussion:	Reminder regarding AG Guide course assigned to committee members.
Action:	All members to complete course by 12/31/21.

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

**University of California, Davis
IACUC Business Administration System**

**December 02, 2021
Meeting Minutes**

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M222, M102, M111, M090, A095, M004, M092, A019, M119, M087, A109, M110, A013, M016, M024, M223, M001, M114

Excused:

M042, M100, M093, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

There have been no Concerns, Events, or Incidents reported.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response. Additional discussion during the meeting included: a. Remains in DMR.			
2. # [REDACTED]	D	[REDACTED]	11-19-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. pending meeting and rewrite and chem Additional discussion during the meeting included: a. pending chem			

3. # [REDACTED]	D Y	[REDACTED]	12-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification regarding Dex treatment. b. Clarify Aqueous Humor (AH) Outflow facility measurements. c. Clarify stated purpose of the Simbadol use. d. Inclusion of ocular hypertension as potential adverse effect. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
4. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending PI's responses. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
5. # [REDACTED]	E	[REDACTED]	12-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Clarification on the procedure. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
6. # [REDACTED]	C	[REDACTED]	11-30-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Further clarification of numbers. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. None. 			
7. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending BUA and VHSS. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
8. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. Pending BUA and VHSS. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Remains in DMR. 			
9. # [REDACTED]	C Y	[REDACTED]	12-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. <p>Additional discussion during the meeting included:</p> <ul style="list-style-type: none"> a. Euthanasia procedures not part of this study removed. 			
10. # [REDACTED]	D Y	[REDACTED]	12-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <ul style="list-style-type: none"> a. None. 			

Additional discussion during the meeting included: a. Cannot be returned to [REDACTED] as originally described, modified to return to designated [REDACTED] cage.			
11. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
12. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
13. # [REDACTED]	C Y	[REDACTED]	12-02-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending reviewer approval. Additional discussion during the meeting included: a. None.			
14. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI. Additional discussion during the meeting included: a. Remains in DMR.			
15. # [REDACTED]	D	[REDACTED]	12-02-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on the compound table. Additional discussion during the meeting included: a. None.			
16. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Chem			
17. # [REDACTED]	D	[REDACTED]	11-19-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on prolonged restraint and pharmaceutical grade VetBond. Additional discussion during the meeting included: a. None.			
18. # [REDACTED]	D	[REDACTED]	12-02-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Additional information requested re effects of suspension on sleep, stress, grooming, feeding.			

b. Clarification of adverse effects. Additional discussion during the meeting included: a. None.			
19. #	D Y		11-24-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Title verification. b. Animal numbers clarification. c. BUA verification. d. Address previous subject matter publication. Additional discussion during the meeting included: a. None.			
20. #	D		11-22-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified techniques. Additional discussion during the meeting included: a. None.			
21. #	C		11-30-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed diet and lactation states of animals. Additional discussion during the meeting included: a. None.			
22. #	D		-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed water consumption monitoring. Additional discussion during the meeting included: a. None.			
23. #	C		12-02-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending Reviewer.			
24. #	C Y		11-29-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI clarified monitoring of animals. Additional discussion during the meeting included: a. None.			
25. #	B		11-29-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending additional information regarding housing.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
2. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending BUA and VHSS.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
3. # [REDACTED]	D	[REDACTED]	12-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	D Y	[REDACTED]	11-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding availability of reader.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. CNPRC veterinarian will review further with PI. Remains in DMR.</p>			
6. # [REDACTED]	D	[REDACTED]	11-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarified breeding numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
7. # [REDACTED]	D	[REDACTED]	11-19-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on wording.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
8. # [REDACTED]	D Y	[REDACTED]	12-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p>			

Additional discussion during the meeting included: a. None.			
9. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify cautery/suture procedure. Additional discussion during the meeting included: a. Remains in DMR.			
10. #	D		12-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI's acknowledgement of chemical safety officers review. Additional discussion during the meeting included: a. Remains in DMR.			
11. #	C		12-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
12. #	C		12-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
13. #	C		12-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
14. #	D Y		11-19-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed subjective evaluations and adjunct sedation. Additional discussion during the meeting included: a. None.			
15. #	D		11-18-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
16. #	D		11-22-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. PI provided clarification regarding anesthesia, routes of administration and incision care. Additional discussion during the meeting included: a. None.			
17. #	D		11-22-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	E		11-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. #	D		12-01-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D Y		11-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D		12-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending PI.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
23. #	D Y		11-24-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C Y		11-30-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

26. # [REDACTED]	D	[REDACTED]	12-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Housing location after imaging updated.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. # [REDACTED]	D	[REDACTED]	11-18-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
28. # [REDACTED]	D	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending Reviewer.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
29. # [REDACTED]	C Y	[REDACTED]	11-23-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VIII. Administrative and Veterinary Verification Amendments:

Total of 154 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D Y	[REDACTED]	01-06-2022

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Clarification of typo.
- b. Inclusion of chute system.
- c. Sampling clarifications.
- d. Shave biopsy procedures.
- d. Clarify procedure location and any related animal movement.
- e. Remove unnecessary lab specific details.

Additional discussion during the meeting included:

- a. Approved for DMR.

IACUC Vote	
Approval	0
Withhold Approval	0

		<table><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>	Abstain	0	Present	19							
Abstain	0												
Present	19												
2. #	D Y		12-02-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Title clarification. Additional discussion during the meeting included: a. None.													
		<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>19</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>	IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19	
IACUC Vote													
Approval	19												
Withhold Approval	0												
Abstain	0												
Present	19												
3. #	D		12-02-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified tumor size monitoring and length of study. Additional discussion during the meeting included: a. Added reference to a specific IACUC policy.													
		<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>20</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>	IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20	
IACUC Vote													
Approval	20												
Withhold Approval	0												
Abstain	0												
Present	20												
4. #	D		12-03-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI. Voted to send to DR.													
		<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>20</td></tr></table>	IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	20	
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	20												
5. #	C Y		12-13-2021										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify abbreviations. b.AAV and disposition clarification. Additional discussion during the meeting included: a. Request additional CNPRC input re endpoints and disposition. b. Approved for DMR.													
		<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr></table>	IACUC Vote		Approval	0	Withhold Approval	0					
IACUC Vote													
Approval	0												
Withhold Approval	0												

	Abstain	0
	Present	19

6. #	C		12-02-2021
------	---	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

7. #	D Y		12-06-2021
------	-----	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Pending PI's response to clarifying questions regarding surgery details.

Additional discussion during the meeting included:

a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	20

8. #	D Y		12-02-2021
------	-----	--	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. PI clarified monitoring for bladder infections.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		12-05-2019	12-02-2021	12-05-2022
	C		12-05-2019	12-02-2021	12-05-2022
	D Y		12-05-2019	12-02-2021	12-05-2022
	D		12-05-2019	12-02-2021	12-05-2022

	C Y		12-05-2019	12-02-2021	12-05-2022
	D		12-05-2019	12-02-2021	12-05-2022
			12-04-2019	12-02-2021	12-04-2022
	C		12-09-2019	12-02-2021	12-09-2022
	D		12-05-2019	12-02-2021	12-05-2022
	D Y		12-04-2019	12-02-2021	12-04-2022
	C		12-06-2019	12-02-2021	12-06-2022
	C		12-05-2019	12-02-2021	12-05-2022
	C Y		12-05-2019	12-02-2021	12-05-2022
	D		12-11-2019	12-02-2021	12-11-2022
	C		12-05-2019	12-02-2021	12-05-2022
	D		12-05-2019	12-02-2021	12-05-2022
	D Y		12-05-2019	12-02-2021	12-05-2022
	D		12-05-2019	12-02-2021	12-05-2022
	C		12-09-2019	12-02-2021	12-09-2022
	D Y		12-05-2019	12-02-2021	12-05-2022
	C		12-05-2019	12-02-2021	12-05-2022
	Y		12-05-2019	12-02-2021	12-05-2022
			12-10-2019	12-02-2021	12-10-2022
			12-13-2019	12-02-2021	12-13-2022
	C		12-05-2019	12-02-2021	12-05-2022
	D		12-10-2019	12-02-2021	12-10-2022
	C		12-16-2020	12-02-2021	12-16-2022
	C		12-15-2020	12-02-2021	12-15-2022
	D Y		12-17-2020	12-02-2021	12-17-2022
	C		12-15-2020	12-02-2021	12-15-2022

	C		12-14-2020	12-02-2021	12-14-2022
	E		12-08-2020	12-02-2021	12-08-2022
	D		12-04-2020	12-02-2021	12-04-2022
	D		12-11-2020	12-02-2021	12-11-2022
	E		12-03-2020	12-02-2021	12-03-2022
	C		12-17-2020	12-02-2021	12-17-2022
	D		12-17-2020	12-02-2021	12-17-2022
	C Y		12-17-2020	12-02-2021	12-17-2022
	C		12-17-2020	12-02-2021	12-17-2022
	D		12-07-2020	12-02-2021	12-07-2022
	C Y		12-17-2020	12-02-2021	12-17-2022
	C		12-17-2020	12-02-2021	12-17-2022
	C		12-16-2020	12-02-2021	12-16-2022
	D		12-17-2020	12-02-2021	12-17-2022
	C Y		12-17-2020	12-02-2021	12-17-2022
	D		12-17-2020	12-02-2021	12-17-2022

Discussion:	[REDACTED] and [REDACTED] One staff member is in the process of updating their OHSS renewal and have either completed their in person exam and are awaiting results or need to complete their in person exam.	
Action Items:	[REDACTED] [REDACTED] and [REDACTED]-Committee approved the annual renewals.	

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	12-14-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending edits. Voted to send to DR.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	20

2. #	D Y	12-02-2021
------	-----	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarify request with objective.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	19
Withhold Approval	0
Abstain	0
Present	19

3. #	D Y	12-02-2021
------	-----	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Chemical safety officer completed review and provided a VHSS.

Additional discussion during the meeting included:

a. Committee voted to approve.

IACUC Vote

Approval	20
Withhold Approval	0
Abstain	0
Present	20

4. #	D Y	12-08-2021
------	-----	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of when animals will be euthanized vs used in control group/other studies.

b. Clarification of analgesia.

c. redaction of names.

Additional discussion during the meeting included:

a. None.

IACUC Vote

Approval	0
Withhold Approval	0
Abstain	0
Present	19

5. #	D	
------	---	--

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Pending PI responses, voted to send to DR

<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>0</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>			IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote												
Approval	0											
Withhold Approval	0											
Abstain	0											
Present	19											
6. # [REDACTED]	D Y [REDACTED]	12-02-2021										
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Updated committee on high dose group and request to eliminate dose to ewe.</p> <p>Additional discussion during the meeting included:</p> <p>a. Committee voted to approve.</p> <table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>20</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>20</td> </tr> </table>			IACUC Vote		Approval	20	Withhold Approval	0	Abstain	0	Present	20
IACUC Vote												
Approval	20											
Withhold Approval	0											
Abstain	0											
Present	20											

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 07-08-2021	[REDACTED]
2. 10-21-2021	[REDACTED]
3. 11-19-2021	[REDACTED]

Discussion:	None.										
Action:	None.										
<table border="1"> <tr> <th colspan="2">IACUC Vote</th> </tr> <tr> <td>Approval</td> <td>19</td> </tr> <tr> <td>Withhold Approval</td> <td>0</td> </tr> <tr> <td>Abstain</td> <td>0</td> </tr> <tr> <td>Present</td> <td>19</td> </tr> </table>		IACUC Vote		Approval	19	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote											
Approval	19										
Withhold Approval	0										
Abstain	0										
Present	19										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 06-24-2021	LAB	[REDACTED]
2. 11-09-2021	LAB	[REDACTED]
3. 11-15-2021	LAB	[REDACTED]
4. 11-16-2021	LAB	[REDACTED]
5. 11-23-2021	LAB	[REDACTED]
6. 11-09-2021	PAM	[REDACTED]

Discussion:	2. Location approved for client and research animals. Oversight of room was ambiguous to users.
Action:	2. PI's and clinicians will ensure room is maintained per IACUC policies and guidelines.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic	
1. record/document humidity	
Discussion:	1. Reviewed policies regarding recording/documentation of environmental controls.
Action:	1. Committee to revise policies when subcommittee meets to clarify expectations.
2. IACUC Policy-04 "IACUC Laboratory/Study Area Inspection Program"	
Discussion:	None.
Action:	Approved
3. IACUC Policy-06 "IACUC Meeting Minutes"	
Discussion:	None.
Action:	Approved
4. IACUC Policy-21 "Provision of Veterinary Care by Veterinarians that are not part of our centralized support Veterinary Teams"	
Discussion:	None.
Action:	Approved
5. IACUC Policy-20 "Rationale for Species and Numbers"	
Discussion:	None.
Action:	Approved
6. IACUC Policy-22 "Guidelines for Rodent Survival Surgery"	
Discussion:	Discussed PPE.
Action:	Approved

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

University of California, Davis
IACUC Business Administration System

December 16, 2021
Meeting Minutes

[\[regular view\]](#) | [\[VA view\]](#)

Attendance:

Present:

M009, M097, M102, M111, M042, A095, M004, M100, M092, A019, M119, M087, M110, A013, M016, M024, M223, M001, M114

Excused:

M222, M090, A109, M093, M112

Guests:

M224, M116, A017, A018

I. Minutes from Previous Meetings:

The IACUC reviewed and approved the October 28, 2021, meeting minutes as written.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

	Action: IACUC Staff will review procedures for congruency with protocol; complainant has also been referred to HR for additional support as reported concern involves personnel issues.
	Action: Procedures outside of protocol, use of glue; Subcommittee will meet with PI to review UCD IACUC policies, procedures and expectations.
	rodent cage changes
	Action: Routine schedule per SOP affected by staffing shortages due to COVID. No animal welfare issue.

V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response on BSL levels. Additional discussion during the meeting included: a. Remains in DMR.			
2. # [REDACTED]	D Y	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. IACUC staff contacted PI informing them the protocol would be withdrawn at the 1/6/22 meeting if the PI does not respond to committee questions. Protocol was submitted in July and requires an updated literature search. Additional discussion during the meeting included: a. Remains in DMR.			
3. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA and VHSS. Additional discussion during the meeting included: a. Remains in DMR.			
4. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA and VHSS. Additional discussion during the meeting included: a. Remains in DMR.			
5. # [REDACTED]	D Y	[REDACTED]	12-02-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Further clarification on number rationale. Additional discussion during the meeting included: a. None.			
6. # [REDACTED]	C	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
7. # [REDACTED]	D	[REDACTED]	-
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:			

a. Pending PI.			
8. # [REDACTED]	D	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI responses</p>			
9. # [REDACTED]	D	[REDACTED]	12-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on and removal of ITT.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
10. # [REDACTED]	D Y	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of typo.</p> <p>b. Additional information requested regarding sampling procedure.</p> <p>c. Further clarification regarding group disposition.</p> <p>Additional discussion during the meeting included:</p> <p>a. Remains in DMR.</p>			
11. # [REDACTED]	C	[REDACTED]	12-06-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Chem provided a VHSS</p>			
12. # [REDACTED]	D	[REDACTED]	12-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on procedures.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
13. # [REDACTED]	C	[REDACTED]	12-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
14. # [REDACTED]	D	[REDACTED]	12-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
15. # [REDACTED]	D	[REDACTED]	12-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

16. # [REDACTED]	C	[REDACTED]	-
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
17. # [REDACTED]	C	[REDACTED]	12-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. # [REDACTED]	C Y	[REDACTED]	12-13-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Modification of study endpoints.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
19. # [REDACTED]	D	[REDACTED]	12-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. # [REDACTED]	C	[REDACTED]	12-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Change to needle size description.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. # [REDACTED]	D Y	[REDACTED]	12-06-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI provided clarification regarding animal numbers justification and monitoring procedure details.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. # [REDACTED]	C	[REDACTED]	12-08-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of animal numbers.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. # [REDACTED]	D	[REDACTED]	12-16-2021

<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of experimental procedures (vs. SOC), animal numbers, and drug dose.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
24. #	D		12-03-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Discussed fluid consumption monitoring.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
25. #	C		12-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of experimental design and statical calculations.</p> <p>b. Clarification of feed additive composition.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
26. #	B Y		12-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
27. #	D		12-14-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Monitoring DO, statistical analysis and parameters tested for after smapling blood.</p>			
28. #	D		12-15-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of dose determination procedures.</p> <p>b. Clarification of thermal threshold determination procedures.</p> <p>c. Clarification of adverse events.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
29. #	C		12-01-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
30. #	D		12-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

31. # [REDACTED]	B	[REDACTED]	12-02-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
32. # [REDACTED]	D	[REDACTED]	12-16-2021
<p>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	12-13-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI clarified housing and procedures in place per BUA for AAV.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
2. # [REDACTED]	D	[REDACTED]	12-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification regarding notification to CVS and IACUC.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
3. # [REDACTED]	D	[REDACTED]	12-09-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. PI clarified potential adverse effects and training of personnel.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
4. # [REDACTED]	D	[REDACTED]	12-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
5. # [REDACTED]	D Y	[REDACTED]	-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Pending additional consult with CNPRC veterinarian.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending additional consult with CNPRC veterinarian.</p>			
6. # [REDACTED]	D Y	[REDACTED]	12-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p>			

a. None.			
7. #	E		12-08-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified procedures. Additional discussion during the meeting included: a. None.			
8. #	E		12-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Discussed adverse effects and mitigation. Additional discussion during the meeting included: a. None.			
9. #			12-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
10. #	D		12-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Chemical safety officer completed their review and provided updated VHSS. PI acknowledge receipt and will communicate with vivarium staff. Additional discussion during the meeting included: a. None.			
11. #	D Y		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
12. #	D		12-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
13. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
14. #	D Y		12-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
15. #	C		12-09-2021

<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. egg production as a performance measure, concentrations thus far, and upper toxic limits</p>			
16. #	D		12-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
17. #	D		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on adverse effects, BUA, and terminology.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
18. #	C		-
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. Pending PI.</p>			
19. #	C Y		12-02-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
20. #	D Y		12-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification of dosing, timing, and proposed next steps.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
21. #	D Y		12-08-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
22. #	C		12-16-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. None.</p> <p>Additional discussion during the meeting included:</p> <p>a. None.</p>			
23. #	C		12-14-2021
<p>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</p> <p>a. Clarification on terminology.</p>			

Additional discussion during the meeting included: a. None.			
24. #	C		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI. Additional discussion during the meeting included: a. Remains in DMR.			
25. #	D Y		12-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
26. #	D		12-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
27. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.			
28. #	D		12-10-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
29. #	C		12-13-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
30. #	C		12-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
31. #	D		12-15-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
32. #	D		12-13-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
33. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
34. #	D Y		12-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			
35. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI			
36. #	B		12-02-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			

VIII. Administrative and Veterinary Verification Amendments:

Total of 119 Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved										
1. # [REDACTED]	D Y	[REDACTED]	01-18-2022										
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Voted for DR, pending response to questions and Biosafety review													
<table><tr><th colspan="2">IACUC Vote</th></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
2. # [REDACTED]	C Y	[REDACTED]	12-16-2021										

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. None.

Additional discussion during the meeting included:

a. Voted to Approved.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

3. # [REDACTED]	D [REDACTED]	12-16-2021
-----------------	--------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. PI clarified procedure details and sample origins. Chemical safety officer completed their review and provided updated VHSS. PI acknowledge receipt and will communicate with vivarium staff.

Additional discussion during the meeting included:

a. Committee voted to approve the protocol.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

4. # [REDACTED]	D [REDACTED]	12-16-2021
-----------------	--------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Replacement protocol with no additional questions from the committee.

Additional discussion during the meeting included:

a. Committee voted to approve protocol.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

5. # [REDACTED]	D [REDACTED]	12-16-2021
-----------------	--------------	------------

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of drug dose and post-op monitoring.

Additional discussion during the meeting included:

a. None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

X. Annual Renewals:

Protocol	Category	Title	Original	Last	Expires
----------	----------	-------	----------	------	---------

			Approval	Reviewed	
	D		12-30-2019	12-16-2021	12-30-2022
	C		01-06-2020	12-16-2021	01-06-2023
	D		01-07-2020	12-16-2021	01-07-2023
	D Y		12-19-2019	12-16-2021	12-19-2022
	C		12-18-2019	12-16-2021	12-18-2022
	E		01-06-2020	12-16-2021	01-06-2023
	E		01-07-2020	12-16-2021	01-07-2023
	C		12-19-2019	12-16-2021	12-19-2022
	C		12-19-2019	12-16-2021	12-19-2022
	E		12-05-2019	12-16-2021	12-05-2022
	C		12-19-2019	12-16-2021	12-19-2022
	D		12-05-2019	12-16-2021	12-05-2022
	C		12-19-2019	12-16-2021	12-19-2022
	C		12-18-2019	12-16-2021	12-18-2022
	D Y		01-07-2020	12-16-2021	01-07-2023
	C		12-20-2019	12-16-2021	12-20-2022
	C		01-03-2020	12-16-2021	01-03-2023
	C		01-06-2020	12-16-2021	01-06-2023
	B		01-07-2020	12-16-2021	01-07-2023
	C Y		12-19-2019	12-16-2021	12-19-2022
	D		12-18-2020	12-16-2021	12-18-2022
	D		01-07-2021	12-16-2021	01-07-2023
	D		12-17-2020	12-16-2021	12-17-2022
	D Y		12-07-2020	12-16-2021	12-07-2022
	C		01-04-2021	12-16-2021	01-04-2023

	D		01-04-2021	12-16-2021	01-04-2023
	C		01-06-2021	12-16-2021	01-06-2023
	C		12-18-2020	12-16-2021	12-18-2022
	D		01-07-2021	12-16-2021	01-07-2023
	C		01-04-2021	12-16-2021	01-04-2023
	B		01-06-2021	12-16-2021	01-06-2023

Discussion:	& [REDACTED] - One person on roster is in process of renewing their OHSS process. All are on the last step. [REDACTED] - Wording in section 9 requests feeding scheduling not regulation. [REDACTED] - Experimental drug may require review by Chemical Safety. [REDACTED] Literature search inadvertently not attached to original protocol. [REDACTED] Other veterinarian listed in section 11.
Action Items:	& [REDACTED] -Committee approved the annual renewals. [REDACTED] - Committee approved moving wording to section 7 and remove from 9. [REDACTED] Committee approved renewal and Chemical safety has been notified to complete review to ensure no VHSS is needed. [REDACTED] IACUC staff working with PI to submit an amendment. [REDACTED] AV working with PI to establish an MOU.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1. # [REDACTED]	D	[REDACTED]	12-16-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Chemical safety officer completed their review and provided an updated VHSS. PI confirmed acknowledgement and will communicate with vivarium staff.

Additional discussion during the meeting included:

- a. Committee voted to approve.

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

2. #	C		12-16-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Discussed stated "change to objective". Change determined to be to the education design but not to overall objective of the study.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
3. #	D Y		02-07-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending SOP for care of lambs. PI working with staff to complete. Additional discussion during the meeting included: a. Voted to send to DMR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>19</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	19
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	19												
4. #	C		12-22-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of Consent Form and adverse effects. Additional discussion during the meeting included: a. Pending CTRB review. Voted to send to DR.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>0</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	0	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	0												
Withhold Approval	0												
Abstain	0												
Present	18												
5. #	D Y		12-16-2021										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.													
<table><tr><td colspan="2">IACUC Vote</td></tr><tr><td>Approval</td><td>18</td></tr><tr><td>Withhold Approval</td><td>0</td></tr><tr><td>Abstain</td><td>0</td></tr><tr><td>Present</td><td>18</td></tr></table>				IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote													
Approval	18												
Withhold Approval	0												
Abstain	0												
Present	18												
6. #	D Y		01-05-2022										
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification requested regarding injection procedure.													

Additional discussion during the meeting included:

a. Voted to send to DMR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

7. #	C		12-22-2021
------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of Consent Form and adverse effects.

Additional discussion during the meeting included:

a. Pending CTRB review. Voted to send to DR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

8. #	C		12-22-2021
------	---	--	------------

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Clarification of Consent Form and adverse effects.

Additional discussion during the meeting included:

a. Pending CTRB review. Voted to send to DR.

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	18

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 07-27-2021	
2. 08-25-2021	
3. 08-25-2021	
4. 09-29-2021	
5. 10-14-2021	
6. 10-19-2021	
7. 10-27-2021	
8. 10-28-2021	
9. 11-03-2021	
10. 11-08-2021	
11. 11-10-2021	
12. 11-12-2021	
13. 11-12-2021	
14. 11-16-2021	
15. 11-17-2021	
16. 11-24-2021	

Discussion:	15. Deficiencies noted were impacted by staffing shortage. 16. Discussed facilities computer monitoring of humidity and documentation.										
Action:	15. All deficiencies have been corrected. IACUC discussed campus wide issue of hiring and maintaining staff in many departments. 16. Committee agreed documentation can be maintained on the computer since it is checked daily and can be reviewed easily for past dates.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>15</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>15</td></tr> </tbody> </table>		IACUC Vote		Approval	15	Withhold Approval	0	Abstain	0	Present	15
IACUC Vote											
Approval	15										
Withhold Approval	0										
Abstain	0										
Present	15										

XIII. Laboratory/Study Area Inspections:

Inspection Date	Type	Location or Protocol
1. 09-30-2021	LAB	
2. 10-29-2021	LAB	
3. 10-29-2021	LAB	
4. 11-12-2021	LAB	
5. 11-29-2021	LAB	
6. 11-29-2021	LAB	
7. 11-29-2021	LAB	
8. 11-30-2021	LAB	
9. 07-28-2021	PAM	
10. 11-17-2021	PAM	
11. 12-03-2021	PAM	
12. 12-06-2021	PAM	

Discussion:	None.										
Action:	None.										
<table border="1"> <thead> <tr> <th colspan="2">IACUC Vote</th></tr> </thead> <tbody> <tr> <td>Approval</td><td>18</td></tr> <tr> <td>Withhold Approval</td><td>0</td></tr> <tr> <td>Abstain</td><td>0</td></tr> <tr> <td>Present</td><td>18</td></tr> </tbody> </table>		IACUC Vote		Approval	18	Withhold Approval	0	Abstain	0	Present	18
IACUC Vote											
Approval	18										
Withhold Approval	0										
Abstain	0										
Present	18										

XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

XV. Other Discussion Items:

Topic
1. ALL courses must be completed by 12/31/21.
Discussion: Reminder to complete training courses.
Action: All members required to complete all courses by 12/31/21.
2. 3rd quarter fluid reports.
Discussion: Compliant.
Action: None.

3. [REDACTED]	
Discussion:	IACUC voted to approve AV clinical decision regarding recovering a lamb that was not manipulated for rescheduled procedure.
Action:	None.
IACUC Policy-13 "Transporting Research and Teaching Animals"	
Discussion:	None.
Action:	Tabled
IACUC Policy-26 "Monoclonal Antibody Production in Mice via Ascites" - Recommendation to retire	
Discussion:	Recommended to retire
Action:	Retired
IACUC Policy-29 "Expired Drugs and Medical Materials"	
Discussion:	None.
Action:	Tabled
IACUC Policy-30 "Anesthesia Machine/Vaporizer Calibration, Use, and Maintenance Guidelines"	
Discussion:	None.
Action:	Tabled
IACUC Policy-41 "Guidelines for Changes in the Use of Therapeutic Drugs on Approved IACUC Protocols"	
Discussion:	None.
Action:	Tabled
IACUC Policy-43 "The Use of Prolonged Physical Restraint in Non-sedated Research and Teaching Animals"	
Discussion:	None.
Action:	Tabled

XVI. Program Updates:

Topic

There were no program updates provided during the meeting.